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Dissertation supervised by Associate Professor Patrick Flaherty 
Cyclophilin A are a class of peptidyl-prolyl isomerases that catalyzes isomerization of the 
proline residue within a protein. Cyclophilin A plays an instrumental role in the pathogenesis of 
HIV and HCV virus. Using structure-based drug we designed and synthesized small molecule 
inhibitors of cyclophilin A. These inhibitors were biologically evaluated for their ability to inhibit 
WT HIV-1 inhibition. 
Mitogen-Activated Protein Kinase signaling cascades plays a critical role in cancer cell survival, 
metastasis, and chemo-resistance. The MEK5/ERK5 pathway, which is a member of MAPK 
signaling cascade, is involved in cell survival, anti-apoptotic signaling, angiogenesis, and cell motility. 
It is found to be significantly upregulated in breast cancers especially triple-negative breast cancers 
(TNBC). Despite its strong correlation with cancer, the MEK5/ERK5 pathway remains under-
explored due to the lack of selective small-molecule inhibitors. Using the x-ray crystal structure 
of known MEK1/2 inhibitors bound to MEK1/2 (PDB ID: 3EQC and 3SLS) the homology model 
 v 
of MEK5 was built, and along with medicinal chemistry approaches, it was utilized for the design 
of diphenylamine and 2-amino-3-carboxythiophene derivatives as selective MEK5 inhibitors. 
During the development of 2-amino-3-carboxythiophene derivatives as MEK5 inhibitors, Ullmann 
couplings reactions were optimized for the installation of aryl ring on the 2-amino position. 
Alzheimer’s disease (AD) is characterized by the buildup of amyloid plaques, accumulation of 
neurofibrillary tangles, inflammation of the neurons, and neuronal loss leading to cognitive 
decline. Current drugs provide only brief symptomatic relief without modifying the underlying 
disease pathology. Emerging data suggest that inhibition of sigma-2 receptors has the potential to 
deliver disease-modifying AD drugs. Using pharmacophore analysis and analog-based drug 
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I Biochemical Review 
1) Cyclophilins 
1.1) Introduction 
Cyclophilins (CyPs) are a family of peptidyl-prolyl isomerase enzymes (PPIase) that catalyze the 
isomerization of the two local energy minima conformers (cis and trans) of the prolyl peptide bond 
at the C-termnal of an internal proline residue (Fig. 1.1), enabling protein folding.1-7 CyPs are 
evolutionarily well-conserved and are present in all prokaryotes and eukaryotes.8  
 
Figure 1.1. cis-trans isomerization by cyclophilins. 
 
There are 20 different human isoforms of CyPs (Table 1.1).9-10 Amongst them cyclophilin A 
(CyPA) is the most abundant PPIase, exhibiting high expression levels in cells (representing 0.1-
0.6% of the total cytosolic protein).11 Cyclosporin A (CsA, 3), a natural product, binds to and 
inhibits all isoforms of CyPs. In addition to the CyPs, there are two other families of PPIases (Fig. 
1.2): FK-506 Binding Proteins (FKBPs) and parvulins. FKBPs binds FK-506 or Tacrolimus (4) 
and mediate immunosuppressive activity analogous to cyclophilins. Parvulins bind juglone (5) and 
do not possess immunosuppressive activities (Fig. 1.3). They are responsible for the cis-trans 
isomerization of PO3H2Ser (PO3H2Thr)-Pro bonds. Recently it has been shown that Pin1, a 











Cytoplasm, Nucleus 18 kDa Inflammation, tumor progression 
Cyclophilin B 
(PPIB gene) 
Cytoplasm, ER, Cell 
surface 
20 kDa Inflammation, secretion 
Cyclophilin C 
(PPIC gene) 
Cytoplasm, ER 33 kDa Cell survival, tumor cell growth 
Cyclophilin D 
(PPID gene) 
Mitochondrion 22 kDa Mitochondrial permeability 
Cyclophilin E 
(PPIE gene) 
Nucleus 33 kDa mRNA processing 
Cyclophilin40 
(PPID gene) 
Cytoplasm 41 kDa Hsp90 chaperone complex 
Cyclophilin NK 
(NKTR gene) 
Nucleus 150 kDa Tumor recognition in NK cells 
Cyclophilin G 
(SR-cyclophilin) 
Nucleus 88 kDa Splicing, Interaction with mRNA 
Cyclophilin H 
(USA-cyclophilin) 
Nucleus, cytoplasm 19 kDa mRNA processing, splicing 
Cyclophilin L1 
(PPIL1 gene) 
Nucleus 18 kDa mRNA processing 
Cyclophilin P60 
(PPIL2 gene) 
Nucleus 59 kDa Cell surface expression of CD147 
Cyclophilin J 
(PPIL3 gene) 
Nucleus 18 kDa mRNA processing 
PPIL4 
(PPIL4 gene) 
Nucleus 57 kDa Unknown 
PPIL6 
(PPIL6 gene) 
Nucleus 35 kDa Unknown 
RanBP2 
(RANBP2 gene) 
Nucleus 358 kDa Unknown 
PPWD1 
(PPWD1 gene) 
Nucleus 73 kDa mRNA processing 
SDCCAG1 
(CWC27 gene) 
Nucleus 54 kDa Unknown 






Figure 1.2. Classification of peptide cis-trans isomerases in humans.12 
 
 





1.2) Mechanism of Cyclophilin 
Numerous enzymatic mechanisms by which cyclophilin catalyzes the cis-trans isomerization of 
an Xaa-Pro bond have been proposed.2-3, 5, 7, 14-15 The currently accepted theory involves distortion 
of the planar amide bond  via dipole interaction with a protonated arginine side-chain guanidinum 
rather than formation of a transient fully sp3 tetrahedral intermediate.14-15 The binding of CyPs to 
the Xaa-Pro substrate and polarization distorts the amide bond, leading to less amide bond 
resonance, resulting in a lower barrier of rotation (Fig. 1.4).14-15 An energy diagram showing the 
cis-tans isomerization in the presence or absence of PPIase is shown in Fig. 1.5.16 The key 
cation/dipole interaction between Arg55 (present in the active site of cyclophilin A) and the 
substrate prolyl amide nitrogen polarizes the pyramidal nitrogen, a key step in isomerization.14-15  
Arg55 is an essential amino acid required for the catalytic activity of cyclophilin A (it is nearly 
ubiquitous in the active site of other cyclophilins). Mutation at Arg55 leads to a catalytic inactive 
mutant of cyclophilin A.17-18 Seminal work of Dugave played a critical role in establishing this 
generally accepted mechanism.14, 19 Ke et al. proposed that since most Xaa-Pro amide bonds prefer 
the trans conformation during synthesis on the ribosome over the cis conformation, it is likely that 
cyclophilins catalyzes both the trans to cis isomerization and cis to trans isomerization.17, 20 
 






Figure 1.5. Energy diagram of the cis-trans isomerization in the presence or absence of PPIases.16 
 
1.3) Cyclophilin A in disease states 
1.3.1) Viral Infections 
Human immunodeficiency virus (HIV-1):  
In 1993, it was proposed that cyclophilin A and cyclophilin B  interact with the HIV-1 Gag 
polyproteins and facilitates HIV-1 replication.21 Subsequent studies showed that cyclophilin A 
(CypA) and not cyclophilin B is incorporated into the HIV-1 particle.22-23 Inhibition of this 
interaction by cyclophilin A inhibitors block HIV infectivity.23 Studies indicate that CypA interacts 
with the HIV-1 capsid and regulates viral infectivity.24 Although the exact mechanism is not 
known, it is proposed that in permissive cells low levels of CypA bind and stabilize the viral capsid 
in the presence of Nup358/TNPO3 to facilitate viral uncoating and viral entry. In non-permissive 
cells, higher levels of CypA or host restriction factors such as Trim5a and Trim-Cyp facilitate 





Figure 1.6. Role of CypA in HIV-1 infection.25 
 
Hepatitis C virus (HCV): 
Analogous to HIV-1 virus replication, studies have shown that CypA plays a key role in HCV 
virus replication. CypA binds to non-structural 5A (NS5A) and non-structural 5B (NS5B) proteins 
and promote HCV replication. Alisporivir inhibits this process by binding to CypA as shown in 
Fig. 1.7.24 
 






Other viruses:  
CypA is involved in the pathogenesis of influenza virus and interacts with the M1 protein of the 
influenza virus. CypA inhibitors also inhibit HBV (Hepatitis B Virus) replication by blocking 
calcium signaling and mitochondrial transition pores. CypA also plays pivotal roles in SARS virus, 
herpes simplex virus (HSV), human cytomegalovirus, human papillomavirus, and nidovirus 
replication.8, 24 
1.3.2) Cancers 
Several lines of evidence link dysregulation of CypA with several types of cancer (Table 1.2).26-
27 Inhibitors of CypA (cyclosporin A and sanglifehrin A) potentiate the chemotherapeutic potential 
of Cisplatin in glioblastoma.28  
Cancer Role and Expression of CypA 
Breast Cancer  Cancer cell progression  
 Regulation of JAK2 
Hepatocarcinoma  CypA overexpression increases growth through calcineurin 
interaction 
 CypA, diagnostic marker found in hepatocarcinoma 
Pancreatic Cancer  CypA facilitates cell growth through CD 147 signaling 
 Increased CypA associated with tumor invasion, metastasis 
Small Cell Lung 
Cancer 
 Overexpression of CyPA stimulates cancer growth 
 CyPA knockdown slows down cancer growth 
Glioblastoma 
multiforme 
 Overexpression of CypA 





1.3.3) Cardiovascular abnormalities: 
Atherosclerosis 
The CypA also contributes to the atherosclerosis progression by promoting inflammation. Five 
mechanisms have been proposed;29 which includes; 1) decrease in the endothelial nitric oxide 
synthase (eNOS) expression, 2) increased expression of adhesion molecule, 3) increased apoptosis 
of the endothelial cells, 4) increased uptake of low-density lipoprotein (LDL), 5) increased 
recruitment of inflammatory cells to the aortic wall (Fig. 1.8).8 
 
Figure 1.8. Role of CypA in atherosclerosis formation.8 
 
Abdominal aortic aneurysm (AAA) 
In the vascular smooth muscle cells, Angiotensin II stimulates the release of CypA which in turn 
activates metalloproteinase 2 (MMP-2) causing AAA30 (Fig. 1.9). Additionally, CypA inhibitors 
and CypA knockdown prevents the formation of AAA in response to Angiotensin II.8, 30 
 





Other cardiac diseases 
Emerging data suggests that CypA is involved in the pathogenesis of myocardial ischemia, acute 
coronary syndrome, and coronary artery disease.8 
1.3.4) Alzheimer disease 
Elevated CypA levels have been proposed to exacerbate Alzheimer disease by at least two 
mechanisms. The first mechanism involves activation of nuclear factor kappa B (NF-κB) and 
MMP-9 by ApoE2-4.31 Activation of these pro-inflammatory pathways damage neurons and their 
synaptic connections accelerating loss of neuronal connectivity and cognitive loss (Fig. 1.10). The 
second mechanism involves an increase in amyloid-β protein levels mediated via CypA by a 
mechanism not yet fully characterized. 
 





1.3.5) Miscellaneous  
In addition to the role of CypA in the aforementioned diseases, dysregulation of CypA has been  
identified  in periodontitis (via activation of inflammatory pathways including MMP-1, MMP-2, 
and MMP-9), aging, asthma, Amyotrophic lateral sclerosis (ALS), Rheumatoid Arthritis, and 
diabetes.8 
1.4) Cyclophilin Inhibitors 
The cyclophilin inhibitors can be subdivided into two broad categories32; 1) large molecule 
inhibitors and 2) small molecule inhibitors.  
 
Figure 1.11. Large molecule inhibitors of CypA. A) Immunosupressive and B) non-





The large molecule inhibitors, which includes cyclosporin A (CsA), sanglifehrin A, NIM-811, 
Debio-025 (Alisporivir) can further be categorized as immunosuppressive or non-
immunosuppressive (Fig. 1.11). The initial CypA inhibitors cyclosporin A and sanglifehrin A are 
immunosuppressive. The overall mechanism of immunosuppression requires initial binding of 
CypA and CsA to form a binary complex followed by recruitment and activation of a third partner, 
calcineurin (CN), that forms an immunosuppressive ternary complex33 (Fig. 1.12).  
 
Figure 1.12. CypA and immunosuppression. 
 
Activated calcineurin dephosphorylates nuclear factor of activated T cells (NF-AT). 
Dephosphorylated NF-AT translocates to the nucleus and activates T-cells (Fig. 1.13).34 Inhibition 






CypA inhibitors would be of therapeutic utility for HIV patients. Fortunately, small structural 
 
Figure 1.13. Mechanism of immunosuppression by calcineurin.34 
 
changes found in some macrocyclic inhibitors eliminate calcineurin recruitment and activation 
while retaining CypA inhibition properties (Fig. 1.14). These compounds include NIM-811 and 
Debio-025.12  
 





X-ray crystallographic study reveals that different structural components of CsA are responsible 
for binding structural locations of CypA and CN (Fig. 1.15).12 Therefore, compounds can be 
rationally designed to selectively inhibit CypA over CN. The biological activities of these 
molecules are presented in Table 1.3.32 The large molecule inhibitors (immunosuppressive and 
non-immunosuppressive) have disadvantages like, poor oral bioavailability, synthetic challenges, 
poor permeability, risk of drug-drug interactions, and potential off-target side effects.35 These 
shortcomings warrant new molecules, especially small molecule inhibitors of CypA.  
 
















Compound Immunosuppression CypA Ki (nM) 
3, CsA Yes 9.79 ± 1.37 
4, Sanglifehrin A Yes 2.4 ± 0.11 
9, Debio-025 No 0.34 ± 0.12 
10, NIM811 No 2.11 ± 0.32 
Table 1.3. Biological activity of large molecule CypA inhibitors. 
The second category involves small molecule inhibitors of Cyclophilin-A. Several categories of 
CypA inhibitors have been designed based on the X-ray crystal structures, NMR studies, virtual 
screening, and computer aided-drug design. These include thiourea,36 diarylurea,37 aryl 1-
indanylketones,38 quinoxaline,39 and N-acylurea derivatives40 (Fig. 1.16).  
 





2) MEK5  
2.1) Introduction 
The mitogen-activated protein kinase (MAPK) signaling pathway converts extracellular signals 
into intracellular responses in the context of cell homeostasis and regulates aspects of cell growth, 
cell proliferation, differentiation, apoptosis, gene expression, and other cellular events.41-43 The 
MAPK pathway can be activated by variety of signaling molecules including cytokines, mitogens, 
and stress. Upon activation, MAPK pathways follow an evolutionally conserved three-tiered 
protein phosphorylation cascade on specific serine, threonine, or tyrosine residues. In the first step, 
mitogen-activated protein kinase kinase kinase (MAPKKK) is phosphorylated, which 
phosphorylates a mitogen-activated protein kinase kinase (MAPKK), which further 
phosphorylates the final mitogen-activated protein kinase (MAPK or ERK). This pERK product 
then directs various cellular processes.44 The MAPK family can be further subdivided into seven 
sub-families namely: ERK1/2, JNK1/2/3, p38 proteins, ERK3/4, ERK5, ERK7, and ERK8 (Fig. 
1.17).44-45 Each member of the family has its specific “MEK” activator. Crosstalk exists between 






Figure 1.17. MAPK pathway and the three-tiered activation cascade and cellular outcome.44 
 
 
2.2) MEK5/ERK pathway overview 
The MEK5/ERK5 pathway is one of the lesser-studied member of MAPK family.44, 46 This has 
been partially attributed to the lack of small molecule inhibitors.46 Upon activation by external 
signal, MEKK2 or MEKK3 phosphorylates and activates MEK5; phosphorylation occurs at 
Ser311 and Thr315.44 Activated MEK5 in turn phosphorylates and activates ERK5 at Thr218 and 
Tyr220. Activated pERK5 phosphorylates downstream partners or can auto-phosphorylate the 
NLS (nuclear localization signal) to facilitate translocation to the nucleus and control gene 








Figure 1.18. Overview of MEK5/ERK5 pathway.44 
 
Structurally, MEK5 contains a phox and Bem1P (PB1) domain on the N-terminus, essential for 
binding to the ERK5 and a kinase domain.49-51 ERK5 contains a MEK5 docking site on its N-
terminal, followed by a kinase domain, and an extended C-terminal. The extended C-terminal is 
unique to ERK5 and has two proline-rich zones, NLS domains, and end with a transcriptional 
activation domain (TAD). The NLS domain promotes the nuclear localization of ERK5 upon 
activation. The TAD region auto-phosphorylates ERK5 (Fig. 1.19).47, 52-54 Known downstream 





Figure 1.19. Structural components of MEK5/ERK5.45 
 
 
Figure 1.20. Downstream partners of MEK5/ERK5 pathway.45 
 
Even though the MEK5/ERK5 pathway follows the same three-tiered activation cascade akin to 
MAPK family, there are unique structural and functional differences that makes it a promising 
target to treat human disease. Differences includes 1) ERK5 is twice the molecular weight of other 
MAPKs, 2) even though most MAPK enzymes require a preceding proline residue, ERK5 can 




and 4) ERK5 can undergo autophosphorylation, after initial MEK5 phosphorylation, a unique 
property of a MAPK.44-46, 60-61 
2.3) Role of MEK5/ERK pathway in cancer 
The MEK5/ERK5 pathway has been strongly linked to cancers by several characteristics as shown 
in Figure 1.21 (bold means established, non-bold refers proposed).62  It has been shown that MEK5 
 
Figure 1.21. Relevance of MEK5/ERK5 pathway to cancer.62 
 
is highly upregulated in many cancers like, triple negative breast cancers (TNBCs),63 prostate 
cancers,64 T cell leukemia,65 hepatocellular carcinoma,66 colon carcinoma,67-68 lung carcinoma,69 
and multiple myeloma.70 Additionally, increase in the concentration of phosphorylated ERK5 is 




promotes development of resistance to first-line hormonal therapy.71 Upregulation of MEK5 and 
ERK5 in both TNBC and HER2+ breast cancer cell is correlated with poor relapse-free survival.72 
Knockdown of the MEK5/ERK5 pathway resulted in significant reduction in growth and 
metastasis of tumor cells in the in-vivo tumor xenograft model.44-45, 67 Despite pharmacological 
relevance, isoform-selective inhibition of MEK5 is under-explored.46 
2.4) MEK5 inhibitors  
2.4.1 Type of kinase inhibitors 
With the help of X-ray crystallography and other experimental techniques, it has been shown that 
kinases can be inhibited at several structural locations characterized by a specific inhibitor-type 
name: type I, type II, type III, and type IV. 
Type I inhibitors: These are the most common type of kinase inhibitors. The inhibitor competes 
at the ATP binding site. These inhibitors target the catalytic domain with the “DFG” motif oriented 
in a “DFG-in” conformation.  Since these inhibitors compete with ATP, their structure and binding 
mimics certain structural features ATP (Fig. 1.22) but can utilize additional isoform-unique 
interactions.73  
 
Figure 1.22. Type I inhibitors mimicking ATP interactions. 
 
Achieving this kinase isoform selectivity is a challenge since ATP-binding sites are highly 




Type II kinase inhibitors75: Type II kinase inhibitors bind the ATP site in an inactive state: the 
“DFG-out” conformation.  This DFG-out conformation reveals a hydrophobic pocket previously 
occupied by the phenyl side chain of the Phe in the DFG motif. This permits additional interactions 
enabling isoform-selective inhibitor design (Fig. 1.23).  As the number of interactions are 
increased and the pocket differentiated by isoform, this enables both selectivity and potency design 
opportunities. However, mutations can occur at these sites modifying prior drug binding sites 
generating a decrease in inhibitor potency. Although type II inhibitors show better selectivity,  
development of resistance is the key challenge with this class of inhibitors. 
 
Figure 1.23. Type II inhibitors design with DFG “out” conformation. 
 
Type III inhibitors76:  Type III inhibitors are also known as allosteric site inhibitors. The type III 
inhibitor pocket lies near the ATP-binding domain (Fig. 1.24).  Type III inhibitors typically do not 
interact with the hinge region of ATP binding pocket. These inhibitors bind in a “side pocket” of 
the kinase adjacent to the γ-phsophate of ATP.  Binding of the type III inhibitors leads to a 
conformational change in the α-C-helix region. This induces a global conformational change in 




compete with ATP providing the possibility that lower affinity inhibitors could result in kinase 
inhibition.  The type III pocket has been used in the design of several MEK1/2 inhibitors many of 
which are approved by the FDA.  
Type IV inhibitors73, 76: These inhibitors resemble the type III inhibitors, but their binding site is 
distant from ATP binding (Fig. 1.24). 
 
Figure 1.24. Type III and type IV binding pockets with type III inhibitor (PD-325089), type IV 
inhibitor and ATP bound in their respective sites (PDB ID: 3EQG).76  
 
The structure of a typical protein kinase along with key binding components are depicted in Figure 
1.25A (PDB ID: 4RRV).77-78 Four different types of kinase inhibitors are shown in Figure 1.25B.77 





Figure 1.25. A) Key components in a protein kinase. B) Types of kinase inhibitors.77 
 
2.4.2 MEK5 inhibitors 
Despite the strong correlation between MEK5 and cancer, MEK5 remains under studied member 
of MAPK signaling cascade. There are only few MEK5 selective ligands reported in the literature. 
These inhibitors can be classified as: 1) non-selective MEK5 inhibitors79-80 (these inhibitors were 
originally reported as MEK1/2 pathway inhibitors but later they were identified to inhibit MEK5 
as well), 2) selective MEK5 inhibitors,60-61, 81 and 3) Miscellaneous82-87 (literature search identified 




compounds may serve as the lead molecules for designing selective MEK5 inhibitors. The 























3) Mesenchymal to Epithelial transition 
Breast cancer is the most common cancer in women affecting every 1 in 8 women. 10-20% of 
breast cancers are triple-negative breast cancer (TNBC).88 The TNBC are more aggressive and 
they do not express estrogen, progesterone, or HER2 (human epidermal growth factor receptor 2) 
receptors. Hence, they do not respond to traditional endocrine therapy, requiring a more aggressive 
treatment strategy that involves surgery, radiation therapy, and chemotherapy.89 Unfortunately, 
only 50% of patients with TNBC respond to chemotherapy.90 After decades of drug-discovery 
efforts, there is no preferred drug approved for the treatment of TNBC.91 Even with estrogen 
positive breast cancers (that can be targeted with ER antagonists such as tamoxifen), about 30% 
patients develop drug resistance, requiring more aggressive treatment.92 Therefore, exploration of 
new therapies is warranted to combat these aggressive type of breast cancers.  
 








Epithelial to mesenchymal transition (EMT) is a reversible cellular program where specialized 
cobblestone-like, less mobile, epithelial cells undergo morphological changes to acquire a more 
mobile invasive mesenchymal morphology (Fig. 1.27).93-96 Under normal conditions, the epithelial 
cells show apical–basal polarity and they are held together by tight junctions and adherens 
junctions (formed by E-cadherin), making them less motile. During EMT, the E-cadherin 
expression is decreased, and the cells acquire a spindle-like mesenchymal morphology. These 
mesenchymal cells induce expression of N-cadherin, vimentin, and fibronectin. Increasing 
evidence suggests that EMT plays an essential role in breast cancer metastasis.97-100 Furthermore, 
data from two independent studies indicate that reduction in E-cadherin expression is a critical 
event in the metastases and recurrence of aggressive lobular breast carcinomas.101-102 Decreased 
expression of E-cadherin is mediated by mesenchymal-associated transcription factors including 
zinc finger E-box binding homeobox1 (ZEB1), Snail, and Slug. 93-96, 103-104 The phenotypic traits, 
general morphology, and molecular features of epithelial and mesenchymal cells are shown in  
Figure 1.28.94 Considering the central role of EMT in cancer progression, targeting EMT 
represents an attractive approach to treat cancer.105 Additionally, EMT is proposed to play a central 
role in the development of cancer stem-like cells106-107 and chemo-resistance.108 Even though less 
is known about the reversion from a mesenchymal-like cell type to an epithelial-like phenotype 
(the reverse of EMT) and re-expression of E-cadherin,109 recent studies highlight the activation of 
MET or inhibition of EMT as an effective anti-cancer strategy.110-112 The compounds targeting 
epithelial-mesenchymal transition can be screened by a variety of readouts like increase in the E-
cadherin expression, decrease in the N-cadherin expression, downregulation of vimentin, 
induction of caspase activation, inhibition of cell migration, induction of apoptosis, inhibition of 












Figure 1.29. Strategies to evaluate compounds causing epithelial-mesenchymal transition.105 
 
4) Sigma-2 receptors 
4.1) Introduction 
In 1976, sigma receptors were discovered as a potential target for cancer and CNS disease 
therapy.113 In 1990, two distinct subtypes of sigma receptors were identified, namely sigma-1 and 




2016), its X-ray crystal structure in the presence of ligand has been deposited (PDB ID: 5HK1 and 
5HK2).116-117 Its role has been reported in cancer and variety of CNS diseases like anxiety, 
Parkinson’s disease, schizophrenia, depression, and drug addiction.118-120 
Sigma-2 receptor on the other hand has remained enigmatic.121-122 Initially, they were reported as 
histone proteins.123 However, this hypothesis was rejected when fluorescent sigma-2 ligands 
exhibited fluorescence in the cytoplasm rather than the nucleus.118 It was also proposed that sigma-
2 receptor is a part of the progesterone receptor membrane component 1 (PGRMC1) complex.124 
Initial experiments supporting this theory included 1) photoaffinity labelling by sigma-2 receptor 
ligand revealed PGRMC1 and sigma-2 receptor are same based on the mass spectrometry analysis, 
2) overexpression of PGRMC1 leads to increased sigma-2 receptor binding and vice-versa, and 3) 
PGRMC1 inhibitor, displaced sigma-2 receptor radioligand.118 However, this hypothesis was also 
rejected. Using flow cytometry study, it was revealed that PGRMC1 inhibitor could not displace 
sigma-2 receptor fluorescent ligands (F412, NO1, and PB385). These fluorescent ligands however 
could be displaced by known sigma-2 receptor ligands.125 Additional studies further supported that 
sigma-2 receptor and PGRMC1 are separate entities.118 Recently, Alon et al. purified sigma-2 
receptor from calf liver tissue and reported its profile similar to TMEM97.121 Despite the 
controversy, sigma-2 receptor have remained as a target of interest for cancer and 
neurodegenerative diseases.  
4.2) Structure of sigma-2 receptor 
The sigma-2 receptor has a molecular weight of 18-21 kda.114 It is primarily expressed in liver, 
kidney, and CNS.118 To clone this receptor, an affinity column resin  (ACR) was prepared 
comprising of an affinity ligand attached to the agarose beads. The ACR was then treated with the 




on the SDS-gel and analyzed by mass spectrometry. Seven potential protein were identified which 
were then assayed for their ability to bind [3H] DTG (a known sigma-2 receptor ligand). From this 
study it was discovered that sigma-2 receptors are TMEM97.121  
 
Figure 1.30. Cloning and isolation of sigma-2 receptor.121 
 
Site-directed mutagenesis was conducted to identify the potential ligand binding site. This study 
identifed two conserved Asp (29 and 56) that were essential for the sigma-2 receptor activity. 
Further ab initio calculations suggest that the protein likely possesses a four-helix bundle fold (Fig. 
1.31A). The two Asp residues essential for binding are located in close proximity to one another 





Figure 1.31. A) Proposed structure of TMEM97/sigma-2 receptor, B) molecular model of 
sigma-2 receptor along with essential Asp residues in red.121 
 
The TMEM97 is associated with cholesterol homeostasis and Niemann-Pick disease.121 Additional 
structural information about sigma-2 receptor could potentially offer insights into its function and 
its exploration as a drug target. Although cloning and purification of the sigma-2 receptor are 
breakthrough, some of the unanswered questions in sigma-2 receptor field include: 1) Is there an 
endogenous ligand for sigma-2 receptor ? and 2) does sigma-2 have widespread activity analogous 
to the sigma-1 receptor ?.122  
4.3) Sigma-2 receptor ligands 
Due to limited information about the structure of sigma-2 receptors, their ligands originate from 
other neurotransmitter projects such as acetylcholine receptors, serotonin receptors, dopamine 
receptors, opioid receptors, and NMDA2B receptors. Serendipity also played a role in the discovery 




are enlisted in Figure 1.32.115, 126-141 Their biological activity against sigma-2 and sigma-1 




















Figure 1.32. Chemical structures of sigma-2 ligands. 
 
 
Compound Sigma-1 Ki (nM) Sigma-2 Ki (nM) Selectivity (S1/S2) 
43 88.5±9.0  35.2±3.0 3 
44 3063±78  16.5±2.7 184 
45 7436±308  13.4±2.0 555 
46 13.6±1.9  0.34±0.02 40 
47 3450±1600  12.6±3.2 273 
48 3.28±0.32  1.90±0.16 1.7 
49 709±133  4.84±0.74 147 
50 7840±264  12930±55.84 0.61 
51 12900±111  8.2±1.4 1573 
52 10412±462  13.3±0.1 783 
53 82.2±5.6  20.7±2.0 4 
54 3078±87  10.3±1.5 300 
55 1442±88  0.82±0.66 1758 
56 10320±363  26.78±2.92 385 
57 Not reported 27 Not applicable 




59 500 9 55.5 
Table 1.4. Biological activity of sigma-2 ligands. 
 
4.4) Sigma-2 receptor and Alzheimer’s Disease (AD) 
Alzheimer's disease (AD) is the sixth leading cause of death in the US.142-143 AD is a 
neurodegenerative disease characterized by a loss of neurons, neuroinflammation, accumulation 
of amyloid-βeta plaques, and neurofibrillary tangles.144-146 So far, five drugs have been approved 
for AD, however, these drugs provide a brief symptomatic relief that slows cognitive decline. 
There are currently no approved disease-modifying therapeutics for Alzheimer’s disease (AD).147  
Increasing evidence suggests that modulating the Sigma-2 receptor can provide beneficial effects 
for neurodegenerative diseases like AD, because of its widespread occurrence in the CNS and its 
involvement in calcium homeostasis.148 In the brain, sigma-2 receptor is primarily expressed in 
the cortex and hippocampus, two regions that play integral roles in cognitive function. 
Additionally, the sigma-2 receptor has been implicated in neuroprotection and mitochondrial 
protection.149-150 Afobazole, a dual sigma-1 and sigma-2 ligand, has been shown to reduce 
neurotoxic microglia stimulation and apoptosis induced by amyloid beta fragments.151 Cognition 
Therapeutics demonstrated that the sigma-2 receptor promotes binding of Aβ oligomers to the 
neurons. Inhibiting sigma-2 receptor, either by ligand or genetic knockdown, mitigates the 
neurotoxic effects of Aβ oligomers. As AD patients experience neuronal cell loss, the relative 
amount of sigma-2 expression increases, consistent with a neurotoxic role for the sigma-2 
receptor.137-138 Analogs from Cognition Therapeutics are currently in clinical trials for the 
treatment of AD.152 In another study, it was reported that sigma-2 selective ligand (SAS-0132) 
modulate intracellular Ca2+ levels and is neuroprotective in a model of amyloid precursor protein‐
mediated neurodegeneration (Fig. 1.33). Furthermore, SAS‐0132 improves cognitive performance 




demonstrate that sigma-2 receptor is a key mediator of the pathological effects of amyloid βeta 
oligomers in AD. Targeting sigma-2 receptor, therefore, is a promising approach to treat 
neurodegenerative disorders including AD.137-138, 153  
 













II Chemical Literature Review 
The chemistry required for every project is subcategorized as: 
1) Cyclophilin A inhibitors 
2) MEK5 inhibitors 
3) Sigma-2 receptor antagonists 
 
1) Cyclophilin A inhibitors project 
1.1) N-acylurea formation 
                                     
Figure 2.1. General structure of N-acylurea and compound 1a2. 
 
The N-acylurea core was present in the literature compound which was our lead molecule 1a2. 
These compounds can be formed by the following methods: 
By the isocyanate method 
One of the most common method for the formation of the N-acylurea involves the reaction between 
isocyanate and an amide precursor.40, 154-160 This method was first discovered by Kühn in 1884.154-




followed by the exclusion of the HCl (Scheme 2.1). The overall mechanism involves the attack of 
amide nitrogen on the electrophilic carbon of isocyanate group (1a4). At R and R’ both aliphatic 
and aromatic groups are tolerated, and the reaction performs well in non-polar solvents like 
toluene. For less nucleophilic amides addition of strong base that can deprotonate the amide ‘NH’ 
improves the yield.  
 
Scheme 2.1. Formation of N-acylurea by the reaction between isocyanate and amide. 
 
By the acyl isocyanate method 
Another common method to form the N-acylurea involves the reaction between acyl isocyanate 
and an amine precursor.40, 159-164 The chemistry involves first the reaction between an amide (1a6) 
and oxalyl chloride (1a5) under thermolytic conditions to yield acyl isocyanate (1a7) which upon 
reaction with a suitable amine (1a8) furnishes N-acylurea (1a1, Scheme 2.2). The formation of 
acyl isocyanate is reported to work better with aromatic amides compared to aliphatic amides. For 
aliphatic amides, the presence of electron-withdrawing group at the α-carbon improves yield. The 
method can also be extended for the synthesis of carbamate derivatives.  
 
Scheme 2.2. Formation of N-acylurea by the reaction of acyl isocyanate and amine. 
 




Recently cross-coupling methods involving Palladium has been published for the construction of 
N-acylurea derivatives.165-166 The overall chemistry involves the conversion of the suitable amine 
to the urea derivative (1a9) via carbamoyl chloride intermediate (1a8). The urea derivative (1a9) 
was then subjected to Pd catalyzed carbonylative arylation to produce the final N-acylurea (1a1, 
Scheme 2.3). For the palladium-catalyzed carbonylation of urea derivatives; aryl iodides and 
bromides were used as the arylation source and carbon monoxide (near-stoichiometric amounts) 
was generated from 9-methylfluorene-9-carbonyl chloride. This synthetic protocol showed good 
functional group tolerance with yields ranging from 65-99 %.165 Microwave can be used to conduct 
this chemistry and allows improved functional group tolerance.166  
 
Scheme 2.3. Palladium-Catalyzed N-Acylation of Ureas. 
 
1.2) Synthesis of α-aminoacyl amide derivatives 
The amides bond formation was required for the synthesis of peptidomimetic compounds 1a10. 
 
Figure 2.2. General structure of α-aminoacyl amide derivative 1a10. 
 




Ugi and coworkers in 1959 reported that isocyanides, amine, aldehyde or ketone could undergo a 
multi-component reaction in the presence of a nucleophile (carboxylic acid) to provide a single 
condensation product.167-169 The general features of the reaction include: 1) It is a smooth reaction 
to carry out. 2) It has very high atom efficiency. 3) It has very good functional group tolerance. 4) 
Many solvents can be used.  Methanol or acetonitrile are preferred. Nonpolar solvents are not 
preferred; it may lead to side reactions, including the Passerini reaction. 5) The Ugi reaction has 
been extensively utilized for the peptide coupling and α-amino acid synthesis. 6) Several 
modifications exist to improve substrate scope. 7) The Ugi reaction has been used for the synthesis 
of tetrazole derivatives, hydantoinimide derivatives, α-amino carboxamides, and α-acyloxyamino 
caboxamide derivatives..170-178 
The Ugi reaction between an aldehyde, an amine, an isocyanide, and a carboxylic acid can be 
utilized for the synthesis of variety of α-aminoacyl amide derivatives (Scheme 2.4). The 
generation of enantioselective derivatives remains elusive with Ugi reaction.  
 
Scheme 2.4. The synthesis of α-aminoacyl amide derivatives via Ugi reaction. 
 
The mechanism of Ugi-condensation involves formation of an imine by condensation of the amine 
(1a12) with the aldehyde (1a11), followed by the addition of the carboxylic acid (1a15) to form 
the iminium ion (1a16), which is then attacked by the isocyanide to generate isoamide. The 







Scheme 2.5. Mechanism of Ugi condensation. 
 
By coupling and acylation reactions 
The α-aminoacyl amide derivatives could also be produced by initial coupling between a protected 
(Boc or CBz-) amino acid (1a20, commercially available) and an amine (1a12) in the presence of 
a standard peptide coupling (discussed later) to produce intermediate 1a21. The intermediate 1a21 
was then deprotected (Boc or CBz-) and acylated with commercially available acyl chloride 
(Scheme 2.6) to produce the α-aminoacyl amide derivatives.  
 





The advantages of this reaction include easy generation of a specific stereoisomer and ease of 
generation of library of compounds since the starting materials are readily available. Additionally, 
SAR can be done on any intermediate. 
2) MEK5 inhibitors project 
2.1) Diphenylamine scaffold synthesis 
 
Figure 2.3. General structure of diphenylamine scaffold. 
 
The formation of aryl-nitrogen bonds has been extensively studied.181-182  The initial coupling was 
reported by Fritz Ullmann (Scheme 2.7).183-184  This coupling also known as Ullmann coupling 
reactions utilized an aryl halide and an aryl amine along with copper and base to form an aryl-
nitrogen bond.  Recent variations of the Ullmann reaction have been published185-191 and modern 
developments include the use of solvating and activating ligands for the metal, the use of less-
reactive electrophilic aryl partners, and the development of methodologies that require less forcing 
conditions: lower temperature, weaker bases, shorter reaction times, and the use of microwave 
heating to both increase yield and reduce side reactions.  The rationale for these strategies is to 
improve substrate scope and versatility.  Even though the exact mechanism is still under 
evaluation, the reaction is proposed to proceed through oxidative addition of copper into the aryl- 
halide bond, followed by ligand displacement by the aryl amid, with reductive elimination to 
furnish the product. Ullmann coupling general trends include: 1) decreasing trends in the reactivity 
of aryl halides: I > Br > Cl >> F (aryl fluorides are least preferred), 2) electron-withdrawing 




groups have minimal effect in terms of reactivity, 4) polar solvents are preferred (DMF, DMSO), 
5) temperature requirements are between 100-300 oC, 6) mild inorganic bases improve the yield 
(K2CO3 and CsCO3) and strong bases are not required. Side reactions includes: 1) reductive 
dehalogenation, 2) homocoupling to form the biaryl ring.185-191 
 
Scheme 2.7. Synthesis of diarylamines by Ullmann Coupling. 
 
Irma Goldberg in 1906, showed that the reaction occurred in the presence of catalytic amounts of 
Cu (Scheme 2.8).192   
 
Scheme 2.8. Goldberg synthesis of diarylamines in 1906.192 
 
Additional metal-mediated couplings have been reported utilizing metals such as palladium, 
nickel, iron and other metal couplings.  Among these palladium-catalyzed couplings pioneered by 
Buchwald-Hartwig have gained immense attention.193-203  This conversion was originally 
conceived by Hartwig but brought to practical utility by Stephen Buchwald.204-207  The typical 
procedure involves an aryl halide (bromide or iodide), an amine, a palladium(0) catalyst which is 
complexed with chelating phosphine type ligands (BINAP, DPPF, and XANTPHOS) or bidentate 
ligands (dibenzylideneacetone), and stoichiometric quantities of base (sodium tert-butoxide or 




reaction conditions become milder, improve substrate scope and lower temperature requirements.  
The adequate solvation of all oxidation forms of the palladium atom, the development of 
metal/ligand complexes that were more stable to the presence of trace amounts of molecular 
oxygen, and optimization of the base employed were all advances that brought this reaction from 
an interesting synthetic observation to a widely-used synthetic methodology.209 
 
Scheme 2.9. Synthesis of diphenylamines using Buchwald Coupling.208 
 
The proposed mechanism involves; 1) the oxidative addition of Pd(0) to the aryl halide; 2) 
formation of the Pd(II)-aryl amide; 3) finally reductive elimination yields the desired compound 





Scheme 2.10. Proposed mechanism of the Buchwald-Hartwig coupling. 
 
Another strategy to construct aryl C-N bond involves SNAr reactions in which the nucleophilic 
aromatic nitrogen attacks the electrophilic haloarenes. 215-222  These SNAr conversions require a 
very nucleophilic aryl nitrogen atom, which is usually prepared by deprotonation using strong base 
with pKa ranging from 20-35 (since the pKa range for aromatic amines is from 15-25) such as 
NaH, NaHMDS, LiNH2, LiHMDS, KOt-Bu, n-BuLi, or KHMDS. Other features of this chemistry 
are; 1) decreasing trends in reactivity Ar-F >> Ar-Cl> Ar-Br (Ar-I are poor substrates); 2) these 
reactions typically work best in polar solvents such as THF or dioxane since polar solvents stabilize 
charged transition states; 3) the counter ion (Na+, Li+, or K+) plays a critical role in determining 
the fate of the product (regioselectivity and yields); 4) Ortho-halo aromatic/het-aromatic rings are 




groups are also frequently used such as ortho nitro haloarenes)215, 220, 223; 5) multiply-halogenated 
arenes works really well provided specific counter ions are employed for regio-selectivity. 
An important specific example employing this chemistry is the synthesis of our desired 
intermediate 2a11 as demonstrated by Davis et al.224 This uses an SNAr reaction to develop a novel 
route of synthesis to diphenylamines using LiNH2 as the base (Scheme 2.11). The authors studied 
lithium amide-promoted coupling of substituted anilines with 2-fluorobenzoic acids or 2-
fluorobenzamides. The authors found that; 1) both primary and secondary anilines efficient 
partners for the reaction; 2) the presence of lithium-ion dictates the regioselectivity towards ortho-
position; 3) both 2-fluorobenzoic acids and 2-fluorobenzamides were effective partners; 4) typical 
temperature for the reaction was 50-65 oC; 5) the yields were good to high; 6) by using 2,3,4-
trifluorobenzoic acid exclusively ortho-product was formed when LiNH2 was used as a base; 7) 
the reaction requires 2-3 equivalents of the base depending upon the substrate; and 8) the reaction 
was scalable to muti-gram to multi-kilogram synthesis. 
The proposed mechanism involves the deprotonation of the aniline, followed by attack at the ortho-
position of the 2,3,4-trifluorobenzoic acid (the lithium-ion stabilizes the transition state by 
coordinating with both the aniline ‘NH’ and carboxylate ion, Fig. 2.4). Finally, expulsion of the 
fluorine atom reinstalls the aromaticity and furnishes the desired compound after work-up.224 
 






Figure 2.4. Li+ ion directs the attack of the aniline anion to the ortho-position of the 2,3,4-
trifluorobezoic acid. 
 
2.2) Amide bond formation to generate Acyl variations 
The next and final step was to convert the carboxylic acids (2a13) to the relevant amides (2a14, 
Scheme 2.12). Since amide bond formation is one of the most important reaction in the 
pharmaceutical industry it is extensively studied and many reviews exists for the same highlighting 
the scope and limitations of the substrates, coupling reagents, solvents, and other reaction 
conditions.225-231 
 
Scheme 2.12.  Conversion of the carboxylic acids to the amides. 
 
One of the most common method to form the amides involves conversion of the acid (2a13) to the 
corresponding acyl chloride (2a15) derivatives which can then be reacted with suitable amine to 
yield the final products (Scheme 2.13).226, 228 The reaction is usually conducted at the room 
temperature and involves mild reaction conditions. General features include: 1) several 




2) the reaction is highly moisture-sensitive; 3) more applicable to aromatic acid then aliphatic 
carboxylic acids; and 4) isolation of the product is simple as the side products are water-soluble.  
 
Scheme 2.13. Synthesis of the amides via acyl chloride intermediate. 
 
Disadvantages associated with this method includes; 1) generation of very reactive species which 
is highly moisture-sensitive; 2) the establishment of acidic reaction environment which makes it 
unsuitable for acid-labile functional groups; 3) the possibility of ketene formation if an -proton 
is present and a sufficiently strong base (pKa 9 or greater) is used; and 4) the likely loss of 
stereochemical integrity if the -carbon is chiral and has a proton.226, 228 
Entry Reagent Structure 
1 Thionyl chloride232 SOCl2 
2 Oxalyl chloride233 
Oxalyl chloride with Cat. DMF  






5 Pivaloyl chloride236 
 
6 Phthaloyl chloride237 
 
7 TPP238 PPh3/CCl4 
Table 2.1. Commonly employed chlorination agents. 
 
Another strategy uses coupling agents to form the amides in a single step. 226, 228, 230-231 Since these 
coupling reagents makes reaction conditions even milder and offer advantages such as retention 
of stereochemistry a lot of progress has been made towards generation of more efficient coupling 
reagents. Some of the coupling reagents are listed in Table 2.2. 
One of the widely studied coupling reagent is carbodiimide reagent.226, 228 There mechanism 
involves first the conversion of the carboxylic acid (2a17) to the O-acyl urea derivative (2a19), 
which is then attacked by a suitable amine (2a20) to yield the final amide (2a22) derivative 






Scheme 2.14. General mechanism of carbodiimide coupling. 
 
Derivative to the corresponding N-acyl urea derivative (2a24) which decreases the reaction yield 
(Scheme 2.15).  
 
Scheme 2.15. Side reactions associated with carbodiimide coupling reagents. 
 
To avoid this side reaction; these reactions are often supplemented with auxiliary nucleophiles 
(such as HOBt and HONB) which reacts with the O-acyl urea intermediate (2a19) to form the 
activated ester (2a26), which reacts with the amine (2a20) and avoids formation of the N-acyl urea 





Scheme 2.16. Formation of the amide via HOBt. 
 
A representative example of carbodiimide coupling method is shown in Scheme 2.17. 
 
Scheme 2.17. Formation of the amide bond via carbodiimide coupling. 
 
Other coupling reagents follows a similar mechanism. General features of this chemistry are; 1) 
stoichiometric quantities of the coupling reagent is required (many time 1.2 equivalents); 2) the 
urea by-product is sometimes difficult to get rid of; 3) these reactions are also moisture sensitive; 
4) amenable to large scale-up; 5) the reactions generally requires low to room temperature and 
allows the use of variety of solvents, though DMF and THF are the preferred solvents; and 6) 
newer coupling reagents have been discovered which can accelerate the rate of amide bond 


































Table 2.2. Commonly used coupling reagents. 
 
2.3) 2-amino-3-carboxy thiophene core synthesis 
 
Figure 2.5. General structure of 2-amino-3-carboxy thiophene core (2b1). 
 
Functionalized 2-amino-3-carboxy thiophene core (2b1) are versatile building blocks for the 
synthesis of variety of biologically relevant molecules.243 There are numerous methods reported 
for their synthesis. However, the most widely used method involved a multicomponent reaction 
pioneered by Karl Gewald’s.244-248 Gewald thiophene synthesis is a 3-component reaction utilizing 
1) electron-deficient methylene nitriles, 2) a carbonyl substrate, and 3) elemental sulfur in the 
presence of a base and protic solvent.  Three variations have been described for Gewald thiophene 
synthesis (Scheme 2.18) 
Variation 1 includes the reaction between α-mercaptoaldehyde or an α-mercaptoketone (2b2) with 
a suitable electron-deficient methylene nitrile (2b3) in a protic solvent (DMF, ethanol, or dioxane) 





Variation 2 involves condensation between ketones or aldehydes (2b5) with electron-deficient 
methylene nitrile (2b3), and a sulfur element in polar solvents in the presence of base at varying 
temperatures.249-250 This variation is the most commonly employed strategy to build the desired 
core. 
Variation 3 involves microwave irradiation of 1,4- dithiane-2,5-diol (2b6) with suitable electron-
deficient methylene nitrile (2b7) in polar solvents in the presence of base.251-253 Microwave-
assisted Gewald reaction has also been reported in the presence of solid support (aluminum oxide) 
under solvent-free conditions.252 
This reaction tolerates wide variation on the electron-withdrawing group on the methylene alpha 
to the nitrile.  The main advantage of the Gewald reaction includes tolerance of a diverse range of 
functional groups.254-255 The Gewald reaction has served as a one-pot reaction strategy for the 
synthesis of 2-amino-3-carboxy thiophenes which then can be functionalized to yield a wide 
variety of pharmacologically active small-molecule compounds.  The chief advantages of this 
strategy include the diverse range of starting materials, mild reaction conditions, and ease of 
purification.256 The product is typically quenched into water and then collected by filtration. This 
reaction can be scaled to kilogram quantities with high reproducibility. The high chemical yield 
and accessible synthesis of the Gewald reaction has led to the use of thiophene derivatives in 

















The mechanism of the Gewald reaction has been studied in-depth, and may follow different 
pathways (Scheme 2.19).254, 262 The points of mechanistic uncertainties include the mechanism for 
the addition of sulfur atom(s) and the loss of sulfur as polysulfide species. Regardless, the Gewald 
reaction remains a valuable reliable conversion for preparing 2-amino-3-carboxy thiophenes. 
2.4) N-arylation of the thiophene core 
 
Figure 2.6. General structure of N-arylated 2-amino-3-carboxy thiophene core (2b21). 
 
The next and most critical step was the arylation at the 2-amino position. Traditionally, this 
arylation is achieved through, 1) Gewald method using glacial acetic acid,245-248 2) SNAr 
reactions,263-268 3) Chan-Lam couplings,269-271 and 4) Buchwald-Hartwig couplings.272 
The first reaction is Gewald method,245-248 which uses acid-catalyzed (glacial acetic acid) 
nucleophilic attack with various aniline derivatives (2b23), into the thiophene ring (2b22). The 2-
amino group is expelled as a leaving group (Scheme 2.20). This approach suffers from harsh 






Scheme 2.20. Acid-catalyzed N-arylation. 
 
The second approach exploits nucleophilic aromatic substitution of the aromatic amines (2b22) 
with aryl halides (2b24, Scheme 2.21).263-268 This system uses commercially available inexpensive 
starting materials and is a traditional approach for the N-arylation. This system however requires 
activated substrates and strong reaction conditions. 
 
Scheme 2.21. N-arylation using SNAr chemistry. 
 
Chan-lam couplings are also reported to install the aryl group on the 2-amino thiophenes 
(2b22).269-271 These reactions use mild conditions and uses aryl boronic acids or aryl 
trifluoroborates (2b25) as substrates (instead of aryl halides). Typical features of this chemistry; 
1) uses stoichiometric quantities of Cu(OAc)2 and base; 2) tolerates variety of solvents but DCM 
and DCE are preferred; 3) molecular sieves tends to improve the reaction yields; and 4) yields are 





Scheme 2.22. Chan-Lam couplings for N-arylation. 
 
Recently, Buchwald-Hartwig couplings have been reported for N-arylation of 2-aminothiophenes 
(Scheme 2.23). 272 These couplings use palladium-based catalyst and a ligand. These couplings 
use inexpensive starting materials and are typically high yielding. However, limited substrate 
scope, high reaction temperatures, and inert conditions requirements are a downside. 
 
Scheme 2.23. Buchwald-Hartwig couplings for the N-arylation. 
 
3) Sigma-2 receptor antagonist’s project 
 
Figure 2.7. Structure of 3a1. 
 
The intermediate 3a1 could be synthesized by several methods. 273-293 The first strategy (Scheme 




cyanopropan-2-yl)piperazine-1-carboxylate (3a3, synthesis discussed later) in the presence of 
methylmagnesium bromide to yield the addition product 3a4.  
 
 
Scheme 2.24. Synthesis of intermediate 3a1 involving Sonogashira couplings. 
 
The intermediate 3a4 then can be explored for Sonogashira couplings277-278 followed by palladium-
catalyzed reductions and Boc-deprotection strategy to produce the desired intermediate 3a1. The 
advantages of this scheme include easier availability of the starting materials, strong literature 
precedence, and mild reaction conditions in terms of temperature. A disadvantage associated with 
the scheme is the large number of steps to synthesize an intermediate molecule. 
Another synthetic approach involves the trapping of intermediate 3a3 with substituted phenethyl 
chlorides 3a5274-276, 279-285, 287-291, 293 by Grignard based chemistry to yield the Boc-protected 




intermediate 3a1 (Scheme 2.25). The advantages of this method involve fewer number of steps 
which could increase the overall efficiency of compounds synthesis permitting rapid SAR 
development. The disadvantages involve lesser literature precedence to produce quaternary carbon  
and handling issues associated with Grignard reagent. 
 
Scheme 2.25. Synthesis of intermediate 3a1 involving Grignard based chemistry. 
 
Similarly the desired intermediate 3a1 could also be produced by the initial reaction between 
substituted ethynylbenzene 3a7 and the intermediate 3a3 in the presence of copper catalyst species 
to produce the alkyne 3a8,292 which can be reduced by palladium on carbon reduction followed by 
Boc-deprotection to furnish the desired compound 3a1 (Scheme 2.26). The advantage of this 
method involves that it is tractable and has fewer steps as compared to scheme 2.25. Potential 





Scheme 2.26. Synthesis of intermediate 3a1 involving addition of alkynes. 
 
Another strategy involves using coupling between ketones, amines, and alkynes for the synthesis 
of intermediate 3a1 (Scheme 2.27).273, 290, 293 The reaction works particularly well in the presence 
of copper nanoparticles.273  
 
 





Salient features of the reaction involve: tunable to solvent-free conditions, moderate to excellent 
yields, reusability of the copper catalyst, low catalyst loading (0.5-mol %), and wide substrate 
scope.273 The coupled intermediate 3a8 can then be reduced and Boc-deprotected to produce 3a1. 
The intermediate 3a3 can be synthesized by modified Brulyant’s method (3a3.1, Scheme 2.28)275-
276, 279, 287 having cyanide as the leaving group or by Katritzky method (3a3.2, Scheme 2.29) 280-
285, 289 which has benztriazole as the leaving group. Since cyanide is a highly poisonous material, 
the Brulyant’s method requires special handling requirement and sodium hypochlorite oxidation 
of cyanide to cyanate prior to disposal of the aqueous phase.294 
 
 
Scheme 2.28. Synthesis of 3a3.1 using modified Brulyant’s chemistry. 
 
 
Scheme 2.29. Synthesis of 3a3.2 using modified Katritzky method. 
 
 




Once the intermediate 3a1 is formed, the final step involves N-arylation which can be achieved by 
very common methods; Chan-Lam couplings (Scheme 2.30)270, 295-296 or Buchwald-Hartwig 
couplings (Scheme 2.31)209, 297-299. The advantage of Chan-Lam coupling is that it can be run at 
room temperature whereas Buchwald-Hartwig coupling requires elevated temperature. However, 
the Chan-Lam couplings require stoichiometric amount of copper and the yields are generally 




Scheme 2.30. Chan-Lam coupling for N-arylation. 
 
 







III Statement of the problem 
Cyclophilin inhibitors 
HIV has infected more than 37 million people and has caused approximately 32 million casualties 
worldwide.300 Although antiretroviral therapy (ART) has proven to be successful, drug resistance 
renders the treatment ineffective.301-303 Even after decades of drug discovery efforts, there is no 
sustainable cure for HIV. Therefore, new anti-viral drugs are urgently needed with novel 
mechanism of actions to combat HIV.300 Cyclophilin (Cyp), a peptidyl-prolyl cis-trans isomerase 
has been identified as an attractive target in treating HIV infections.304 It is a host-derived cellular-
factor that catalyzes the cis-trans isomerization of prolyl peptides. Increasing evidence from 
genetic studies, biochemical studies, and clinical trials indicate that cyclophilins are essential 
cofactors that support the replication of HIV-1 and HCV. In the case of HIV-1, CypA regulates 
replication kinetics, infectivity, protects the virus from cellular sensors, and promotes the 
translocation of viral genome into the nucleus of infected cells (Fig. 3.1).24, 304-306  
 
Figure 3.1. Role of cyclophilins in HIV replication.304 
 
Why CypA inhibitors?24, 304, 307-308 




2) CypA inhibition creates a high barrier to resistance (being host targeting antivirals). 
3) When combined with current ART in animal models, CypA inhibitors provide additive 
effects. 
4) CypA inhibitors show no cross-resistance to the current ART drugs in animal models. 
5) CypA expands the list of potential therapeutic strategies. Using hepatitis C virus (HCV) as 
an example, even though there are more than 20 drugs in the clinical testing, drug resistance 
is a known problem with these drugs targeting the virus directly. It is because HCV is an 
RNA virus which is highly prone to mutation, and even a single mutation in the virus may 
render the drug obsolete. Cyclophilin inhibitors have shown promising results in 
preventing the emergence of resistance, and to treat HCV infection both in lab and in 
clinical settings, either alone or in combination.  
While the road to developing host-targeted antivirals is tedious, and there are multiple concerns 
that need to be answered or addressed including potential on-target toxicity, effect of host 
polymorphism, translation of in vitro to in vivo efficacy, and delineating the complex mechanism 
of action, this road has the potential to deliver novel anti-viral drugs which are potentially 
resistance-resistant and can remarkably shorten the duration of anti-viral therapy.24 
Initially developed CypA inhibitors (like CsA, sanglifehrin A, and Debio-025) were large (high 
MW) and had disadvantages like poor oral bioavailability, synthetic challenges, poor permeability, 
risk of drug-drug interactions, and potential off-target side effects.35 Our idea was to develop 
structurally novel, small molecule inhibitors of CypA as potential anti-HIV agents. We initiated 
our efforts by analyzing the x-ray crystal structure of sanglifehrin A bound to CypA (PDB ID: 
1NMK).309 H-bonding interactions between the Gln63 and the carbonyl of the amide, ion-dipole 




between Arg55 and carbonyl of the amide, and H-bond between the backbone NH of the Asn102 
and the carbonyl group of the amide (Fig. 3.2) were identified as critical for binding, in particular, 
the interaction involving Arg55, an essential residue for CypA catalysis. Therefore, the idea was 
to retain these interactions.  
 
 
Figure 3.2. Dock pose of sanglifehrin A (4) in CypA (PDB ID: 1NMK), docking score = -9.90 






Figure 3.3. Small molecule inhibitors of CypA. 
 
Literature analysis revealed that CypA could also be inhibited by small molecules.9, 36-37, 39-40, 310 
Few of these derivatives are shown in Figure 3.3. We chose analog 15 (1a2) based on its reported 
potency. Docking studies revealed that analog 15 (1a2) binds CypA in a similar manner as 
sanglifehrin A (Fig. 3.4) displaying same key interactions. Additionally, 2,6-dichloro group on the 
phenyl ring (of analog 1a2) orients itself perpendicular to the N-acylurea group, potentially 





















Figure 3.4. A) structure of analog 1a2 (15), B) Dock pose of analog 1a2 in CypA (PDB ID: 
1NMK). docking score = -7.73 kcal/mol. Generated using MOE 2016.08. 
 
SAR of the N-acylureas derivative 15a40 reveals that the fluorene ring is essential for the activity.  
Replacement of the fluorene ring with nonplanar rings like indane ring (15b) or the 
diphenylmethine group (15c) completely abolishes CypA inhibition whereas replacement with the 








# Substitution CypA IC50 (nM) 
15a 
 









370 ± 12 
Table 3.1. SAR of analog 15a. 
 
The presence of 2,6-dichloro group as in compound 15 substantially enhances activity when 
compared with a 2,6-difluoro group (15h) or a 2,6-dihydroxy group (15a). Removal of one 
chlorine atom as in analog 15g, reduces the activity by 50-fold whereas removal of both the 
chlorine atoms as in analog 15f renders the compound inactive (Table 3.2). This SAR information 








# R1, R2 CypA IC50 (nM) 
15 (1a2) Cl, Cl 2.59 ± 0.20 
15f H, H inactive 
15g Cl, H 103 ± 5 
15h F, F 263 ± 24 
15a OH, OH 31.6 ± 2.0 
Table 3.2. SAR of N-acylurea analogs. 
 
For the design of novel analogs, we choose a hybrid approach in which we combined the 
components of both the sanglifehrin A and the N-acylurea analog 15, resulting in hybrid analog 
1a44 (Fig. 3.5). To understand the impact of stereochemistry on the bioactivity, we also 
synthesized its enantiomer analog 1a45 (Fig. 3.6).  
One of the key challenges of this project was the synthesis of literature standard 15 (1a2). The 
synthesis of analog 15 (1a2) was essential to confirm the bioactivity of the compound and hence 
the validity of the project. Initial attempts at the synthesis (by using the literature reported method) 
failed multiple times. The difficulties were encountered by other researchers in our group and even 
by other research groups. When the literature protocol was modified, the only compound that was 
isolated was identified to be analog 1a32 (Fig. 3.6). Since this analog was structurally similar to 





Figure 3.5. Approach for the design of small molecule CypA inhibitors. 
 
 
Figure 3.6. Designed analogs for CypA inhibition. 
 
Analog 1a44 shows similar interactions with CypA as sanglifehrin A and N-acylurea analog 1a2 
when docked in the MOE (dock score = -8.52 kcal/mol). Additional interactions include, H-




to the 2,6-dichlorophenyl moiety. The fluorene ring makes contacts with the hydrophobic floor 














Figure 3.7. Dock pose of analog 1a44 in the CypA (PDB ID: 1NMK), docking score = -8.52 
























Cancer is a significant disease resulting in approximately 9.6 million deaths in 2018. Statistically, 
cancer is the second most prevalent cause of death. Alteration of the MAPK cascades contribute 
to cancer cell survival, metastasis, and chemo-resistance.44, 311 The MAPK cascade transduces 
extracellular signals into appropriate intracellular response. The MAPK pathway employs a three-
tiered protein phosphorylation cascade initiated by phosphorylation and activation of an  
MAPKKK. The activated pMAPKKK phosphorylates and activates the second cascade member: 
MAPKK (MEK).  The activated pMAPPKK (pMEK) phosphorylates and activates the third 
cascade member: MAPK (ERK).44 The three-tiered activation cascade for the MEK5/ERK5 
pathway is shown in Figure 3.8. Activated pERK5 undergoes a second autophosphorylation then 
translocate to the nucleus, interacts with transcription proteins, and regulates cell proliferation, 
differentiation, and apoptosis.45 Even though conventional MAPK pathways (MEK1/2) are well-
characterized for cancer biology, MEK5/ERK5 pathway remains understudied due to the lack of 














Figure 3.8. Three-tiered activation cascade for MEK5/ERK5 pathway. 
 
Why selective MEK5 inhibitors44-45, 67 
1) MEK5 is upregulated in a variety of cancers including, TNBCs, prostate cancers, lung 
cancers, multiple myeloma, etc. Additionally, increased concentration of pERK5 is 
observed in 70% human breast cancer cells. 
2) Overexpression of MEK5 and ERKS is correlated with poorer relapse-free survival in 
breast cancers. 
3) Knockdown of the MEK5/ERK5 pathway resulted in a significant reduction in growth and 
metastasis of tumor cells in a in vivo tumor xenograft model. 





5) Selective MEK5 inhibitors can also shed light on how selective MEK5 inhibitors perform 
compared to pan-MEK inhibitors. 
The need for type-III (allosteric) inhibitors76 
1) The ATP site is highly conserved amongst kinases, and thus it is a significant challenge to 
achieve selectivity by targeting the ATP-site. The type III inhibitor sites are highly divergent 
among the different kinases, and therefore offer opportunities for gaining target selectivity.  
2) The ATP site inhibitors compete with millimolar concentrations of ATP within the cell, whereas 
the allosteric inhibitors do not compete with ATP for binding. This theoretically could lead to 
lower doses which would increase the therapeutic index.  
3) A recent study has shown that the combination of ATP-site inhibitors with ATP-noncompetitive 
decreases the likelihood of resistance when compared with the administration of a single 
agent. 
4) Inhibition of a kinase by a type III inhibitor is a proven strategy as exemplified with the 
FDA approval of Trametinib, Cobimetinib, and Binimetinib (Fig. 3.9). All these three 
drugs are type III inhibitors of MEK1/2 pathway.313  
 
Figure 3.9. FDA approved type-III MEK1/2 inhibitors. 
 
Development of diphenylamine analogs as selective type III (allosteric) MEK5 inhibitors 
Our overall goal was to develop selective and potent diphenylamine core based MEK5 inhibitors. 




a homology model. The Uniprot sequence for MEK5 beta isoform (Q13163) was inserted in the 
Swiss-Prot homology model program SwissModel. A homology model of MEK5 was constructed 
based on the x-ray crystal structure of MEK1 (PDB ID: 3EQC) bound to PD325901 (Fig. 3.10).314  
 
Figure 3.10. A) Structure of PD325901, B) ATP and type III binding sites of the MEK1 crystal 
structure (PDB ID: 3EQC) overlaid on a homology model of MEK5.  
 
Analysis of the docking of PD325901 into MEK1 (Fig. 3.11A-B) and MEK5 (Fig. 3.12A-B) 
suggested subtle differences between the two kinases which could be utilized for gaining potency 
and selectivity at MEK5. Briefly, for MEK1 the key interactions involved are halogen bond 
between 4’-iodo atom and a lone pair from the backbone acyl oxygen of Val127, a 
hydrogen/halogen bond between Ser212 and 4-fluoro atom, water mediated H-bonding interaction 
from the NH of the hydroxamic acid to Asp190, and an ion-dipole interaction between the carbonyl 
of the hydroxamic acid and Lys97. Also, there is an intramolecular H-bond between the NH of the 
aniline to the carbonyl group of the hydroxamic acid. In MEK5, the pocket near the 4’-iodo was 
larger and a halogen bond from the 4’-iodo to the backbone amides was prohibitively long. 
Similarly, Ser305 of MEK5 (which maps to Ser212 in MEK1) did not made H-bonding with the 
4-fluoro atom. The carbonyl group of the hydroxamic acid did show likely ion-dipole interactions 




Traditional medicinal chemistry approaches along with computationally suggested differences 
from the homology model assisted analog design (the differences along with the design strategy 
are discussed in detail in the following section). 
 
Figure 3.11. A) Dock pose of PD325901 in MEK1 (PDB ID: 3EQC) generated by MOE 2016. 












Figure 3.12. A) Dock pose of PD325901 in MEK5 (PDB ID: 3EQC) generated by MOE 2016. 
Docking Score = -7.42 kcal/mol. 
 








Prior SAR of the diphenylamine scaffold 
Our prior SAR on the diphenylamine core led to the identification of analog 66a (Fig. 3.13) which 
was less active at MEK1/2 as compared to the PD325901. However, the compound 66a also lost 
potency at MEK5. Other findings from this SAR was that at R1 carboxylic acids and N-




Figure 3.13. Prior SAR of the diphenylamine scaffold in our lab leading to the identification of 
66a. 
The N,N-diphenylamine moiety was selected as the core structure to be elaborated because it exists 
in the PD325901 structure (MEK1/2 inhibitor), provides a rapid synthesis of analogs, and permits 
structural variation at locations that interact with the proposed type III pocket. The sites of 





Figure. 3.14 A) Diphenylamine scaffold for MEK5 inhibition.      
 
Figure. 3.14 B) Rationale for the proposed modifications on the diphenylamine scaffold. 
 
I: Side-chain variations 
The variations in the side chain were conducted to achieve desired pharmacodynamic and 
pharmacokinetic profile. Specifically, providing increased hydrogen bonding on the side chain 
would lower the cLogP as well as offer an opportunity to interact with the more polar lip of the P-
Rationale 
I: Side-chain variations 
       Increase aqueous solubility 
       Examine MEK5 predicted interactions 
       Explore HBD/HBA and anionic variations 
II:  Left side arene variations 
      Establish minimal necessary substitution 
      Predict MEK5 selective interactions  
III:  Right side arene variations 
      Establish minimal necessary substitution 
      Predict MEK5 selective interactions 
IV: R4 variation 




loop. This region is associated with ATP triphosphate transfer and is the location where the 
glycerol portion of PD325901 interacts with MEK1. This region in the MEK5 homology model 
displays a very polar solvent-exposed domain with subtle variations from MEK1/2 offering 
differential affinity for MEK5 versus MEK1 or MEK2. First, although the Asp283 of the MEK5 
is proposed to correlate with Asp 190 of the MEK1, the side chain carboxylates differ by at least 
2 Å in distance from the type III binding site. Second, the C-helices near the ATP binding site are 
non-identical; the MEK5 Tyr315 residue corresponds to the MEK1 Phe223 residue. The prepared 
compounds are presented in Figure 3.15. In analog 2a71, the homology model suggested ion-
dipole interaction between the NH2 group of the amide and the Asp283. The carbonyl group of the 
amide forms ion-dipole interactions with the Lys195 of MEK5 (Fig. 3.16). Analogs 2a72 and 2a73 
were prepared to examine the need and utility of the NH2 group of the primary amide analog 2a71. 
To understand the need and utility of a basic amine group on analog 66a, analog 2a75 was 
prepared. Since prior research in our group already made compounds on the diphenylamine 
scaffold, this dissertation work focuses on design and synthesis of remaining compounds for the 
SAR. The docked pose of analog 2a71 in the MEK5 homology model is depicted in Figure 3.16. 
Key interactions involved ion-dipole interactions between the NH2 of the amide and Asp283, and 
ion-dipole interactions between the carbonyl of the amide and the Lys195. Additionally, the NH 















Figure 3.16. Dock pose of analog 2a71 in MEK5 homology model (PDB ID: 3EQC). Docking 
Score = -7.20 kcal/mol, generated using MOE 2016. 
 
II: Left side arene variations 
Prior literature indicated that the fluorine atoms at position 3 and 4 of the central arene ring, present 
on the lead compound PD325901,314 functioned as more than just simple electron-withdrawing 
groups. In x-ray crystal structure the 4-fluorine atom, forms an electrostatic or hydrogen/halogen 
bond interaction with the Ser212 of the C-helix at MEK1. Although this Ser212 of the MEK1 
(distance = 3.11 Å with 4-fluoro) corresponds to the Ser305 of the MEK5 (distance = 3.48 Å with 
4-fluoro), the homology model revealed no hydrogen/halogen bond interaction between the 
PD325901 ligand and MEK5 (Fig 3.12). With an eye toward eventual replacement of the central 
arene, an initial survey of the requirement and utility of 3,4-difluorine substitution on the central 





Figure 3.17. Designed and synthesized analogs for left-side variations. 
The other analogs (66d) in this series were prepared by other researchers in our group (Fig 3.18). 
The analogs with point variations at the 3-fluoro position and the 4-fluoro position will be pursued 
in future. 
 







III: Right side arene variations 
Terminal arene variations were prepared to survey the need and utility of fluorine and iodine atom 
substitution for MEK5 inhibition. Specifically, the 4′-iodine atom presented multiple sub-ideal 
chemical features: high molecular weight (126 Da), large hydrophobic area, and potential photo-
instability. Despite these disadvantages, the 4′-iodophenyl moiety is present in all the FDA 
approved MEK1/2 inhibitors. Docking of PD325901 in the MEK5 revealed absence of the halogen 
bond potentially due to a larger void in MEK5 near the 4’-iodo pocket (Fig. 3.12). This further 
prompted us to remove the 4’-iodo group. Point variations in Figure 3.19 were examined with the 
dual goal of decreasing MEK1/2 activity and increasing MEK5 activity. The docked pose of analog 
2a98 in MEK5 is depicted in Figure 3.20. The N-methylpiperazine moiety shows ionic 
interactions with Asp283, the carbonyl group attached to the N-methylpiperazine shows ion-dipole 
interactions with the Lys195 with an intra-molecular H-bond from the aniline NH to the acyl 
oxygen. Additionally, the phenyl ring (right side arene) occupies a hydrophobic floor formed by 












Figure 3.20. Dock pose of analog 2a98 in MEK5 (PDB ID: 3EQC). Docking Score = -7.87 
kcal/mol, generated using MOE 2016. 
 
The rationale for the meta-cyano and pyridine derivatives 2a107-108 arises from an exploration 
of the back of the type III binding pocket of the MEK5 homology model. We utilized 
computational program FTMap,315 a fragment mapping algorithm. Significant opportunities were 
identified for interacting with the back pocket of the type III binding pocket.  This is formed by 
the backbone residues where the beginning of C-helix attaches to the back of the type III binding 
site. Uniquely in the MEK5 homology model there is a void located that potentially could be 
accessed by the meta-cyano group of analog 2a107.  Additionally, there was the potential for this 
group to behave as an electrophilic trap of the Cys300 residue.  Unfortunately, this residue is not 
unique to MEK5, but access through this void was uniquely presented in the MEK5 homology 
model. The meta-pyridine analog 2a108 was synthesized since it would improve the water 




IV: R4 variation  
Internal hydrogen bonding from the aniline NH to the carbonyl oxygen lone pair is present in 
PD325901 and generally all the deposited x-ray crystal structures of MEK1/2 inhibitors (type III). 
The same internal H-bonding is found in our MEK5 homology model resulting in a 6-membered 
ring as shown in Figure 3.21. It is unclear if this internal bond from the aniline NH to the acyl 
lone pair is necessary or useful for MEK5 inhibition. The N-methyl N,N-diphenylaniline analogs, 
compounds 2a40, 2a79, 2a110, 2a80, 2a41, and 2a81 as shown in Figure 3.22 are unable to 
participate in internal H-bonding and were prepared to examine the contribution of internal 
hydrogen bonding toward MEK1 and MEK5 activity. Analog 2a71 was our initial best MEK5 
inhibitor (MEK5 inhibition at 10 µM = 59 %), therefore its N-methylated analog 2a79 was 
synthesized. Similarly, analog 66a was our early lead, so we synthesized its N-methylated analog 
2a80. Analog 2a81 was synthesized retrospectively after we identified analog 2a98 as the most 
potent and selective MEK5 inhibitor (MEK5 inhibition at 10 µM = 82.4 % and no MEK1/2 
inhibition). The acids 2a40 and 2a41 were evaluated as they were the synthetic intermediates to 
get to the corresponding amide derivatives and to evaluate whether they also displayed any need 
for intra-molecular H-bonding for MEK5 inhibition. During the synthesis of 2a79 we also isolated 




Figure 3.21. Internal hydrogen bonding results in a more conformationally restricted analog 
(compound 2a71, left); the N-methyl group in compound 2a79 prevents internal hydrogen bonding 
and results in a less conformationally restricted structure. 
 
 







Development of N-arylated 2-amino-3-carboxythiophene analogs as selective type III 
(allosteric) MEK5 inhibitors 
The overall goal of this research was to develop structurally distinct (from diphenylamines), 
potent, and selective MEK5 inhibitors. There were multiple reasons for exploring thiophene 
scaffold for MEK5 inhibition: 
1) The 2-amino-3-carboxythiophene core was present in prior MEK inhibitors (Fig. 3.23).266-
268 We, therefore, envisioned that we could turn these non-selective MEK inhibitors and 
MEK1/2 inhibitors into MEK5 selective inhibitors using our prior SAR knowledge of the 
diphenylamines and medicinal chemistry approaches. 
2) X-ray crystal structure of thiophene and pyrrole based MEK inhibitors were also present 
which would aid in the preparation, validation of MEK5 homology model, and the design 
of analogs.266, 316 
 
Figure 3.23. Literature known pan-MEK and MEK1/2 inhibitors. 
 
3) Thiophene derivatives also bind at the type-III site.266-268  
4) Some of the thiophene analogs were found to be fluorescent.317-319 The idea was that we 





5) It appeared on the paper that the thiophene analogs could be prepared with ease thereby 
allowing extensive SAR (well as you will see in chemical discussion it was hardly true!).  
6) Thiophene derivatives reported in literature as MEK inhibitors were originally derived 
from PI3K/AKT pathway inhibitors. We hypothesized that we could potentially generate 
dual-targeting MEK5 and PI3K inhibitors too from these series. This would be useful since 
it is known that both MEK and PI3K pathway shows crosstalk and simultaneous inhibition 
of both the pathways shows a synergistic reduction in tumor cell viability. 
7) Since both the diphenylamines and thiophene derivatives bind at the type III site this would 
further validate our homology model. 
In the absence of x-ray crystal structure of MEK5 we built its homology model using literature 
known thiophene analog 73 bound to MEK1 (PDB ID: 3SLS).266 We then docked ligand 73 into 
MEK1 (Fig. 3.24A-B) and MEK5 (Fig. 3.25A-B). The model suggested unique residues for 
gaining selectivity and potency at MEK5. The model also suggested potential structural features 
as potential targets for new analog design. The pocket near the 4’-iodo group is larger in MEK5 
and the corresponding valine residue is absent (MEK1 has Val127 residue, the lone pair electrons 
from the backbone carbonyl group of Val127 form a halogen bond with the 4’-iodo atom and is 
proposed as an essential group for MEK1 inhibition). Therefore, the removal of 4’-iodo group 
should retain MEK5 activity while reducing activity at MEK1. Additionally, removal of 4’-iodo 
also reduces MW liability and potential photo instability. Our prior diphenylamine SAR is 
consistent with this observation (removal of 4’-iodo group reduces activity at MEK1 and MEK2 
while retaining or improving activity at MEK5). The molecular modelling also suggests that 
Tyr316 residue in MEK5 could be utilized towards gaining potency and selectivity for MEK5 (it 






Figure 3.24. A) Dock pose of analog 73 in MEK1 (PDB ID: 3SLS). Docking Score = -8.69 






Figure 3.24. B) 2-D ligand interaction plot of analog 73 in MEK1 (PDB ID: 3SLS) generated 







Figure 3.25. A) Dock pose of analog 73 in MEK5 homology model (PDB ID: 3SLS). Docking 






Figure 3.25. B) 2-D ligand interaction plot of analog 73 in MEK5 (PDB ID: 3SLS) generated 
using MOE 2016. 
 
Three series of thiophene derivatives were designed and synthesized towards MEK5 selective 





Figure 3.26. Designed series of thiophene derivatives for MEK5 inhibition. 
R1 variations: For the 7-membered fused thiophene ring analogs at R1 esters (2b77 and 2b78), acid 
(2b79 and 2b80), and N-methylpiperazinamides (2b81 and 2b82) were prepared and biologically 
evaluated (Fig. 3.27). Since the synthesis of primary amides seemed elusive even with different 
methodologies they were not pursued. The homology model suggested both the esters (2b77 and 
2b78) and acid (2b79 and 2b80) derivatives forms H-bonding interactions with Tyr316 residue at 
MEK5. Also, the pocket near R1 contains a Lys195 residue which could form ionic interactions 
(distance approximately 4-4.5 Å) with the carboxylic acid derivatives (2b79 and 2b80) and ion-
dipole interactions (distance approximately 3.8-4.2 Å) with the ester’s derivatives (2b77 and 
2b78). Even though it is very likely that the esters derivatives (2b77 and 2b78) will undergo in 
vivo hydrolysis to the corresponding acids, we still tested both the esters (2b77 and 2b78) and acid 
derivatives (2b79 and 2b80) since we found the ester hydrolysis (chemical) to be slow. The esters 
(2b77 and 2b78) could also serve as the prodrug for the acid analogs thereby increasing their 




because it would improve the water solubility of the analogs. Also, in the emerging diphenylamine 
SAR, N-methylpiperazinamide analogs showed high potency and selectivity at MEK5. Docking 
studies suggests the possibility of an ionic interaction between the basic nitrogen of the N-
methylpiperazinamide (analog 2b82) and the phosphate group (distance 2.84 Å). Finally, the N-
methylpiperazinamides analogs show H-bonding interactions between the carbonyl of the lactam 
and Ser305 which were absent in the esters (2b77 and 2b78) or acid analogs (2b79 and 2b80) in 
MEK5. A docked pose of analog 2b82 is shown Figure 3.28. For the six-membered fused 
thiophene ring analogs only the esters (2b61 and 2b62) were examined  as shown in Figure 3.29 
(since the ester hydrolysis failed and other methods to generate the corresponding acids, amides, 
and N-methyl piperazinamides also failed, we only tested the esters). Molecular docking study also 
suggests that both the 7-membered fused thiophene analogs and 6-membered fused thiophene 
analogs bind in a similar manner at MEK5.  
R2 variations were prepared to survey the need and utility of fluorine atom substitution for MEK5 
inhibition. From the SAR of diphenylamines and the homology model it was clear that the removal 
of 4’-iodo group increases both the selectivity and potency at MEK5. Therefore, we kept the 4’-
position unsubstituted. Ortho-fluoro derivatives were initially prepared due to synthetic curiosity 
and their consistently high docking score (docking score was about -1.2-2.2 kcal/mol higher) when 
compared with the unsubstituted phenyl ring system. Upon testing of the ester analog 2b78 and 
acid analog 2b80 we found that the presence of ortho-fluoro atom enhances both the selectivity 
and potency at MEK5 when contrasted to the corresponding unsubstituted phenyl ester analog 
2b77 or acid analog 2b79 (see chapter VIII), therefore, synthesis of ortho-fluoro derivatives 
became an essential part of our SAR. We hypothesize that presence of fluoro group at the ortho-




a stronger HBD thereby strengthening the intra-molecular H-bond with the carbonyl group. 
Second, the ortho-fluoro group could form an intra-molecular H-bond with the NH group and may 
lock the molecule into bioactive conformation. Third, the ortho-fluoro group may polarize the 
arene facilitating pi-pi interactions. 
At R3 we synthesized analog 2b67-2b68 (Fig. 3.29) to examine the effect of removal of Boc-group 
on MEK5 inhibition. In the homology model of MEK5 for Boc-protected analog 2b61 the nitrogen 
of the carbamate is in close proximity to the Asp200 (distance = 4.12 Å). Therefore, removal of 
the Boc-group may lead to the formation of ionic interactions between the basic amine and the 
Asp200. The removal of Boc-group would also improve the water solubility of the compounds.  
 






Figure 3.28. Dock pose of analog 2b81 in MEK5 homology model (PDB ID: 3SLS). Docking 










The 5-methyl thiophene analogs were initially envisioned as the structurally simplified version of 
seven-membered thiophene ring analogs and six-membered fused thiophene analogs. The 
hypothesis was that 5-methyl thiophene analogs would help us understand the need and utility of 
fused ring for MEK5 inhibition. Additionally, it would give us an idea about the minimum 
structural requirements for MEK5 inhibition which we could use for the design of future analogs. 
However, docking studies on 5-methyl thiophene analogs revealed that they may bind to an 
overlapping yet distinct binding site at MEK5 when compared with the 7-membered and 6-
membered fused thiophene analogs (Fig 3.30). Therefore, the 5-methyl thiophene analogs offers 
an opportunity to explore a novel pocket in MEK5 which may furnish selective MEK5 inhibitors.  
  
Figure 3.30. Overlay of 2b80, 2b62, and 2b49, relative to ATP  in the MEK5 homology model 
(PDB ID: 3SLS). 
In the 5-methyl thiophene ring series at R1, esters (2b39 and 2b41), acid (2b48 and 2b49), primary 
amides (2b51 and 2b56), and N-methylpiperazinamides (2b52 and 2b57) were prepared and 
biologically evaluated (Fig. 3.31). The homology model suggests that the ester analogs 2b39 and 




carboxylic acid derivatives (2b48 and 2b49) shows ionic interactions with the Lys195 and ion-
dipole interactions with the Tyr316. Even though it is very likely that the esters derivatives (2b39 
and 2b41) will undergo in vivo hydrolysis to the corresponding acids (2b48 and 2b49), we still 
tested both the derivatives since we found the ester hydrolysis (chemical) to be slow. The primary 
amides 2b51 and 2b56, were synthesized since they interact with previously unexplored residue 
Asp301. The NH2 group of the amide is involved in ion-diploe interactions with the Asp301 and 
carbonyl group of the amide show H-bonding interactions with the Tyr316. Since these residues 
are unique to the MEK5 it may lead to higher selectivity and potency at MEK5. The N-
methylpiperazinamides derivatives 2b52 and 2b57 were synthesized because 1) the N-
methylpiperazinamides in diphenylamine series showed the best MEK5 inhibitory profile, 2) the 
presence of a basic group would improve the water solubility of these hydrophobic analogs, and 
3) the N-methylpiperazine ring shows ionic interactions with the Asp283 residue at MEK5. To 
keep consistency similar variations at R2 were explored (phenyl and the ortho-fluoro phenyl ring).. 
The docked pose of the highest scoring analog 2b49 in MEK5 is shown in Figure 3.32. Key 
interactions include, the 5-methyl group occupies a hydrophobic cavity formed by Ile239, Ile197, 
Leu213, Leu199, and Leu308. The carboxylic acid participates in ionic interactions with the 




Figure 3.31. Designed and prepared 5-methyl thiophene derivatives. 
 
Figure 3.32. Dock pose of analog 2b49 in MEK5 homology model (PDB ID: 3SLS). Docking 







Sigma-2 receptor antagonists 
Alzheimer’s disease (AD) is a progressive brain disorder that affects memory, problem-solving 
skills, and the ability to think and carry out even the simplest tasks.320 AD is characterized by the 
build-up of amyloid plaques, accumulation of neurofibrillary tangles, inflammation of the neurons, 
and neuronal loss.144-145 Even after arduous drug-discovery efforts, no new medications has been 
approved within the last decade that can cure the disease.320 AD remains the sixth leading cause 
of death in the US, and is ranked as third leading cause of deaths in older patients.142 There are 
only five drugs that are approved for treating AD, however these drugs provide brief symptomatic 
relief; thus there is an urgent need to develop drugs that can treat AD.321 
Recent studies suggest that sigma-2 receptor is an attractive target for the development of novel 
disease-modifying AD drugs.137-138, 153 
Why Sigma-2 receptors? 
1) Sigma-2 receptors are highly expressed in the cortex and hippocampus region of the brain 
(two areas which are vital to the cognitive functions) and it maintains calcium homeostasis  
(calcium ion homeostasis disruption has been proposed as neurotoxic).137-138, 148 
2) Sigma-2 receptors have been implicated in variety of CNS diseases including 
mitochondrial and neuronal protection.149-150 
3) Sigma-2 density remains the same in the AD patients when compared with the normal 
individual of the same age group. This suggests that sigma-2 receptor may be upregulated 
in AD.137-138 
4) The knockdown of sigma-2 receptors decreases the binding of the Abeta oligomers to the 
neurons. Also, the treatment of the neurons with Abeta oligomers leads to an increase in 




prevents the Abeta mediated synaptotoxicity in vitro in a dose-dependent manner. 
Furthermore, blocking sigma-2 receptors improves the cognitive functions in the mouse 
models.137-138 
Through high-throughput screening, Cognition Therapeutics identified analog CT0109 as a potent 
sigma-2 receptor antagonist.138 The objective of our project is to design and synthesize 
metabolically stable, orally efficacious, potent analogs related to CT0109 (Fig. 3.33). Though this 
molecule showed good brain permeability and efficacy in the mouse model, it suffers from 
metabolic instability (t1/2 = 16 min). This instability has been proposed to be due to the free 
phenolic OH group and the aromatic methyl ether group. Earlier efforts to mitigate the metabolic 
instability resulted in analog 80 and 81.138 These analogs improved the metabolic profile (t1/2 = 33 
min for 80, 27 min for 81), but suffered from unacceptable hERG inhibition (IC50 = 4.4 μM).  
 
Figure 3.33. Structure of CT0109 (59), CT1344 (80), and CT1346 (81). 
 
To address these shortcomings, an isoindoline based series was designed and evaluated as sigma-
2 receptor antagonist (Fig. 3.34).322-323 The molecules from this series showed favorable hERG 





Figure 3.34. General structure for the isoindoline based sigma-2 antagonists. 
The structural layout of CT0109 and isoindoline based sigma-2 antagonists is presented in Figure 
3.35. 
 
Figure 3.35. Structural layout of the sigma-2 receptor antagonists based on CT0109 and 
isoindoline derivatives. 
Since the structural information about the sigma-2 receptor, its binding pocket, and its natural 
ligand is unknown, the SAR of the sigma-2 ligands has been largely based on analog based drug 
design or pharmacophoric models. Briefly, the pharmacophore consists (Fig. 3.36) of two 
hydrophobic sites separated by a basic amine linker. Hydrophobic group 1 is located at about 3-5 
carbon length (4 is generally optimal) whereas the hydrophobic group 2 is located about 2-4 carbon 
length chain from the basic amine. The basic amine group is proposed to participate in ionic 
interactions with the anionic residue present in the sigma-2 receptor (most likely aspartic acid).121 
Additionally, it has been suggested that HBA acceptors (two) on the hydrophobic groups tends to 





Figure 3.36. Proposed pharmacophore for sigma-2 ligands. 
 
Based on the pharmacophore model and prior SAR at sigma-2 receptor (performed by Cognition 
Therapeutics and other researchers) we designed structural template 84 (Fig. 3.37) for sigma-2 
receptor antagonism. To identify structurally distinct backups to the Cognition Therapeutics 
clinical candidate in the event said candidate fails to advance to the clinic we chose the piperazine 
moiety since it has been extensively studied for sigma-2 receptor ligands, it enable easier access 
to arene 2 variations, and is CNS penetrable.324 The gem-dimethyl group was chosen over the plain 
methyl substitution since it will avoid chiral center. 
 
Figure 3.37. Designed template for the sigma-2 receptor project. 
To deliver the required compounds within the limited scope, funding, and time of the STTR 
funding mechanism, a single arene 1 variation was selected with a late branching synthesis of 






Figure 3.38. Designed scaffold for the SAR studies. 
The 4-fluoro arene 85 was selected for the following reasons.  The 4-fluoro analog displayed good 
activity in the CT0109 series.  A 4-fluoro group prevents P450-mediated oxidation which typically 
occurs at the most electron rich CH bond; in the case of a phenethyl arene, this would be the 4-
postion of the arene.   The fluorine atom weighs 19 amu while the trifluoromethyl group weighs 
69 amu; the lower weight substituent permits remote compound elaboration while reducing 
compound molecular weight; keeping the MW lower (ideally below 500 amu) is a necessary 
strategy for successful CNS penetration.  The best right hand arene variations will be coupled to 
the trifluoromethyl variation of arene 1 with other Topliss variants in subsequent studies. The 
safety and selectivity data on select compounds will provide us with an early determination on the 
extent of further optimization that may be required to furnish clinical candidates. The desired 











Criteria Target Value 
Aβ-trafficking assay EC50 < 1 μM 
Receptor affinity Sigma-2 < 100 nM 
Selectivity Sigma-1/Sigma-2 > 10 
hERG IC50 > 10 μM 
Bioavailability % F > 30% 
Clearance < 14 μL/min 
Table 3.3. Target criteria for achieving candidate milestones. 
In the CT01019 SAR simple aryl ring substitution at arene 2 have generated potent and selective 
compounds for the sigma-2 receptor. Therefore, the analog 3a40 was synthesized. Prior SAR of 
the isoindoline series of compounds at Cognition Therapeutics analogs revealed that the presence 
of meta-substituents improves the potency at sigma-2 and in the membrane trafficking assay (by 
5-10 folds as compared to the unsubstituted ones, Fig. 3.39).322-323 Therefore, analogs 3a41, 3a44, 
and 3a45 were synthesized. Additionally, these analogs would probe the effect of electron 
withdrawing group vs electron donating group towards sigma-2 receptor antagonism.  
 
Figure 3.39. Prior SAR of isoindoline series of compounds. 
 
The benzo[1,3]dioxole ring and the 3,4-dimethoxyphenyl ring is present in variety of sigma-2 




selectivity at the sigma-2 receptor. Therefore, analogs 3a42 and 3a43 were synthesized. Analogs 
3a44 and 3a46 would examine the need and utility of meta-methoxy and para-methoxy group. 
The esters 3a47-3a48 would be hydrolyzed in vivo and could make ionic interactions with the 
sigma-2 receptor. Since carboxylic acids have not been studied for sigma-2 receptor it may help 
in understanding the binding pocket. Also, the carboxylic acids could be used as a precursor for 
the synthesis of amides and other moieties.   
Berardi et al. in their SAR of the piperazine based molecules found that addition of a carbonyl 
group between the piperazine ring and the cycloalkyl ring leads to increased selectivity towards 
sigma-2 receptor (20-500 fold improvement by decreasing affinity at the sigma-1 receptor, Fig. 
3.40).130  
 
Figure 3.40. Effect of the addition of carbonyl group towards sigma-2 selectivity. 
Furthermore Stavitskaya et al. probed the effect of 2-, 3-, and 4-pyridyl groups attached to the 
piperazine ring and found that all were well tolerated at sigma-2 receptors (Fig. 3.41) with 2-
pyridyl derivative displaying highest affinity for sigma-2 receptor.326 SAR of the Cognition 
Therapeutics compounds also suggests that the incorporation of an heterocyclic ring (for example 
2-pyridyl) improves affinity at the sigma-2 receptors (5 to 10-fold) when compared with the phenyl 
ring.322-323, 327 Our hypothesis was that the addition of electron withdrawing groups to the 
piperazine ring would not only increase the affinity of the ligands to the sigma-2 receptor, but 




We, therefore, designed and synthesized analog 3a54-3a58. The synthesized analogs are shown in 
Figure 3.42. 
 
Figure 3.41. Effect of the pyridine nitrogen on sigma-2 affinity. 
 





IV Chemical Discussion 
Cyclophilin A inhibitors 
 
Compound 1a2 was reported be 2.59 nM inhibitor (IC50) of cyclophilin A. To confirm the activity 
of the lead its re-synthesis was required. We followed the reported literature protocol (Scheme 
4.1)40 in which the 9-aminofluorene hydrochloride (1a24) was reacted with triphosgene in the 
presence of triethylamine to produce carbamoyl chloride intermediate 1a25 which was then 
refluxed to furnish isocyanate 1a26. The isocyanate was refluxed with 2,6-dichlorobenzamide 
(1a27) to yield the desired compound 1a2. However, even after multiple attempts, this reaction 
failed to produce the desired compound 1a2. With the help of IR spectroscopy, we confirmed the 
formation of carbamoyl chloride (1/λ = 1748 cm-1) and isocyanate (1/λ = 2250 cm-1) intermediate. 
 





There was a complication at the final reaction between isocyanate 1a26 and 2,6-
dichlorobenzamide (1a27). Varying temperature, solvent, and base (Table. 4.1) did not produce 
the anticipated final compound. 
# Base Temperature Yield 
1 TEA 110 oC 0 % 
2 No base Reflux 0 % 
3 TEA 200 oC 0 % 
4 TEA 100 oC 0 % 
5 TEA 90 oC 0 % 
6 TEA 80 oC 0 % 
7 NaOH Reflux 0 % 
8 DIPEA Reflux 0 % 
Table 4.1. Variations tried for the synthesis of 1a2. 
 
Our next hypothesis was that since 2,6-dichlorobenzamide (1a27) is a weak nucleophile it may be 
unable to react with the isocyanate intermediate 1a26. To test that hypothesis, we converted the 
2,6-dichlorobenzamide (1a27) to its corresponding potassium salt (1a28, a much stronger 
nucleophile) by treating it with KHMDS (Potassium hexamethyldisilazide) and react it with the 





Scheme 4.2. Modified route for the synthesis of 1a2. 
 
The literature protocol did not yield the stated product as written.  We focused our attention on a 
new route159 (Scheme 4.3) with conversion of the 2,6-dichlorobenzamide (1a27) to the 2,6-
dichlorobenzoyl isocyanate (1a30, acyl isocyanate) using oxalyl chloride (1a29) and the 9-
aminofluorene (1a31). The advantage of this route was that both the electrophile (acyl isocyanate) 
and nucleophile (9-aminofluorene) were stronger providing a more likely generation of the desired 
product. Gratifyingly, the reaction worked, isolation of the desired compound 1a2 was achieved. 
Isolated yields were unsatisfactory (3%) with compound 1a32 as the impurity (7%). Another 
complication was the difficulty of separating compounds 1a2 and 1a32 using column 






Scheme 4.3. New route (reaction of acyl isocyanate with an amine) for the synthesis of 1a2. 
 
Solvent substitution was explored; replacing the DCM with the DCE in the first step of acyl 
isocyanate formation and using 1,4-dioxane in the second step, permitted successful synthesis of 
compound 1a2 in moderate yield (Scheme 4.4. 67%). The reaction did not produce any side 
product 1a32. The exact reason for the increase in yields by changing the solvents is unclear. DCE 
has a higher boiling point compared to DCM (83.4 vs 39.6 oC); it is likely that the first reaction 
requires higher temperature for the efficient formation of the acyl isocyanate 1a30. In the final 
step it is likely that 1,4-dioxane solvates the transition state better than THF. Such solvation effects 





Scheme 4.4. Modified route (reaction of acyl isocyanate with an amine) for the synthesis of 1a2. 
 
Since compound 1a32 was isolated as a side product and its structure bears resemblance to 
compound 1a2, it was tested in the cyclophilin A assay. A de novo synthesis was undertaken to 
prove identity of 1a2. 9-Aminofluorene hydrochloride (1a24) was reacted with ethyl 2-chloro-2-
oxoacetate (1a33) under Schotten-Baumann conditions to furnish ethyl 2-((9H-fluoren-9-
yl)amino)-2-oxoacetate (1a34) in quantitative yield. This ester (1a34) was hydrolyzed to the 
corresponding acid (1a35) using LiOH monohydrate. The acid 1a35 was reacted with oxalyl 
chloride in the presence of cat. DMF to yield the acyl chloride 1a36 which was then reacted with 
the potassium salt of 2,6-dichlorobenzamide (1a28) to produce the final compound 1a32 in 





Scheme 4.5. De novo synthesis of compound 1a32. 
 
For the synthesis of α-acylamino carboxamide derivatives 1a44 and 1a45 Scheme 4.6 was 
followed. Commercially available Boc-protected amino acids 1a37 or 1a38 were coupled with 9-
aminofluorene hydrochloride (1a24) to furnish intermediates 1a39 or 1a40. The Boc-group was 
deprotected using 40% TFA/DCM. Finally, the free amine 1a41 or 1a42 was acylated using 
commercially available 2,6-dichlorobenzoyl chloride (1a43) to manufacture the final compounds 











The synthesis of acids 2a37-2a42 utilized a procedure based on the method of Davis et al.224 In 
this procedure, 2,3,4-trifluorobenzoic acid (2a30) was reacted with a suitable aryl amine (2a31-
2a36) in the presence of LiNH2 to produce anthranilic acid derivatives 2a37-2a42 (Scheme 4.7). 
Substitution occurred exclusively at the ortho-position as indicated in scheme 4.7 and as reported 
in the literature. 224 The compounds prepared along with relevant reactions details appear in Table 
4.2. Regioselectivity can be explained by 1) coordination of lithium-ion with the carboxyl group 
and the fluoro atom (leaving group) facilitating the elimination reaction329 and/or 2) coordination 
of the lithium carboxylate with the incoming aryl amid (nucleophile), promoting substitution 





Scheme 4.7. Synthesis of anthranilic acid derivatives (diphenylamines) via LiNH2 method (SNAr 
chemistry). 
 














































LiNH2, 58 oC 
48h 
54% 
Table 4.2. Synthetic details of anthranilic acid derivatives (diphenylamines) prepared by the 
LiNH2 method. 
 
Furthermore, to support this hypothesis, Davis et al. conducted an experiment in which 4-
fluorobenzoic acid (2a43)  was reacted with N-methylaniline in the presence of LiNH2 and in this 
case no product was formed, whereas when 2-fluorobenzoic acid (2a44) was used as a substrate 






Scheme 4.8. Comparison of reactivities between 2-fluorobenzoic acid and 4-fluorobenzoic acid 
with LiNH2.224 
 
Another important aspect of this methodology was the choice of ion. When LiNH2 was used as a 
base, the reaction predominantly furnished the ortho-product. In contrast, when NaNH2 was used, 
a mixture of ortho/para product (Scheme 4.9) resulted. We hypothesized that the lithium ion has 
four empty orbitals and high polarizability to efficiently coordinate with both the carboxylate and 





Scheme 4.9. Comparison of regioselectivities between LiNH2 and NaNH2. 
 
Initial attempts for the synthesis of unhalogenated diphenylamine derivatives 2a51 and 2a52 by 
the SNAr chemistry using NaH or LiNH2 as base were unsuccessful (Scheme 4.10) 
 





One possible explanation is the absence of fluoro atoms at position 3- and 4- of benzoic acid. These 
fluorine atoms may polarize the aromatic ring for efficient SNAr reaction with the anilide ion. 
Another explanation is that the rate of SNAr reaction decreases from F>>Cl>Br>I, therefore iodine 
may not be well suited for SNAr chemistry.  
Thus, a new strategy was required for the synthesis of derivatives 2a53-54. As mentioned in 
chemical literature review, several strategies were considered and ultimately based on the literature 
precedence, scope, and easy availability of starting materials Ullmann coupling strategy was 
selected (Scheme 4.11).  
 
Scheme 4.11. General scheme for the synthesis of diphenylamines by Ullmann Coupling. 
 
Varying temperature, base, and solvents further optimized the reaction.331-335  Optimized 
conditions are shown in Scheme 4.12. Yield and compound structures prepared by Ullmann 
coupling are listed in Table 4.3. Microwave heating led to improved yields when compared to 
conventional benchtop heating strategies. 
 



















2 h, 100 oC 
Microwave 
69% 
Table 4.3. Synthetic details of derivatives 2a51-52 by Ullmann couplings. 
 
The next and final step was to convert the carboxylic acids to the desired amides. Several strategies 
were envisioned as illustrated in the chemical literature review. Conversion of the acid (2a37, 
2a40-41, 2a51-52) to the corresponding acyl chloride (2a60-64) followed by reaction with a 
suitable amine (2a65-70) furnished the desired products (2a71-81, Scheme 4.13).  
 





Oxalyl chloride with catalytic DMF was used a chlorinating agent. The overall mechanism 
proceeds via the formation of the imidoyl chloride derivative (2a86, Me2N=CHCl+), which acts as 
the active chlorinating agent (Scheme 4.14). This step is analogous to the first step of Vilsmeier-
Haack reaction. The reaction is usually diffusion-limited, occurs at low temperatures, and with 
easily removable side-products.  
 
Scheme 4.14. Mechanism of acyl chloride formation by oxalyl chloride. 
 
Compounds 2a71-81 were synthesized according to this method; the synthetic details are 





































































































































Table 4.4. Synthetic details of amide derivatives 2a71-2a81 by the oxalyl chloride method. 
 
The assumption that all amides desired could be formed by the acyl chloride method was false; 





Scheme 4.15. Unsuccessful synthesis of the amides 2a94, 2a97-2a98 by the oxalyl chloride 
method. 
 
During the synthesis of compounds 2a94, starting material was consumed but desired compound 
was not seen. For compounds 2a97and 2a98, the TLC indicated multiple spots with similar Rf 
values.  Therefore, product isolation was complicated.  
Peptide coupling reagents were explored to synthesize the desired compounds. DCC and DIC 
couplings  were examined for the synthesis of 2a94; both reagents led to the side product urea 





Scheme 4.16. Attempted synthesis of 2a94 by DCC and DIC couplings. 
 
Since the DIC and DCC couplings produced the desired compounds, a coupling reagent whose 
urea by product is much more water soluble was explored: EDC (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide). The urea by-product of EDC is more water soluble 
compared to DCC and DIC by-product ureas and should easily separate from desired compound.   
The EDC method was successfully employed for the synthesis of 2a94, 2a97, and 2a98 (Scheme 
4.17). The specific details are listed in table 4.5. For the synthesis 2a94, addition of HONB was 








Scheme 4.17. Synthesis of amide derivatives (2a94, 2a97-98) by EDC couplings. 
 






























Table 4.5. Synthetic details of amide derivatives (2a94, 2a97-98) by EDC couplings. 
 
Even though, EDC couplings were successful, the yields were moderate to low. To further 
streamline the synthesis of desired amide compounds we envisioned a single step synthesis in 
which the amide starting material was reacted with the aryl amine using LiNH2 as the base (SNAr 




single step (Scheme 4.18). Details for the starting materials, conditions, and yields are presented 
in Table 4.6.  
 





















































Table 4.6. Synthetic details of analogs 2a106-109. 
 
Although the yields were moderate with this methodology (29-55%), they were still better than 
the yield from the EDC couplings and reduced the number of steps permitting synthesis of a large 
number of compounds efficiently. 
Thiophene derivatives 
Three series of thiophene derivatives were considered for MEK5 inhibition (Scheme 4.19). The 
proposed synthesis involved Gewald reaction for the construction of 2-amino-3-carboxythiophene 
core 2b32, which could then be N-arylated to produce intermediate 2b34. Ester hydrolysis 






Scheme 4.19. Designed thiophene series for MEK5 inhibition. 
 
 
Scheme 4.20. Proposed synthesis for the thiophene derivatives. 
 
Optimization of the N-arylation was not well precedented on the 2-amino-3-carboxythiophene 
scaffold for the desired 5-methylthiophene ring analogs.  A series of reactions (Scheme 4.21) were 




2b37 was reacted with the aniline in the presence of glacial acetic acid under refluxing conditions. 
This method failed to furnish the desired compound 2b39. Instead partially degraded starting 
material was isolated. The next strategy involved SNAr chemistry266-268 with the 2-amino group of 
intermediate 2b37 attacking the electrophilic aryl halide 2b40 or 2b42 to form desired compound 
2b41. However, this chemistry did not produce the desired product and starting material 2b37 was 
recovered. Possible explanations include that the 2-amino anion charge may be delocalized over 
the thiophene ring with the ester group making it less nucleophilic and less prone to attack the aryl 
halide. The next attempt was a Chan-Lam coupling;271 met with limited success. this approach met 
with limited success. The coupling worked for the installation of the phenyl ring on intermediate 
2b37 producing the desired analog 2b39, but it failed to install the 2-fluoro phenyl ring and analog 
2b41 could not be generated by Chan-Lam coupling. Alteration in the reaction conditions 
including change of solvent, change in concentration, increase in the temperature, and change in 
the reagent equivalents did not yield the desired analog 2b41. It was proposed that electrons from 
















Scheme 4.21. Optimization of N-arylation. 
 
Buchwald-Hartwig couplings272 were examined and proved to be successful for the installation of 
phenyl group in low yields; these conditions were unsuccessful for attachment of the 2-fluoro 
phenyl ring. Ullmann couplings were examined next. Even though Ullmann couplings are not 
precedented for N-arylation of 2-aminothiophenes they were attempted based on prior experience 
and inability to synthesize analog 2b41: none of the tried method produced 2b41. Ullmann 





Scheme 4.22. Optimization of the Ullmann couplings for N-arylation. 
 









1 K2CO3 DMF 120 μW 5 Air 3% 
2 K2CO3 DMF/Water 
(9/1) 
120 μW 5 Air 7% 
3 CsCO3 DMF/Water 
(9/1) 
120 μW 5 Air 6% 
4 K2CO3 DMF/Water 
(9/1) 
110 μW 5 Air 1% 
5 K2CO3 DMF/Water 
(9/1) 
130 μW 5 Air 4% 
6 K2CO3 DMF/Water 
(9/1) 
120 μW 5 inert 56% 
7 K2CO3 DMF/Water 
(9/1) 
120 Bench-top 24 inert 57% 
Table 4.7. Optimization of reaction conditions for the Ullmann couplings. 
However, yields were unsatisfactory and required optimization (Scheme 4.22). Best conditions 
following optimization are presented in Table 4.7 (entry 6 and 7). The optimized method worked 
similarly well under the microwave heating or benchtop heating. Longer times were needed for 
bench-top Ullmann coupling. The Ullmann coupling was successfully scaled to 4 gm scale. 
The optimized Ullmann coupling method was employed for the synthesis of analogs 2b39 and 




























Table 4.8. Synthetic details of analogs 2b39 and 2b41. 
 
The next step in the sequence was the ester hydrolysis which was successfully performed by 




conditions.267-268 The method was used for the synthesis of compounds 2b48-49 (Scheme 4.24). 
Details of the synthesis along with the compounds prepared are presented in Table 4.9. 
 
 
Scheme 4.24. Synthesis of 2b48-49. 
 













Table 4.9. Synthetic details for analogs 2b48-49. 
 
Synthesis of the amides was attempted by converting the acid 2b48 to the corresponding acyl 
chloride 2b49 then treating it with a suitable amine. However, this method failed to furnish the 
desired compounds 2b51-52. In the case of compound 2b51 the reaction did not finish even after 




starting material was consumed within 12 hours. However, the reaction produced a complex 
mixture which was difficult to purify by column chromatography (Scheme 4.25). 
 
 
Scheme 4.25. Attempted synthesis of 2b51-52. 
 
Modification of this process with diluted acyl chlorides (2b50, 2b53) added to the solution of 





Scheme 4.26. Synthesis of analogs 2b51-52, and 2b56-57. 
 
It was hypothesized that the addition of the electrophile (acyl chloride) to the solution of 
nucleophile (amine) encountered an excess of nucleophile preventing side reactions including self-
condensations. Analogs 2b51-52, 2b56-57 were prepared using this method (Table 4.10).  
















































Table 4.10. Synthetic details for derivatives 2b51-52, 2b56-57. 
 
For the 6-membered fused thiophene ring system, a Gewald condensation produced the desired 2-
amino-3-carboxy-thiophene core 2b60 without the need for further purification;337 this core was 
then N-arylated using our previously optimized Ullmann coupling method (Scheme 4.27) to 





























The next step was the ester hydrolysis to furnish the desired acid derivatives (Scheme 4.28). We 
initially used 2 M LiOH in THF/water (4/1) for the ester hydrolysis.267 However, even after 
multiple trials this reaction failed. Increasing the molarity of LiOH was not successful, changing 
the solvent from THF to dioxane did not work, and increasing the reaction temperature or time 
were also found to be unsuccessful. In all cases starting material was retrieved. The next approach 
was to increase the aggressiveness of the base by using 2 M NaOH338 or 2M KOH.339 However, 
this also proved to be unsuccessful and degraded the starting material into multiple uncharacterized 
products without generating the desired acid. The last resort was to use 5% alcoholic KOH.  This 
also did not produce the desired product; only degradation of the starting material was seen. 
Possible explanations of the unsuccessful ester hydrolysis include; 1) The presence of intra -
molecular H-bond between the oxygen of the ester group with the 2-amino hydrogen atom partially 
blocking access of the base to the carbonyl group, 2)  A steric block provided by the N-aryl 
substituent hindering access of the base to the electrophilic carbonyl group, and 3) Electron-





Scheme 4.28. Attempted synthesis of analog 2b63 by ester hydrolysis. 
 
Because ester hydrolysis was found to be difficult, synthesis of the acid by different approach was 
explored (Scheme 4.29). A first approach used ester hydrolysis of intermediate 2b60 followed by 
N-arylation using the Ullmann couplings to prepare 2b63. However, this reaction sequence yielded 






Scheme 4.29. Alternative route for the attempted synthesis of analog 2b63. 
 
The next approach was to replace the ethyl ester with the t-butyl ester. The rationale was a t-butyl 
ester was acid labile and there was literature precedence for selective t-butyl ester cleavage in the 
presence of N-Boc group.340 A Gewald condensation provided intermediate 2b65 which upon N-
arylation furnished 2b66. However, upon treatment with CeCl3 in the presence of NaI deprotection 
of both the t-butyl ester and the N-Boc group was observed. The synthesis of acid derivatives 2b63 
was not pursued further. 
Boc-deprotected derivatives 2b67-2b68 can be generated by either 4M HCl/dioxane or by 






Scheme 4.30. Synthesis of analogs 2b67-68. 
 
In order to generate the amides our initial strategy was to use the Gewald intermediate 2b70 and 
then conduct the N-arylation at the 2-amino group (Scheme 4.31). However, even after trying 
various coupling strategies the desired compounds were still refractory to synthetic approaches 
examined. Ullmann coupling and Buchwald-Hartwig couplings led to poly-arylated derivatives, 
whereas conversion of 2-amino group to the 2-iodo or 2-boronic acid derivatives led to the 
generation of complex mixtures from which the desired compound could not be isolated. 
 
Scheme 4.31. Attempted synthesis of analog 2b71. 
 
The seven-membered fused thiophene ring analogs synthesis began with a Beckmann 




then subjected to Gewald reaction to form the 2-amino-3-carboxy intermediate 2b76266-268 which 
was N-arylated using the Ullmann coupling to produce derivatives 2b77-78 (Scheme 4.32). The 
derivatives prepared and the synthetic details are presented in table 4.12. 
 
Scheme 4.32. Synthesis of analogs 2b77-78. 
 


















Table 4.12. Synthetic details for analogs 2b77-78. 
 
The next step in the synthesis was the ester hydrolysis to yield acids 2b79-80. The hydrolysis was 
successfully conducted with LiOH under refluxing conditions266-268 (Scheme 4.33) and the specific 
compounds prepared are summarized in Table 4.13. 
 
Scheme 4.33. Synthesis of derivatives 2b79-80. 
 
















Table 4.13. Synthetic details for analogs 2b79-80. 
 
The next step was the conversion of the acids (2b79-80) to the N-methylpiprazinamides analogs 
2b81-82. This was done using HATU couplings341 in the presence of DIPEA at room temperature 
in 38-55% yields (Scheme 4.34 and Table 4.14) 
 
 
Scheme 4.34. Synthesis of analogs 2b81-82. 
 




























Table 4.14. Synthetic details of analogs 2b81-82. 
 
For the synthesis of primary amide 2b84, various protocols were tried without any success 
(Scheme 4.35). The first trial was with oxalyl chloride336 where starting material was recovered. 
Use of coupling reagents (EDC)341 was unfruitful; the reaction produced only trace amount of 
desired compounds not enough for full characterization. The last strategy employed conversion of 
the acid derivative to the corresponding pentafluoro esters derivative267 which was reacted with 








Scheme 4.35. Attempted synthesis of analog 2b84. 
Sigma-2 receptor antagonist’s  
 
Figure 4.1. Structure of 3a10. 
 
Several synthetic schemes were originally envisioned for the synthesis of the intermediate (3a10). 
273-293 Four potential routes were identified including Katritzky benzotriazole trapping of an 
iminium,280-285 a Brulyants trapping of an iminium, 275-276, 279, 287 sequential addition of two methyl 
groups into an amide, and rearrangements to the gem-dimethyl group.  The first two strategies had 
the best-precedent and viewed as the most efficient strategies; both were explored simultaneously.  
All attempts at the Katritzky benztriazole reactions failed in our hands.  Although the initial 
benztriazole adduct 3a14 was formed, conversion to the desired quaternary compound 3a10 was 





Scheme 4.36. Attempted synthesis of 3a10 by the Katritzky method. 
 
Brulyants conversion as shown in Scheme 4.37, provided a reliable pathway to the desired gem-
dimethyl quaternary compound 3a17.  Synthesis of the cyano-adduct 3a17 appeared in the 
literature shortly after we started working on the project279 (impeccable timing!).  Although this 
conversion was presented in the literature at a sub-gram scale, the use of concentration-induced 
precipitation of the product enabled reaction scaled up even at 40-gram scale with 83% yield.  
 
Scheme 4.37. Synthesis of 3a17. 
 
Initial attempts to generate intermediate 3a10 by the addition of the intermediate 3a18 to the 
cyano-adduct 3a17 in the presence of magnesium failed repeatedly (Scheme 4.38). Our 
investigation revealed that we were unable to form the Grignard of 2-(4-fluorophenyl)ethyl 
bromide/chloride.  Although metallic magnesium was consumed by the alkyl halide 3a18, the 




the dimer 3a20 obtained in near quantitate yield.  This product could have formed by either a 
Wurtz-type coupling (pathway A, Scheme 4.39) or by Grignard  formation then subsequent 
nucleophilic attack into the alkyl halide (pathway B, Scheme 4.39).  
 
Scheme 4.38. Attempted synthesis of intermediate 3a10 by Grignard addition. 
 
Strategies employed to suppress dimer formation included; a) using refluxing Et2O, b) using THF 
at room temperature, c) scrupulous elimination of oxygen with fresh distillation of Et2O from 
  





metallic sodium, d) use of excess Mg, and e) first order addition of halide as a dilute solution. In 
all cases, the magnesium was consumed, but in a sub-stoichiometric manner, and yielded a gray-
green solution consistent with the formation of a Grignard reagent.  Titration of the organometallic 
solution did not indicate any Mg(OH)2 -yielding organo base.  This is consistent with the Grignard 
being formed and then self-quenching with the precursor alkyl chloride.  The rigorous exclusion 
of oxygen and the first order exotherm with the addition of the chloride is consistent with Grignard 
formation, followed by internal quench by starting material as indicated in pathway B. This 
strategy was abandoned for the synthesis of compound 3a10. 
About this time alkyne intermediate 3a21 became available at commercially viable price making 
this route the greatly preferred route and therefore attention was focused on the efficient 
condensation between the intermediate 3a21 and 3a17 to produce alkyne 3a22.  A parallel run of 
the magnesio- (method 1, Scheme 4.40.), lithium- (method 2, Scheme 4.40.), copper (method 3, 
Scheme 4.40.) addition into 3a21 was conducted. We focused our attention on method 1 
optimization since it showed highest yield based on the TLC analysis. For the optimization of 
method 1, we assayed the commercially available methyl magnesium bromide.  A proper assay of 
Grignard reagent concentration against anhydrous 2-butanol with 1,10-phenanthroline as the 
indicator permitted full alkyne deprotonation but more importantly, a proper stoichiometry 
suppressed an impurity (the t-butyl side product).  This side product was found to poison the 
subsequent reaction if present in even trace quantities.  Attack of an alkynyl magnesium bromide, 
although precedented to give tertiary carbon products, has no patent or literature precedent to 
generate a quaternary carbon product. A single patent details addition of a copper acetylide into a 
Brulyants adduct.342 Further optimization of this reaction included adding the Brulyants product 




chromatography then recrystallization from ethyl acetate for consistent subsequent chemistry. 
Selected method 1 (magnesio-addition) was found to be novel, repeatable, and furnished reliable 
yield (80-85%) of intermediate 3a22 on multigram scale. Since the chemistry was novel, we 
wanted to confirm the chemistry worked as anticipated and therefore we took x-ray crystal 


















Fig. 4.2. X-ray crystal structure of 3a22. 
 
Several combinations of catalysts, solvents, and adjuncts were examined for the reduction of the 
internal alkyne 3a22 to the corresponding alkane 3a10. A reduction using Pt2O5 with 
MeOH/EtOAc,342 proceeded in 5 hours, and rather than generating the desired alkane gave a 44 % 
isolated yield of the cis-alkene 3a23 (Scheme 4.41).  Similar observation was made when Pd/C 







Scheme 4.41. Attempted synthesis of 3a10. 
 
A modification in which we added 3 eq. of AcOH worked well for the reduction of the alkyne 
3a22 to the corresponding alkane 3a10 (Scheme 4.42). Full reduction was realized in 2 hours at 
50 PSI H2 using 10 % loading of 5% Pd/C (Strem) with 80 % ethanol and 3 equivalents of acetic 
acid.  Isolated yield following neutralization with Na2CO3, removal of solvent, extraction, and 
column chromatographic purification gave 3a10 in 73 % yield.  This procedure was repeated by 
another researcher and gave the product in identical yield and purity.  Acetic acid was necessary 
to protonate the amine attached to the gem-dimethyl quaternary carbon and prevent catalyst 
poisoning.  
 





The next step was Boc-deprotection of 3a10 to the 3a24, it was initially attempted using 2N HCl 
in dioxane.  Upon isolation of products as the HCl salt, it was apparent that the Boc group was 
removed, but the quaternary carbon attached to the amine was also degraded with isolation of 3a28  
 
Scheme 4.43. Attempted synthesis of 3a30. 
 
and 3a29 suggesting the proposed side reaction (reverse-Ritter reaction type, Scheme 4.43). This 
observation warranted milder deprotection conditions for the removal of Boc group. We therefore 
surveyed both non-HCl based strategies (ZnBr2,343 AlCl3,344 CAN,345 and TFA/DCM), and milder 
HCl based strategies for the removal of the Boc group. Out of these methods TFA/DCM and 1M 
HCl in acetonitrile gave the desired compound in quantitative yields (Scheme 4.44). Compound 
3a30 was isolated as the free base to avoid the reverse-Ritter reaction as indicated in Scheme 4.44.  






Scheme 4.44. Synthesis of 3a30. 
 
Once the intermediate 3a30 is formed, the final step involved either 1) N-arylation (Scheme 4.45) 
or 2) N-acylation (Scheme 4.46). The N-arylation was achieved by Chan-Lam couplings270, 295-296 
(Scheme 4.45). The list of analogs prepared are presented in Table 4.15.  
 
 
Scheme 4.45. Chan-Lam coupling for the synthesis of compounds 3a40-48. 
 
























































Table 4.15. Synthetic details for compounds 3a40-48. 
 
The N-acylation was conveniently achieved by HATU coupling341 in the presence of DIPEA as 
the base and DMF (anhydrous) as the solvent (Scheme 4.46). The list of analogs prepared are 





Scheme 4.46. Synthesis of N-acylated derivatives 3a54-58. 
 




















































All solvents and reagents were used as received unless noted otherwise.  All reactions were 
conducted in dry glassware and under an atmosphere of argon unless otherwise noted.  Microwave 
reactions were conducted in sealed tube and utilized a multimode Milestone Start apparatus for 
irradiation with power and control parameters as noted. Melting points were determined on a 
MelTemp apparatus and are uncorrected.  All proton NMR spectra were obtained with a 500 MHz 
or a 400 MHz Oxford spectrospin cryostat, controlled by a Bruker Avance system, and were 
acquired using Bruker TOPSPIN 2.0 acquisition software. Acquired FIDs were analyzed using 
MestReC 3.2 or MestReNova 9.0. Elemental analyses were conducted by Atlantic Microlabs and 
are ± 0.4 of theoretical. HRMS analysis was conducted either at University of Pittsburgh or 
Duquesne University and are ± 10 PPM or ± 0.003 dalton of theorotical.  All 1H NMR spectra 
were taken in CDCl3 (Chloroform-d) unless otherwise noted and are reported as ppm relative to 
TMS as an internal standard. Coupling values are reported in Hertz.  All TLCs were obtained on 
Sorbent Technologies polyester backed Silica G TLC Plates of thickness 200 µm.  
 
N-((9H-fluoren-9-yl)carbamoyl)-2,6-dichlorobenzamide (1a2, MG-42-AU): In a dry RBF (100 
mL) 2,6-dichlorobenzamide (1.0 gm, 5.26 mmol) in 20 mL of anhydrous 1,2-dichloroethane was 
added. The reaction mixture was cooled to 0 oC (ice bath) and oxalyl chloride (1.2 mL, 14.11 
mmol) was added dropwise and the reaction was allowed to stir for 15 minutes. The ice-bath was 




was evaporated under reduce pressure and excess of oxalyl chloride was chased with toluene (3 X 
10 mL). The intermediate (1a30) was then dissolved in 1,4-dioxane (anhydrous, 3 mL).  
In a separate RBF 9H-fluoren-9-amine hydrochloride salt (1a24, 1 gm, 4.6 mmol) was suspended 
in 1N NaOH/DCM (1/1 60 mL) and the reaction was allowed to stir for 3 h. The free base (9H-
fluoren-9-amine, 1a31) was extracted from DCM, washed with brine, dried over Sodium sulfate 
and finally the solvent was removed under reduce pressure. The free base was dissolved in 1,4 -
dioxane (anhydrous, 3 mL) and was cooled to 0 oC using ice-bath. To this the intermediate 1a30 
was added dropwise and the reaction was stirred for 12 h. The reaction was diluted with water (15 
mL) and the precipitate was filtered and washed with cold water. The crude was chromatographed 
on SiO2 gel using hexane/ethylacetate (4/1) as the eluent to yield 1.23 gm (67.3 %) of a white solid. 
MP: 189.4 – 191.2 oC. 1H NMR (400 MHz, Chloroform-d): δ 9.17 (s, 1H), 8.55 (d, J = 8 Hz, 1H), 
7.7 (d, J = 7.2 Hz, 2H), 7.64 (d, J = 7.2 Hz, 2H), 7.43 (t, J = 10.8 Hz, 2H), 7.36-7.33 (m, 4H), 7.29-
7.25 (m, 1H), 6.01 (d, J = 8 Hz, 1H). HRMS: (C21H14Cl2N2O2), Calculated for 395.0330 [M – H]-
, found 395.0354. 
 
Ethyl 2-((9H-fluoren-9-yl)amino)-2-oxoacetate (1a34, MG-59-i1): In a overnight dried 250 mL 
RBF was added the 9H-fluoren-9-amine hydrochloride salt (1a24, 1.085 gm, 5 mmol), 20 % 
aqueous Na2CO3 (2.65 gm, 25 mmol), and DCM (45 mL). To this ethyl 2-chloro-2-oxoacetate 
(1a33, 0.566 mL, 6 mmol) dissolved in DCM (5 mL) was added slowly and the reaction was 
allowed to stir overnight at room temperature. The DCM layer was collected and the aqueous layer 




over Sodium sulfate and finally concentrated under reduce pressure to afford the compound 1a34 
as a slightly yellow solid, 1.3 gm (92 %). MP: 98 – 99.2 oC. 1H NMR (400 MHz, Chloroform-d) 
δ 7.76 – 7.69 (m, 2H), 7.62 – 7.55 (m, 2H), 7.48 – 7.40 (m, 2H), 7.32 (td, J = 7.5, 1.1 Hz, 2H), 
6.19 (d, J = 9.2 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 
ESI (m/z): (C17H15NO3), calculated for 280.1 [M – H]-, found 280.0. 
 
2-((9H-fluoren-9-yl)amino)-2-oxoacetic acid (1a35, MG-59-i2): In a 25 mL RBF the ester 1a34 
(1.125 gm, 4 mmol) was dissolved in THF (10 mL) and then LiOH.H2O (0.84 gm, 20 mmol) was 
added. The reaction was refluxed for 4 hours after which the TLC showed complete loss of the 
starting material. The reaction mixture was poured into a separating funnel (500 mL) containing 
diethyl ether (50 mL) and 1M HCl (50 mL). The ether layer was collected, and aqueous layer was 
extracted with diethyl ether (3 X 50 mL). The combined organic fractions were washed with brine, 
dried over Sodium sulfate and finally concentrated under reduce pressure to afford the compound 
1a35 as a creamy yellow solid, 860 mg (85 %). MP: 205.9 – 206.5 oC. 1H NMR (400 MHz, DMSO-
d6) δ 9.32 (d, J = 8.6 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.49 – 7.38 (m, 4H), 7.31 (t, J = 7.4 Hz, 2H), 
5.95 (d, J = 8.8 Hz, 1H). ESI (m/z): (C15H11NO3) calculated 252.0 (M – H)-, found 252.0 
 
N-(2,6-dichlorobenzoyl)-N-(9H-fluoren-9-yl)oxalamide (1a32, MG-83-DA): 1a35 (860 mg, 




chloride (0.585 mL, 6.78 mmol) was added slowly. As soon as the oxalyl chloride was added 
evolution of CO2 was observed. The reaction was allowed to warm to room temperature and stirred 
for additional 4 hours. The solvent was removed under reduced pressure and the excess oxalyl 
chloride was chased with toluene (3 X 5 mL) to obtain intermediate 1a36. 
In a separate 25 mL RBF 2,6-dichlorobenzamide (1a27, 805 mg, 4.23 mmol) was dissolved in 1,4-
dioxane. To this KHMDS (840 mg, 4.23 mmol) was added in small portions (over 15 mins) at 0 
oC. The reaction was allowed to stir at 0 oC for additional 1 hour. The suspension was then added 
to the dissolved solution of 1a36 (923 mg, 3.39 mmol) in 1,4-dioxane in a dropwise manner. The 
reaction was allowed to stir for 12 hours at room temperature followed by at 40 oC for additional 
36 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduce pressure 
and subjected to SiO2 column chromatography using hexane/ethyl acetate (3/1) to give 364 mg (25 
%) of a white solid. MP: 212.2 – 212.9 oC. 1H NMR (400 MHz, Chloroform-d): δ 10.14 (s, 1H), 
7.71 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 7.6 Hz, 2H), 7.46 – 7.41 (m, 3H), 7.37 – 7.30 (m, 5H), 6.1 
(d, J = 8.8 Hz, 1H). HRMS: Calculated for 424.0389, found 424.0381. Elemental analysis: 
C22H14Cl2N2O3, calculated C, 62.13; H, 3.32; N, 6.59; Cl, 16.67; found C, 61.87; H, 3.20; N, 6.44; 
Cl, 16.62. 
 
tert-butyl (R)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (1a40, MG-
67): (tert-butoxycarbonyl)-R-valine (1a38, 250 mg, 1.15 mmol), DIC (0.3 mL, 2 mmol), and HOBt 
(162 mg, 1.2 mmol) was added to an RBF containing anhydrous DMF (10 mL). The reaction was 




triethylamine (1.4 mL, 10 mmol) was added and the reaction was stirred overnight at room 
temperature. After 12 hours the starting material was completely consumed as indicated by TLC. 
The solvent was removed, and the crude was purified using SiO2 column chromatography using 
hexane/ethyl acetate (4/1) as the solvent system. A white flaky solid was obtained, 260 mg (68 %). 
MP: 160 oC. 1H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J = 6.9 Hz, 2H), 7.52 (d, J = 7.4 Hz, 
2H), 7.42 – 7.37 (m, 2H), 7.29 (td, J = 7.5, 1.0 Hz, 2H), 6.17 (s, 1H), 3.99 (dd, J = 8.3, 5.9 Hz, 
1H), 2.26 (s, 1H), 1.41 (s, 9H), 1.04 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H). Elemental 
Analysis: C23H28N2O3, calculated C, 72.60; H, 7.42; N, 7.36; found C, 72.82; H, 7.48; N, 7.41. 
 
(R)-2-amino-N-(9H-fluoren-9-yl)-3-methylbutanamide TFA salt (1a42, MG-73): In a dry RBF 
(25 mL) tert-butyl (R)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (1a40, 
400 mg, 1.05 mmol) was added to a 40 % solution of TFA in DCM at 0 oC. The reaction was 
allowed to stir for 4 hours after which TLC indicated complete consumption of the starting 
material. The solvent was removed under reduce pressure to yield a white solid, 410 mg 
(quantitative). MP: 302.3 oC. 1H NMR (400 MHz, Methanol-d4) δ 7.78 (d, J = 7.3 Hz, 2H), 7.59 
(d, J = 7.4 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.33 (td, J = 8.0, 7.6, 2.5 Hz, 
2H), 6.14 (s, 1H), 3.66 (d, J = 5.9 Hz, 1H), 2.29 – 2.17 (m, 1H), 1.17 – 1.06 (m, 6H). 







MG-77): 1a42 (394 mg, 1 mmol) was added to a dry RBF containing a solution of anhydrous THF 
(16 mL) and anhydrous DMF (4 mL) under continuous argon supply at 0 oC (using ice-bath). TEA 
(0.7 mL, 5 mmol) was added to the reaction mixture followed by the addition of the 2,6-
dichlorobenzoyl chloride (1a43, 0.286 mL, 2 mmol) in a dropwise manner while maintaining the 
temperature to 0 oC. After 30 min. the ice-bath was removed, and the reaction was allowed to stir 
for additional 12 hours. The crude was filtered and washed with cold water (30 mL), diethyl ether 
(30 mL), and DCM (50 mL). The solid was dried and purified using SiO2 column chromatography 
using DCM/ethyl acetate (4/1) as the solvent system to yield a white solid powder, 320 mg (70 %).  
MP: 328.4 oC. 1H NMR (500 MHz, dimethyl sulfoxide-d): δ 8.88 (d, J = 9 Hz, 1H), 8.53 (d, J = 
8.5 Hz, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.49 – 7.40 (m, 7H), 7.33 – 7.31 (m, 2H), 6.07 (d, J = 8.5 
Hz, 1H), 4.40 (t, J = 10 Hz, 1H), 2.11 (s, J = 10 Hz, 1H), 1.03 (d, J = 7 Hz, 3H), 0.99 (d, J = 6.6 
Hz, 3H). Elemental analysis: C25H22Cl2N2O2, calculated C, 66.23; H, 4.89; N, 6.18; Cl, 15.64; 
found C, 65.99; H, 4.86; N, 6.16; Cl, 15.10. 
 
tert-butyl (S)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (1a39, MG-
32): (tert-butoxycarbonyl)-S-valine (1a37, 250 mg, 1.15 mmol), DIC (0.3 mL, 2 mmol), and HOBt 




allowed to stir for 15 minutes. To this 9H-fluoren-9-amine HCl (1a24, 218 mg, 1 mmol) and 
triethylamine (1 mL, 10 mmol) was added and the reaction was stirred overnight at room 
temperature. After 12 hours the starting material was completely consumed as indicated by TLC. 
The solvent was removed, and the crude was purified using SiO2 column chromatography using 
hexane/ethyl acetate (4/1) as the solvent system. A white flaky solid was obtained, 279 mg (73 %). 
MP: 179.5 oC. 1H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 7.5 Hz, 2H), 7.57 – 7.53 (m, 2H), 
7.45 – 7.40 (m, 2H), 7.32 (td, J = 7.4, 0.8 Hz, 2H), 6.26 (d, J = 9.0 Hz, 1H), 6.20 (s, 1H), 5.26 (s, 
1H), 4.01 (dd, J = 8.3, 5.8 Hz, 1H), 2.29 (s, 1H), 1.45 (s, 9H), 1.06 (d, J = 6.8 Hz, 3H), 1.00 (d, J 
= 6.9 Hz, 3H). Elemental Analysis: C23H28N2O3, calculated C, 72.60; H, 7.42; N, 7.36; found C, 
72.23; H, 7.34; N, 7.56. 
 
(S)-2-amino-N-(9H-fluoren-9-yl)-3-methylbutanamide TFA salt (1a41, MG-38): In a dry RBF 
(25 mL) tert-butyl (S)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (1a39, 
400 mg, 1.05 mmol) was added to a 40 % solution of TFA in DCM at 0 oC. The reaction was 
allowed to stir for 4 hours after which TLC indicated complete consumption of the starting 
material. The solvent was removed under reduce pressure to yield a white solid, 410 mg 
(quantitative). MP: 170 oC. 1H NMR (400 MHz, Methanol-d4) δ 7.79 (d, J = 8.1 Hz, 2H), 7.59 (dd, 
J = 7.3, 0.8 Hz, 1H), 7.54 – 7.49 (m, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.33 (tdd, J = 7.4, 2.4, 1.0 Hz, 
2H), 6.14 (s, 1H), 3.65 (d, J = 7.2 Hz, 1H), 2.28 – 2.18 (m, 1H), 1.14 – 1.08 (m, 6H). Elemental 
Analysis: C18H20N2O · 1.0813 CF3COOH, calculated C, 59.99; H, 5.26; N, 6.93; found C, 59.95; 






MG-79): 1a41 (394 mg, 1 mmol) was added to a dry RBF containing a solution of anhydrous THF 
(16 mL) and anhydrous DMF (4 mL) under continuous argon supply at 0 oC (using ice-bath). TEA 
(0.7 mL, 5 mmol) was added to the reaction mixture followed by the addition of the 2,6-
dichlorobenzoyl chloride (1a43, 0.286 mL, 2 mmol) in a dropwise manner while maintaining the 
temperature to 0 oC. After 30 min. the ice-bath was removed, and the reaction was allowed to stir 
for additional 12 hours. The crude was filtered and washed with cold water (30 mL), diethyl ether 
(30 mL), and DCM (50 mL). The solid was dried and purified using SiO2 column chromatography 
using DCM/ethyl acetate (4/1) as the solvent system to yield a white solid powder, 356 mg (78 %). 
MP: 328.7 oC. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 9.4 Hz, 1H), 8.54 (d, J = 8.3 Hz, 1H), 
7.87 (d, J = 7.4 Hz, 2H), 7.50 – 7.46 (m, 3H), 7.46 – 7.40 (m, 4H), 7.37 – 7.30 (m, 2H), 6.08 (d, J 
= 8.5 Hz, 1H), 4.40 (t, J = 8.4 Hz, 1H), 2.12 (dq, J = 14.3, 7.3 Hz, 1H), 1.03 (d, J = 6.7 Hz, 3H), 
1.00 (d, J = 6.7 Hz, 3H). Elemental Analysis: C25H22Cl2N2O2 . 0.5 H2O calculated C, 64.94; H, 
5.01; N, 6.06; found C, 65.28; H, 4.71; N, 6.18. 
MEK5 Project 
Diphenylamines: 
General procedure A: Acid chloride approach to synthesize amides: 
A dry 100 mL round bottomed flask was charged with a mixture of the substituted benzoic acid, 
and 5 mL of DCM. The reaction mixture was cooled with an ice-bath to 0 oC. A 100 μL volume 




over 5 min.  The reaction was stirred at 23 oC for 4 h. The solvent was removed under reduced 
pressure. Excess oxalyl chloride was azeotropically removed with 2 X 5 mL portions of DCM 
under reduced pressure. The crude acid chloride was dissolved into 5 mL of DCM and a greater 
than 2-fold stoichiometric ratio the appropriate amine was added neat at 0 oC. The ice bath was 
removed after 10 min and the reaction was permitted to warm to room temperature. The reaction 
was then stirred at 23 oC for 6 h; completion of reaction was determined by TLC. A mixture of 10 
mL of H2O and 10 mL of Et2O was added and the resultant mixture was extracted with twice with 
10 mL portions of Et2O, washed twice with 10 mL portions of NaCl (aq, sat), and dried over 
Sodium sulfate. The extract was decanted and then the solvent was removed under reduced 
pressure. The crude product was isolated on SiO2 using hexane/EA. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (2a37):  A 250 mL round bottom 
flask was charged with 2-fluoro-4-iodoaniline (2.38 g, 10.0 mmol), 2,3,4-trifluorobenzoic acid, 
(1.80 g, 10.2 mmol), and 30 mL of anhydrous THF. The reaction mixture was cooled with an ice-
bath to 0 oC and LiNH2 (561.2 mg, 24.45 mmol) was added in 3 portions over a 10 min interval.  
The reaction was then warmed to an internal temperature of 58 oC and stirred for 12 h. The mixture 
was cooled to 0 oC and 1 N HCl was added maintaining the reaction mixture below 5 oC to yield 
a final pH of 1.0 (red to pHydrion paper). The reaction mixture was then extracted three times with 
10 mL portions of Et2O, washed three times with 5 mL portions of 1 N HCl, washed with NaCl 
(aq, sat), and dried over Sodium sulfate. The extract was decanted, and the solvent was removed 




2.11 g (53%) of a white solid.  MP = 199.0 - 200.1 oC (lit. MP = 200 - 201 oC).224  1H NMR (400 
MHz, Methanol-d4): δ 7.89 (br, 1H), 7.47 (dd, 1H, J = 1.8 Hz and J = 10.5 Hz), 7.38-7.45 (d, 1H, 
J = 8.5 Hz), 6.91 (m, 1H), 6.74 (m, 1H). Anal Calcd for C13H7F3INO2: C, 39.72; H, 1.79; N, 3.56. 
Found: C, 39.41; H, 1.91; N, 3.52. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (2a71) was synthesized using 
procedure A from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (2a37, 1.2 g, 3.0 
mmol), 100 μL DMF, oxalyl chloride (514 μL, 6 mmol), and 7 N NH3 in methanol (2 mL, 15.73 
mmol). The crude product was isolated on SiO2 using 2:1 hexane/EA to give 740 mg (62 %) of a 
pink-white powder. MP = 160.9 – 162.0 oC. 1H NMR (400 MHz, Chloroform-d): δ 8.71 (s, 1H), 
7.39-7.43 (m, 2H), 7.34 (d, 1H, J = 8.5 Hz), 6.85-6.90 (m, 1H), 6.60-6.64 (m, 1H), 5.72-6.22 (br 
d, 2H). Anal Calcd for C13H8F3IN2O: C, 39.82; H, 2.06; N, 7.14. Found: C, 39.86; H, 2.18; N, 
7.24. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N,N-dimethylbenzamide (2a72) was 
synthesized using a modification of  procedure A from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (2a37, 200.0 mg, 0.51 mmol), 100 μL DMF, oxalyl chloride (85 




5 mL H2O was added with dropwise addition to a suspension of Na2CO3 (7 mmol), H2O (5 mL), 
DCM (25 mL), and DMAP (5.0 mg, 0.04 mmol) at 0 oC. The solution of acid chloride in DCM 
was added to this mixture over 5 min and the reaction was stirred at 23 oC for 2 h. Standard isolation 
as described in procedure A followed. The crude product was isolated on SiO2 using 2:1 
hexane/EA to give 58 mg (27 %) of a white solid. MP = 115.4 – 117.7 oC. 1H NMR (400 MHz, 
Chloroform-d): δ 7.36-7.39 (dd, 1H, J = 1.9 Hz and J = 10.4 Hz), 7.29-7.31 (d, 1H, J = 8.5 Hz), 
7.02-7.06 (m, 1H), 6.91-6.95 (m, 1H), 6.82 (s, 1H), 6.53-6.59 (m, 1H), 2.96 (br, 3H), 2.91 (br, 
3H). Anal Calcd for C15H12F3IN2O: C, 42.8; H, 2.8; N, 6.67; F, 13.5; I, 30.2. Found: C, 42.69; H, 
2.89; N, 6.53; F, 13.45; I, 29.99. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-methylbenzamide (2a73) was synthesized 
using procedure A from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (2a37, 315 
mg, 0.8 mmol), 100 μL DMF, oxalyl chloride (136 μL, 1.6 mmol) and methylamine in methanol 
(0.5 mL, 4 mmol, 8 M solution). The crude product was isolated on SiO2 using 5:1 hexane/EA and 
recrystallized from EtOH to give 188 mg (58 %) of a white solid. MP = 159.0 – 160.2 oC. 1H NMR 
(500 MHz, Chloroform-d): δ 8.61 (s, 1H,), 7.40 (dd, 1H, J = 1.9 Hz and J = 10.3 Hz), 7.28-7.32 
(m, 2H), 6.82-6.88 (m, 1H), 6.54-6.59 (m, 1H), 6.23 (br, 1H), 2.95 (d, 3H, J = 4.8 Hz). Anal Calcd 
for C14H10F3IN2O: C, 41.40; H, 2.48; N, 6.90; F, 14.03; I, 31.25. Found: C, 41.67; H, 2.51; N, 





N-ethyl-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (2a74)  was synthesized 
using procedure A from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (2a37, 315 
mg, 0.8 mmol), 100 μL DMF, oxalyl chloride (136 μL, 1.6 mmol) and ethyl amine 2M solution in 
THF (2.25 mL, 4.5 mmol). The crude product was isolated on SiO2 using 2:1 hexane/EA and 
recrystallized from hot EtOH to give 158 mg (42 %) of a white solid. MP = 172.5 – 173.6 oC. 1H 
NMR (400 MHz, Chloroform-d): δ 8.52 (s, 1H), 7.40 (dd, 1H, J = 2.0 Hz, J = 10.3 Hz), 6.82-6.89 
(m, 1H), 7.31 (m, 2H), 6.54-6.59 (m, 1H), 6.22 (br, 1H), 3.38-3.45 (m, 2H), 1.19 (t, 3H, J = 7.3 
Hz). Anal Calcd for C15H12F3IN2O: C, 42.88; H, 2.88; N, 6.67; F, 13.56; I, 30.20. Found: C, 42.89; 
H, 2.89; N, 6.60; F, 13.57; I, 30.47. 
 
Tert-butyl 4-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)piperazine-1-
carboxylate (2a75) was synthesized using a modification of procedure A from 3,4-difluoro-2-
((2-fluoro-4-iodophenyl)amino)benzoic acid, (2a37, 1.00 g, 2.54 mmol) and N-Boc-piperazine 
(2.85 g, 5.08 mmol). A solution of acid chloride in 6 mL DCM was added with dropwise addition 
to a solution of N-Boc-piperazine, TEA (0.70 mL, 5.08 mmol), DCM (12 mL) and DMAP (5.0 




on SiO2 using 2:1 hexane/EA to give 760 mg (53 %) of a white solid. MP = 188.4 oC. 1H NMR 
(400 MHz, Chloroform-d): δ 7.39 (dd, 1H, J = 1.9 Hz and J = 10.4 Hz), 7.30 (d, 1H, J = 8.9 Hz), 
7.03 (m, 1H), 6.92-6.96 (m, 1H), 6.62 (s, 1H), 6.53-6.58 (m, 1H), 3.34-3.55 (m, 8H), 1.45 (s, 9H). 
Anal Calcd for C22H23F3IN3O3: C, 47.07; H, 4.13; N, 7.49; F, 10.15; I, 22.61. Found: C, 47.22; H, 
4.18; N, 7.40; F, 9.94; I, 22.64. 
 
2-((2-fluorophenyl)amino)benzoic acid (2a52)  A microwave reactor tube was charged with 
ortho-iodo benzoic acid (496 mg, 2 mmol), 2-fluoro aniline (0.1 mL, 1 mmol), K2CO3 (416 mg, 3 
mmol), CuI (200 mg, 1.04 mmol) and 5 mL DMF/H2O (9:1).  The reaction was subjected to 300-
Watt microwave irradiation with the internal temperature maintained at 100 oC for 2 h. After 
completion of the reaction was analyzed by TLC, 1 N HCl (~ 4 mL) was added to the reaction 
mixture to obtain a final solution pH of 6.0. The solvent was then removed under reduced pressure. 
The crude compound was isolated on SiO2 using 1:1 hexane/EA to give after recyrstalization from 
ethanol, 160 mg (69 %) of grey-black crystals. MP = 182.6-182.9. 1H NMR (500 MHz, Methanol-
d4): δ 8.00-8.03 (m, 1H), 7.36-7.40 (m, 1H), 7.08-7.22 (m, 4H), 7.47-7.50 (m, 1H), 6.79-6.83 (m, 
1H). Anal. Calcd. for C13H10FNO2: C, 67.53; H, 4.36; N, 6.06. Found: C, 67.23; H, 4.58; N, 5.96. 
 
2-((2-fluorophenyl)amino)benzamide (2a76) was synthesized using procedure A from 2-((2-
fluorophenyl)amino)benzoic acid (462 mg, 2 mmol), oxalyl chloride (0.343 mL, 4 mmol), DMF 




which was then reacted with 7 N NH3/MeOH (3 mL, 21 mmol),  DMAP (catalytic), and DCM (7 
mL). Recrystallization from 1:3 (toluene:hexane) afforded the final compound 51 mg (11%) as a 
white-creamish powder. MP = 90.9 – 92.0 0C. 1H NMR (500 MHz, Chloroform-d): δ 9.50 (s, 1H), 
7.51-7.53 (dd, 1H), 7.39-7.43 (dt, 1H), 7.33-7.36 (m, 1H), 7.02-7.21 (m, 4H), 6.81-6.84 (m, 1H), 
5.86 (bs, 2H). Anal. Calcd. for C13H11FN2O: C, 67.82; H, 4.82; N, 12.17; Found: C, 67.59; H, 4.94; 
N, 12.06. 
 
2-((2-fluoro-4-iodophenyl)amino)benzoic acid (2a51): A microwave reactor tube was charged 
with ortho-iodo benzoic acid (496 mg, 2 mmol), 2-fluoro-4-iodo aniline (237 mg, 1 mmol), K2CO3 
(416 mg, 3 mmol), CuI (200 mg, 1.04 mmol) and 5 mL DMF/H2O (9:1). The reaction was 
subjected to 300-Watt microwave irradiation with the internal temperature maintained at 100 oC 
for 2 h. After completion of the reaction was analyzed by TLC, 1 N HCl (~ 4 mL) was added to 
the reaction mixture to obtain a final solution pH of 6.0. The solvent was then removed under 
reduced pressure. The crude compound was isolated on SiO2 using 1:1 hexane/EA to give 217 mg 
(61%) of white solid; MP = 186.2 – 186.5 oC. 1H NMR (400 MHz, Chloroform-d): δ 9.25 (s, 1H), 
8.06 (dd, 1H, J = 1.6 Hz and J = 8.1 Hz), 7.50 (dd, 1H, J = 2.0 Hz and J = 9.8 Hz), 7.42 (m, 2H), 
7.20 (t, 1H, J = 8.4 Hz), 7.11 (d, 1H, J = 8.6 Hz), 6.85 (t, 1H, J = 7.1 Hz). Anal Calcd for 






hydrochloride (2a77) A dry 100 mL round bottom flask was charged with 2-((2-fluoro-4-
iodophenyl)amino)benzoic acid (140 mg, 0.39 mmol) and 5 mL of DCM.  The reaction mixture 
was cooled with an ice-bath to 0 oC. 100 μL of anhydrous DMF was added followed by dropwise 
addition of oxalyl chloride (70 μL, 0.8 mmol) over 2 min at 0 oC.  The reaction was stirred at 23 
oC for 2 h. The solvent was then removed under reduced pressure.  The crude product was 
dissolved into 5 mL of DCM and N-methyl piperazine (0.5 mL, 4.5 mmol) was added neat at 23 
oC.  The reaction was stirred at 23 oC for 2 h; completion of reaction was determined by TLC.  A 
mixture of 10 mL of DCM and 5 mL of 5% Na2CO3 was added and the resultant mixture was 
extracted with DCM, washed with NaCl (aq, sat), and dried over Sodium sulfate. The extract was 
decanted and then the solvent was removed under reduced pressure and water chased with toluene. 
The crude product was isolated on SiO2 using EA/0.5% TEA/10% ethanol and recrystallized as 
the HCl salt (ethereal HCl) to give 20 mg (12%) of off-white powder. MP = 217.2 – 217.5 oC. 1H 
NMR (400 MHz, Methanol-d4): δ 7.49 (dd, 1H, J = 2.0 Hz and J = 10.7 Hz), 7.34-7.42 (m, 3H), 
7.15 (d, 1H, J = 8.2 Hz), 7.09 (t, 1H, J = 7.5 Hz), 6.92 (t, 1H, J = 8.7 Hz), 3.60 (q, 2H, J = 7.1 Hz), 
3.49 (q, 2H, J = 7.0 Hz), 2.89 (s, 3 H), 1.18 (t, 4H, J = 7.0 Hz). Anal Calcd for C18H20ClFIN3O. 
0.38 % EtOH: C, 45.68; H, 4.55; N, 8.51; F, 3.85; I, 25.71; Cl, 7.18. Found: C, 45.9; H, 4.49; N, 
8.54; F, 3.66; I, 25.68; Cl, 7.49. 
 
2-((2-fluoro-4-iodophenyl)amino)benzamide (2a78): A oven-dried round bottom flask was 
charged with 2-((2-fluoro-4-iodophenyl)amino)benzoic acid (714 mg, 2 mmol) and 3 mL of 




DMF was added followed by dropwise addition of oxalyl chloride (0.343 mL, 4 mmol) over 2 min.  
The ice-bath was removed after 15 minutes and the reaction was allowed to stir at 23 oC for 4 h. 
The solvent was removed and excess oxalyl chloride was azeotropically removed with 3 X 5 mL 
portions of dichloromethane under reduced pressure. The crude product obtained, was dissolved 
in 7 mL of dichloromethane and treated with catalytic amount of DMAP (5 mg). The reaction 
mixture was cooled to 0 oC with ice-bath and 7 N NH3/MeOH (3 mL, 21 mmol) was added in a 
drop-wise manner. The ice bath was removed after 10 min and the reaction mixture was stirred at 
23 oC for 24 h; completion of the reaction was determined by TLC. The solvent was removed, and 
the crude was dissolved in 20 mL of dichloromethane and washed with 5 mL of 1N NaOH, 2 X 
25 mL water, 2 X 10 mL 0.5N HCl, followed by brine wash, and dried over Sodium sulfate. The 
solvent was removed, and the crude was purified with SiO2 chromatography using 1:1 
hexane/ethyl acetate to afford the final compound 2a78, as a light brown powder 128 mg (18 %). 
MP = 244.1 - 246.2 0C. 1H NMR (500 MHz, Chloroform-d) δ 8.41 (dd, J = 8.1, 1.4 Hz, 1H), 8.20 
(s, 1H), 7.84 – 7.78 (m, 2H), 7.67 – 7.62 (m, 1H), 7.56 – 7.51 (m, 1H), 7.26 – 7.21 (m, 1H), 6.85 
(d, J = 8.4 Hz, 1H). ESIMS (m/z): calculated for 354.97 [M – H]-, found 355.0, Anal Calcd for C, 
43.84; H, 2.83; N, 7.87; found C, 43.69; H, 2.74; N, 7.79. 
 
 
3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid (2a38)  A 100 mL dry round bottom flask 
was charged with 2-fluoroaniline (0.27 mL, 2.97 mmol), 2,3,4-trifluorobenzoic acid, (528 mg, 3 




and LiNH2 (165.2 mg, 7.2 mmol) was added in 2 portions over a 10 min interval.  The reaction 
was then warmed to 58 oC (external temperature) and stirred for 4 h.  1 N HCl was then added to 
the reaction mixture at 0 oC to obtain a final pH of 1.0 (red to pHydrion paper). The reaction 
mixture was extracted three times with 5 mL portions of Et2O, washed three times with 5 mL 
portions of 1 N HCl, washed with NaCl (aq, sat), and dried over Sodium sulfate.  The extract was 
decanted and the solvent was removed under reduced pressure. The crude product was isolated on 
SiO2 using hexane/EA to provide 471 mg (59 %) of white crystals.  MP = 170 – 172 oC. 1H NMR 
(400 MHz, Chloroform-d): δ 8.92 (s, 1H), 7.87-7.91 (ddd, 1H, J = 2.1, 5.8, and 9.1), 7.00-7.13 (m, 
4H), 6.72-6.78 (dt, 1H, J = 6.8 Hz and J = 9.1 Hz). Anal Calcd for C13H8F3NO2: C, 58.44; H, 3.02; 
N, 5.24; found: C, 58.41; H, 3.02; N, 5.23. 
 
3,4-difluoro-2-(phenylamino)benzoic acid (2a39)  A 250 mL round bottom flask was charged 
with aniline (0.57 mL, 5.7 mmol), 2,3,4-trifluorobenzoic acid, (1 g, 5.7 mmol), and 15 mL of 
anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (327 mg, 
14.25 mmol) was added in portions 2 portions over 10 min.  The reaction was then warmed to 58 
oC (external temperature) and stirred for 7 h.  1 N HCl was then added to the reaction mixture at 0 
oC to obtain a final pH of 1.0 (red to pHydrion paper). The reaction mixture was extracted three 
times with 5 mL portions of Et2O, washed three times with 5 mL portions of 1 N HCl, washed 
with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was decanted, and the solvent was 
removed under reduced pressure. The crude product was isolated on SiO2 using hexane/EA and 




Chloroform-d): δ 8.99 (s, 1 H, OH), 7.87-7.90 (m, 1H), 7.32 (t, 2H, J = 7.6 Hz), 7.10 (t, 1H, J = 
7.4 Hz), 7.05 (d, 2H, J = 7.5 Hz), 6.73-6.78 (m, 1H). Anal Calcd for C13H9F2NO2: C, 62.65; H, 
3.64; N, 5.62; Found C, 62.64; H, 3.76; N, 5.59. 
 
3,4-difluoro-2-(phenylamino)benzamide (2a94): A oven dried round bottomed flask was 
charged with 3,4-difluoro-2-(phenylamino)benzoic acid (13) (500 mg, 2 mmol), EDC (N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, 1150 mg, 6 mmol), HONB (N-
hydroxy-5-norbornene-2,3-dicarboximide, 432 mg, 2.4 mmol) and 10 mL of DMF at 0 0C. 7 N 
NH3/MeOH (3 mL, 21 mmol) was added dropwise over a period of 5 minute. After 1 hour the ice-
bath was removed and the reaction was allowed to stir at room temperature for 24 hours. After this 
the solvent was removed to remove the excess amine and the crude was dissolved in 50 mL of 
DCM and washed with 3 X 20 mL of 1N NaOH followed by brine wash. The crude was dried over 
Sodium sulfate and purified using SiO2 chromatography at 1:1 Hexane/Ethylacetate to give rise to 
the final compound 126 mg (25%) as a white-pink powder. MP = 144.9 oC. 1H NMR (400 MHz, 
CDCl3): δ 8.45 (s, 1H), 7.40-7.44 (m, 1H), 7.24-7.28 (m, 1H), 6.97-7.01 (m, 1H), 6.90-6.92 (bs, 
2H), 6.80-6.86 (m, 1H), 5.86-6.36 (bs, 2H).  HRMS: (C13H10F2N2O) calculated for 249.08394 [M 






A solution of 2a38 (430 mg, 1.61 mmol), N-Methyl piperazine (0.35 mL, 3.22 mmol) was prepared 
in 10 mL anhydrous DMF and then EDCI (615 mg, 3.22 mmol) was added. The reaction mixture 
was stirred at 23 oC for 6 hrs; completion of reaction was followed by TLC. The crude product 
was isolated on SiO2 using CH2Cl2, 2 % 7 N NH3/MeOH, followed by fumarate salt formation to 
give 75 mg (10 %) of a white solid. MP = 155.0 – 160 oC. 1H NMR (400 MHz, Chloroform-d): δ 
7.14-7.18 (m, 1 H, Ar), 7.04-7.12 (m, 2 H, Ar), 6.97-7.01 (m, 1 H, Ar), 6.89-6.94 (m, 1 H, Ar), 
6.82-6.86 (m, 1 H, Ar), 3.57 (br, 4 H, 2CH2), 2.83-2.94 (br, 4 H, 2CH2), 2.68 (s, 3 H, CH3). Anal 
Calcd for C22H22F3N3O5. 0.55 % Fumaric acid. 0.78 %  EA: C, 54.87; H, 5.13; N, 7.02. Found: C, 
54.98; H, 4.88; N, 6.86. 
 
3,4-difluoro-2-(phenylamino)phenyl)(4-methylpiperazin-1-yl)methanone (2a98)  A solution 
of 2a39 (249 mg, 1 mmol), N-methyl piperazine (0.25 mL, 2 mmol) was prepared in 10 mL 
anhydrous DMF, then EDCI (382 mg, 2 mmol) was added in one portion. The reaction mixture 
was stirred at 23 oC for 12 hrs. The solvent was removed under reduced pressure and a mixture of 
50 mL of ether and 1 mL H2O was added. The resultant mixture was washed three times with 1mL 
portions of H2O, 5 mL of saturated NaCl and then dried over anhydrous Sodium sulfate. The crude 
product was isolated on SiO2 using CH2Cl2, 2 % 7 N NH3/MeOH to give 186 mg (58 %) of a white 
solid. MP = 153.0 – 155.3 oC. 1H NMR (500 MHz, Chloroform-d) δ 7.28 – 7.24 (m, 2H), 7.06 – 




3.50 (bd, 4H), 2.27 (bd, 7H). Anal Calcd for C18H19F2N3O: C, 65.24; H, 5.78; N, 12.68; F, 11.47; 
Found: C, 65.38; H, 5.89; N, 12.72; F, 11.46. 
 
2-fluoro-4-iodo-N-methylaniline (2a34): 2-fluoro-4-iodoaniline (474 mg, 2 mmol) was added to 
a dry 100 mL round bottom flask containing a suspension of NaOMe (540 mg, 10 mmol) in MeOH 
(5 mL). This mixture was poured into a suspension of paraformaldehyde (84 mg, 2.8 mmol) in 
anhydrous MeOH (4 mL) and the reaction mixture was stirred at 25 oC for 5 h. After 5 h, NaBH4 
(75 mg, 2 mmol) was added and the reaction mixture was heated to 90 oC for 2.5 h. The solvent 
was evaporated, and the reaction mixture was treated with 5 mL 1 M KOH. The product was 
extracted into diethyl ether (2 X 8 mL) and dried over Sodium sulfate. The extract was decanted, 
and the solvent was removed under reduced pressure. The crude product was isolated on SiO2 
using 20% EA/ hexane to provide 270 mg (54%) of white needles. MP = 44 oC.  1H NMR (400 
MHz, Chloroform-d): δ   7.22-7.26 (m, 1H), 7.30 (d, 1H, J = 9.3 Hz), 6.43 (t, 1H, J = 8.8 Hz), 3.97 
(s, 1 H), 2.85 (d, 3H, J = 4.6 Hz),. Anal Calcd for C7H7FIN: C, 33.39; H, 2.81; N, 5.58. Found: C, 
33.69; H, 2.67; N, 5.64. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid (2a40)  A 100 mL dry 
round bottom flask was charged with 2-fluoro-4-iodo-N-methylaniline (270 mg, 1.07 mmol), 
2,3,4-trifluorobenzoic acid (192 mg, 1.09 mmol), and 10 mL of anhydrous THF. The reaction 




2 portions over 5 min.  The reaction was then warmed to 58 oC (external temperature) and stirred 
for 48 h. 1 N HCl was then added to the reaction mixture at 0 oC to obtain a final pH of 1.0 (red to 
pHydrion paper). The reaction mixture was extracted three times with 5 mL portions of Et2O, 
washed three times with 5 mL portions of 1 N HCl, washed with NaCl (aq, sat) and dried over 
Sodium sulfate.  The extract was decanted, and the solvent was removed under reduced pressure. 
The crude product was isolated on SiO2 using 3:1 hexane/EA and recrystallized from toluene and 
hexanes to provide 286 mg (66 %) of brown crystals. MP = 86.2 – 89.1 oC. SiO2 TLC Rf 0.45 (2:1 
hexane/EA). 1H NMR (500 MHz, Chloroform-d): δ 8.07-8.10 (m, 1H), 7.50 (d, 1H, J = 8.6 Hz), 
7.35-7.37 (dd, 1H, J = 2.0 Hz and J = 11.4 Hz), 7.24-7.27 (m, 1H), 6.97 (t, 1H, J = 8.8 Hz), 3.34 
(s, 3H). Anal Calcd for C14H9F3INO2. 0.0436 % C6H5CH3: C, 41.78; H, 2.29; N, 3.40. Found: C, 
41.77; H, 2.42; N, 3.35. 
 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzamide (2a79)  was synthesized 
using procedure A from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid (1.3 
g, 3.2 mmol), oxalyl chloride (0.55 mL, 6.4 mmol), DMF (catalytic), and DCM (25 mL) to form 
the intermediate 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoyl chloride, which 
was then reacted with 7 N NH3/MeOH (3 mL, 21 mmol),  DMAP (catalytic), and DCM (10 mL) 
to give rise to the final compound 264 mg (20%) as a white solid. MP = 121.2 – 121.9 oC. 1H NMR 




(m, 1H), 7.23 – 7.13 (m, 1H), 6.90 – 6.79 (m, 1H), 5.98 (s, 1H), 3.31 (s, 3H). Anal. Calcd. for 
C14H10F3IN2O: C, 41.40; H, 2.48; N, 6.90; Found: C, 41.37; H, 2.55; N, 6.92. 
 
Methyl 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoate (2a110) was obtained 
as a side product during the synthesis of 2a79 as a white solid 188 mg (14%). MP = 89 oC. 1H 
NMR (500 MHz, Chloroform-d) δ 7.58 – 7.53 (m, 1H), 7.39 – 7.35 (m, 1H), 7.26 – 7.22 (m, 1H), 
7.09 (q, J = 8.5 Hz, 1H), 6.69 (t, J = 8.9 Hz, 1H), 3.67 (s, 3H), 3.33 (s, 3H). Anal. Calcd. for 
C15H11F3INO2: C, 42.78; H, 2.63; N, 3.33; Found: C, 43.00; H, 2.69; N, 3.30. 
 
 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)phenyl)(4-methylpiperazin-1-
yl)methanone (2a80): A oven dried round bottomed flask was charged with 3,4-difluoro-2-((2-
fluoro-4-iodophenyl)(methyl)amino)benzoic acid (145 mg, 0.35 mmol) and 3 mL of DCM. The 
reaction mixture was cooled with an ice-bath to 0 oC. 1-2 drops of anhydrous DMF was added 
followed by dropwise addition of neat oxalyl chloride (0.06 mL, 0.7 mmol) over 2 min.  The 
reaction was stirred at room temperature for 4 h. The solvent was then removed under reduced 
pressure. Excess oxalyl chloride was azeotropically removed with 3 X 5 mL portions of DCM 
under reduced pressure. To the crude product catalytic amount of DMAP was added (5 mg) and 




ice bath was removed after 10 min and the reaction was permitted to warm to room temperature. 
The reaction was then stirred at room temperature 24 h; completion of reaction was determined by 
TLC. After this the solvent was removed to remove the excess amine and the crude was dissolved 
in 20 mL of DCM and washed with 5 mL of 1N NaOH, 2 X 25 mL water, 2 X 10 mL 0.5N HCl, 
followed by brine wash. The crude was dried over Sodium sulfate and purified using SiO2 
chromatography using 89/10/1 DCM/EtOH/NH4OH to afford the final compound as a white 
creamish powder 142 mg (81 %). MP = 143-144.1 oC. 1H NMR (500 MHz, Chloroform-d): δ 7.37 
(m, 1H), 7.23 (m, 1H), 7.00-7.05 (m, 1H), 6.86-6.89 (m, 1H), 6.79 (t, 1H), 3.48 (b, 2H), 3.30 (s, 
3H), 3.06-3.28 (b, 2H), 2.26 (s, 3H), 2.21-2.37 (b, 2H), 1.96-2.08 (b, 2H). Anal. Calcd. for  
C19H19F3IN3O: C, 46.64; H, 3.91; N, 8.59; Found: C, 46.69; H, 3.93; N, 8.60. 
 
3,4-difluoro-2-((4-iodophenyl)amino)benzamide (2a106): A oven-dried round bottom flask was 
charged with 2,3,4-trifluorobenzamide (1.57 g, 9 mmol), 4-iodoaniline, (2.16 g, 9.9 mmol), and 
30 mL of anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 
(621 mg, 27 mmol) was added in 3 portions over a 10 min interval.  The reaction was then warmed 
to an internal temperature of 62 oC and stirred for 12 h. The mixture was cooled to 0 oC and 1 N 
HCl was added maintaining the reaction internal temperature below 5 oC to yield a final pH of 1.0 
(red to pHydrion paper). The reaction mixture was then extracted three times with 30 mL portions 
of ethyl acetate, washed three times with 5 mL 1N HCl, brine, and then dried over Sodium sulfate. 
The extract was decanted, and the solvent was removed under reduced pressure. The product was 




MP = 188.6 oC. 1H NMR (500 MHz, Chloroform-d) δ 8.69 (s, 1H), 7.58 – 7.53 (m, 2H), 7.43 – 
7.38 (m, 1H), 6.86 (td, J = 9.0, 6.9 Hz, 1H), 6.73 – 6.68 (m, 2H), 5.92 (d, 2H). ESIMS (m/z): 
calculated for 372.97 [M – H]-, found 373.0, HRMS: (C13H9F2IN2O) calculated for 396.9620 [M 
+ Na]+, found 396.9642. 
 
3,4-difluoro-2-(methyl(phenyl)amino)benzoic acid (2a41): A 100 mL dry round bottom flask 
was charged with N-methylaniline (115 µL, 1.07 mmol), 2,3,4-trifluorobenzoic acid, 2, (192 mg, 
1.09 mmol), and 10 mL of anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 
oC and LiNH2 (60 mg, 2.6 mmol) was added in portions 2 portions over 5 min.  The reaction was 
then warmed to 58 oC (external temperature) and stirred for 48 h. 1 N HCl was then added to the 
reaction mixture at 0 oC to obtain a final pH of 1.0 (red to pHydrion paper). The reaction mixture 
was extracted three times with 5 mL portions of Et2O, washed three times with 5 mL portions of 
1 N HCl, washed with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was decanted, 
and the solvent was removed under reduced pressure. The crude product was isolated on SiO2 
using 4:1 hexane/EA and recrystallized from toluene and hexanes to provide 188 mg (71 %) of 
light grey powder. MP: 122.8 – 124.7 oC. 1H NMR (500 MHz, Chloroform-d) δ 11.66 (s, 1H), 8.12 
– 8.06 (m, 1H), 7.32 – 7.26 (m, 3H), 7.00 (t, J = 7.4 Hz, 1H), 6.82 (d, J = 7.9 Hz, 2H), 3.33 (s, 






(3,4-difluoro-2-(methyl(phenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone (2a81): A 
oven dried round bottomed flask was charged with 3,4-difluoro-2-(methyl(phenyl)amino)benzoic 
acid (92 mg, 0.35 mmol) and 3 mL of DCM. The reaction mixture was cooled with an ice-bath to 
0 oC. 100 μL of anhydrous DMF was added followed by dropwise addition of neat oxalyl chloride 
(0.06 mL, 0.7 mmol) over 2 min.  The reaction was stirred at room temperature for 4 h. The solvent 
was then removed under reduced pressure. Excess oxalyl chloride was azeotropically removed 
with 3 X 5 mL portions of DCM under reduced pressure. To the crude product catalytic amount 
of DMAP was added (5 mg) and then 4 mL of DCM and the N-methyl piperazine (1 mL, 10.5 
mmol) was added neat at 0 oC. The ice bath was removed after 10 min and the reaction was 
permitted to warm to room temperature. The reaction was then stirred at room temperature 24 h; 
completion of reaction was determined by TLC. After this the solvent was removed to remove the 
excess amine and the crude was dissolved in 20 mL of DCM and washed with 5 mL of 1N NaOH, 
2 X 25 mL water, 2 X 10 mL 0.5N HCl, followed by brine wash. The crude was dried over Sodium 
sulfate and purified using SiO2 [the slurry was prepared in 2 % 7 N NH3 (in 
methanol)/dichloromethane] using 2-4 % 7 N NH3 (in methanol)/dichloromethane to provide 98 
mg (82 %) of a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.20 (tt, J = 7.4, 2.2 Hz, 2H), 
7.13 (td, J = 8.9, 7.0 Hz, 1H), 7.06 – 7.02 (m, 1H), 6.80 (tt, J = 7.4, 0.9 Hz, 1H), 6.66 (d, J = 8.6 
Hz, 2H), 3.60 (s, 1H), 3.48 (s, 1H), 3.28 (s, 3H), 3.27 – 3.21 (m, 1H), 3.11 – 3.05 (m, 1H), 2.36 – 
2.29 (m, 1H), 2.24 – 2.20 (m, 1H), 2.18 (s, 3H), 2.13 – 2.07 (m, 1H), 1.96 – 1.89 (m, 1H). HRMS: 






2-((2,4-difluorophenyl)amino)-3,4-difluorobenzoic acid (2a42): A 100 mL dry round bottom 
flask was charged with 2,4-difluoroaniline (110 µL, 1.07 mmol), 2,3,4-trifluorobenzoic acid (192 
mg, 1.09 mmol), and 10 mL of anhydrous THF. The reaction mixture was cooled with an ice-bath 
to 0 oC and LiNH2 (60 mg, 2.6 mmol) was added in portions 2 portions over 5 min.  The reaction 
was then warmed to 58 oC (external temperature) and stirred for 48 h. 1 N HCl was then added to 
the reaction mixture at 0 oC to obtain a final pH of 1.0 (red to pHydrion paper). The reaction 
mixture was extracted three times with 5 mL portions of Et2O, washed three times with 5 mL 
portions of 1 N HCl, washed with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was 
decanted, and the solvent was removed under reduced pressure. The crude product was isolated on 
SiO2 using 3:1 hexane/EA to provide 156 mg (54 %) of light brown powder. MP: 190.0 – 192.1 
oC. 1H NMR (400 MHz, Methanol-d4) δ 7.97 – 7.87 (m, 1H), 7.14 – 7.06 (m, 1H), 7.05 – 6.99 (m, 
1H), 6.95 – 6.79 (m, 2H). HRMS (C13H7F4NO2), Calculated for [M + Na]+ 308.0305, found 
308.0296. 
 
(4-methylpiperazin-1-yl)(2,3,4-trifluorophenyl)methanone (2a101): A oven dried round 




DCM. The reaction mixture was cooled with an ice-bath to 0 oC. 1-2 drops of anhydrous DMF 
was added followed by dropwise addition of neat oxalyl chloride (1.2 mL, 14 mmol) over 2 min.  
The reaction was stirred at room temperature for 4 h. The solvent was then removed under reduced 
pressure. Excess oxalyl chloride was azeotropically removed with 3 X 5 mL portions of DCM 
under reduced pressure. To the crude product catalytic amount of DMAP was added (5 mg) and 
then 25 mL of DCM and the N-methylpiperazine (3 mL, 31.5 mmol) was added neat at 0 oC. The 
ice bath was removed after 10 min and the reaction was permitted to warm to room temperature. 
The reaction was then stirred at room temperature 24 h; completion of reaction was determined by 
TLC. After this the solvent was removed to remove the excess amine and the crude was dissolved 
in 100 mL of DCM and washed with 2 X 50 mL water, 3 X 30 mL 0.5N HCl, followed by brine 
wash. The crude was dried over Sodium sulfate and purified using SiO2 [the slurry was prepared 
in 2 % 7 N NH3 (in methanol)/dichloromethane] using 2 % 7 N NH3 (in methanol)/2 % methanol/96 
% dichloromethane to provide 1.93 gm (74 %) of a yellow oil that solidified overnight to a canary 
yellow solid. MP: 71.3 oC. 1H NMR (500 MHz, Chloroform-d) δ 7.18 – 7.13 (m, 1H), 7.10 – 7.04 
(m, 1H), 3.83 (s, 2H), 3.37 (s, 2H), 2.51 (t, J = 5.0 Hz, 2H), 2.39 (t, J = 5.0 Hz, 2H), 2.35 (s, 3H). 
HRMS: (C12H13F3N2O) Calculated for 259.1052 [M + H]+, found 259.1053. 
 
 
3-((2,3-difluoro-6-(4-methylpiperazine-1-carbonyl)phenyl)amino)benzonitrile (2a107): A 
100 mL dry round bottom flask was charged with 3-aminobenzonitrile (127 mg, 1.07 mmol), (4-




anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (60 mg, 2.6 
mmol) was added in portions 2 portions over 5 min.  The reaction was then warmed to 65 oC 
(external temperature) and stirred for 24 h. The reaction was quenched by the addition of 10 mL 
of water. The reaction mixture was then extracted three times with 25 mL portions of 
dichloromethane, washed with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was 
decanted, and the solvent was removed under reduced pressure. The crude product was isolated on 
SiO2 [the slurry was prepared in 2 % 7 N NH3 (in methanol)/dichloromethane] using 2-4 % 7 N 
NH3 (in methanol)/dichloromethane to provide 140 mg (39 %) of creamy white crystals. MP: 155.3 
– 156.4 oC. 1H NMR (500 MHz, Chloroform-d) δ 7.35 – 7.31 (m, 1H), 7.19 (dt, J = 7.6, 1.2 Hz, 
1H), 7.12 (s, 1H), 7.07 – 6.96 (m, 4H), 3.55 (d, 4H), 2.25 (d, 7H). HRMS: (C19H18F2N4O) 
Calculated for 357.1522 [M + H]+, found 357.1518. 
 
(3,4-difluoro-2-(pyridin-3-ylamino)phenyl)(4-methylpiperazin-1-yl)methanone (2a108): A 
100 mL dry round bottom flask was charged with pyridin-3-amine (101 mg, 1.07 mmol), (4-
methylpiperazin-1-yl)(2,3,4-trifluorophenyl)methanone (258 mg, 1 mmol), and 10 mL of 
anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (60 mg, 2.6 
mmol) was added in portions 2 portions over 5 min.  The reaction was then warmed to 65 oC 
(external temperature) and stirred for 24 h. The reaction was quenched by the addition of 10 mL 
of water. The reaction mixture was then extracted three times with 25 mL portions of 
dichloromethane, washed with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was 




SiO2 [the slurry was prepared in 2 % 7 N NH3 (in methanol)/dichloromethane] using 2-4 % 7 N 
NH3 (in methanol)/dichloromethane to provide 122 mg (36 %) of light brown powder. MP: 139.5 
oC. 1H NMR (400 MHz, Chloroform-d) δ 8.17 (s, 1H), 8.12 (d, J = 4.6 Hz, 1H), 7.13 (dd, J = 8.3, 
4.6 Hz, 1H), 7.09 – 7.04 (m, 1H), 7.03 – 6.97 (m, 2H), 6.91 (td, J = 9.0, 7.0 Hz, 1H), 3.48 (bd, 





(2a109): A 100 mL dry round bottom flask was charged with 2,4-difluoroaniline (110 µL, 1.07 
mmol), (4-methylpiperazin-1-yl)(2,3,4-trifluorophenyl)methanone (258 mg, 1 mmol), and 10 mL 
of anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (60 mg, 
2.6 mmol) was added in portions 2 portions over 5 min.  The reaction was then warmed to 65 oC 
(external temperature) and stirred for 24 h. The reaction was quenched by the addition of 10 mL 
of water. The reaction mixture was then extracted three times with 25 mL portions of 
dichloromethane, washed with NaCl (aq, sat) and dried over Sodium sulfate.  The extract was 
decanted, and the solvent was removed under reduced pressure. The crude product was isolated on 
SiO2 [the slurry was prepared in 2 % 7 N NH3 (in methanol)/dichloromethane] using 2-4 % 7 N 
NH3 (in methanol)/dichloromethane to provide 108 mg (29 %) of light blue powder. MP: 89.7 oC. 




1H), 6.49 (s, 1H), 3.52 (bd, 4H), 3.52 (bd, 4H), 2.33 (bs, 4H), 2.28 (s, 3H). HRMS: (C18H17F4N3O) 
Calculated for 368.1381 [M + H]+, found 368.1365. 
Thiophenes: 
 
Methyl 5-methyl-2-(phenylamino)thiophene-3-carboxylate (2b39, MG-3-110): An overnight 
oven-dried 100 mL high-pressure reaction vessel was charged with methyl 2-amino-5-
methylthiophene-3-carboxylate (855 mg, 5 mmol), iodobenzene (0.84 mL, 7.5 mmol), copper 
iodide (1428 mg, 7.5 mmol), potassium carbonate (1382 mg, 10 mmol), dimethylformamide (45 
mL), and water (5 mL). The reaction vessel was sealed with septum and it was subjected to argon 
filling and vacuum purging (3 times). The reaction mixture was allowed to stir at room temperature 
for 15 min. After this, it was heated at 120 oC for 24 hours. The reaction mixture was allowed to 
cool down to the room temperature. The contents were filtered and the filtrate was treated with a 
mixture of NH4OH:H2O:NH4Cl:DCM (15:30:45:90 mL). The aqueous layer was discarded, and 
the organic layer was treated with 50 mL water (5 times). The organic layer was washed with brine 
and dried over Sodium sulfate. The organic layer was concentrated under vacuum and subjected 
to SiO2 column chromatography 20-40 % (Ethyl acetate/Hexanes) mixture to give rise to 667 mg 
of yellow-creamish solid (54 %). MP = 38 – 39 oC 1H NMR (500 MHz, Chloroform-d) δ 9.81 (s, 
1H), 7.37 (tt, J = 7.4, 2.0 Hz, 2H), 7.31 – 7.27 (m, 2H), 7.06 (tt, J = 7.4, 1.1 Hz, 1H), 6.79 (q, J = 
1.3 Hz, 1H), 3.86 (s, 3H), 2.35 (d, J = 1.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.18, 157.13, 




Calculated for [M + H]+ 248.07, found 248.2. HRMS: (C13H13NO2S): Calculated for 248.0739 [M 
+ H]+ 248.0739, found 248.0727.  
 
5-methyl-2-(phenylamino)thiophene-3-carboxylic acid (2b48, MG-3-104): An oven-dried 100 
mL round bottom flask was charged with methyl 5-methyl-2-(phenylamino)thiophene-3-
carboxylate (494 mg, 2 mmol) and dissolved in to a solution of THF (20 mL) and water (5 mL). 
Then lithium hydroxide monohydrate (1.43 gm, 34 mmol) was added and the reaction was allowed 
to stir for additional 15 minute at room temperature. The reaction mixture was then refluxed for 
48 h. The progress was monitored using TLC. After completion, the reaction was allowed to be 
cooled and 5% citric acid (10 mL) was added (pH ~ 3-4). The resulting precipitate was filtered and 
dried in vacuo to give the title compound as a black solid 320 mg (68 %). MP = 54.3 – 55.1 oC. 1H 
NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 9.77 (s, 1H), 7.35 (tt, J = 7.3, 2.0 Hz, 2H), 7.30 – 
7.26 (m, 2H), 7.05 – 7.00 (m, 1H), 6.76 – 6.73 (m, 1H), 2.28 (d, J = 1.2 Hz, 3H). HRMS: 
(C12H11NO2S) calculated 234.0583 [M + H]+, found 234.0584. 
 
5-methyl-2-(phenylamino)thiophene-3-carboxamide (2b51, MG-3-106): An oven-dried 25 mL 
round bottom flask was charged with 5-methyl-2-(phenylamino)thiophene-3-carboxylic acid (100 
mg, 0.42 mmol), DMF (3-4 drops), and DCM (10 mL). The reaction mixture was cooled to 0 oC 




to stir for additional 15 minute at 0 oC. The ice-bath was removed, and reaction mixture was stirred 
for additional 4 hours at room temperature. The solvent was removed under reduce pressure and 
the excess oxalyl chloride was chased with anhydrous DCM (3 × 2 mL). The intermediate acyl 
chloride (quantitative conversion) was dissolved in 1 mL of DCM. 
In a separate 25 mL round bottom flask 7 N NH3/methanol (1.5 mL, 10.5 mmol) was added to 
anhydrous DCM (6 mL) and cooled to 0 oC using ice-bath. To this intermediate acyl chloride was 
added in a dropwise manner. The reaction was allowed to stir at 0 oC for 2 hours after which it was 
stirred at room temperature for additional 48 hours. The progress of reaction was monitored using 
TLC. After completion, the solvent was removed under reduce pressure and the contents were 
dissolved in DCM (10 mL) and washed with water (3 × 5 mL), brine, and dried over sodium 
sulfate. The crude product was isolated on SiO2 [the slurry was prepared in 1% 7 N NH3 (in 
methanol)/dichloromethane] using 1-3% 7 N NH3 (in methanol)/dichloromethane to provide 8 mg 
(8 %) of light brown powder. MP: 182.4 oC. 1H NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 7.32 
– 6.93 (m, 5H), 6.84 (t, J = 1.3 Hz, 1H), 2.36 (t, J = 20 Hz, 3H). HRMS: (C12H12N2OS) calculated 
233.0743 [M + H]+, found 233.0745. 
 
(5-methyl-2-(phenylamino)thiophen-3-yl)(4-methylpiperazin-1-yl)methanone (2b52, MG-3-
108): An oven-dried 25 mL round bottom flask was charged with 5-methyl-2-
(phenylamino)thiophene-3-carboxylic acid (100 mg, 0.42 mmol), DMF (3-4 drops), and DCM (10 
mL). The reaction mixture was cooled to 0 oC using ice-bath. Then oxalyl chloride (70 µL, 0.82 




bath was removed, and reaction mixture was stirred for additional 4 hours at room temperature. 
The solvent was removed under reduce pressure and the excess oxalyl chloride was chased with 
anhydrous DCM (3 × 2 mL). The intermediate acyl chloride (quantitative conversion) was 
dissolved in 1 mL of DCM. 
In a separate 25 mL round bottom flask 1-methylpiperazine (0.55 mL, 5 mmol) was added to 
anhydrous DCM (6 mL) and cooled to 0 oC using ice-bath. To this intermediate acyl chloride was 
added in a dropwise manner. The reaction was allowed to stir at 0 oC for 2 hours after which it was 
stirred at room temperature for additional 12 hours. The progress of reaction was monitored using 
TLC. After completion, the solvent was removed under reduce pressure and the contents were 
dissolved in DCM (10 mL) and washed with water (3 × 5 mL), brine, and dried over sodium 
sulfate. The crude product was isolated on SiO2 [the slurry was prepared in 1% 7 N NH3 (in 
methanol)/dichloromethane] using 1-4% 7 N NH3 (in methanol)/dichloromethane to provide 44 
mg (33 %) of light-yellow powder. MP: 175.3 oC. 1H NMR (400 MHz, Chloroform-d) δ 9.01 (s, 
1H), 7.30 – 7.25 (m, 2H), 7.19 – 7.15 (m, 2H), 6.93 (tt, J = 7.3, 1.1 Hz, 1H), 6.44 (q, J = 1.1 Hz, 
1H), 3.69 (t, 4H), 2.44 (t, 4H), 2.34 (d, J = 1.2 Hz, 3H), 2.32 (s, 3H). HRMS: (C17H21N3OS) 
calculated 316.1478 [M + H]+, found 316.1479. 
 
 
Methyl 2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxylate (2b41, MG-3-96): An 
overnight oven-dried 100 mL high-pressure reaction vessel was charged with methyl 2-amino-5-




copper iodide (1428 mg, 7.5 mmol), potassium carbonate (1382 mg, 10 mmol), 
dimethylformamide (45 mL), and water (5 mL). The reaction vessel was sealed with septum and 
it was subjected to argon filling and vacuum purging (3 times). The reaction mixture was allowed 
to stir at room temperature for 15 min. After this, it was heated at 120 oC for 24 hours. The reaction 
mixture was allowed to cool down to the room temperature. The contents were filtered and the 
filtrate was treated with a mixture of NH4OH:H2O:NH4Cl:DCM (15:30:45:90 mL). The aqueous 
layer was discarded, and the organic layer was treated with 50 mL water (5 times). The organic 
layer was washed with brine and dried over Sodium sulfate. The organic layer was concentrated 
under vacuum and subjected to SiO2 column chromatography 20-40 % (ethyl acetate/hexanes) 
mixture to give rise to 760 mg of white solid (57 %). MP = 56 - 58 oC. 1H NMR (500 MHz, 
Chloroform-d) δ 10.01 (s, 1H), 7.60 (td, J = 8.2, 1.4 Hz, 1H), 7.20 – 7.13 (m, 2H), 7.02 – 6.95 (m, 
1H), 6.83 (q, J = 1.3 Hz, 1H), 3.88 (s, 3H), 2.38 (d, J = 1.3 Hz, 3H). Mass m/z: (C13H12FNO2S) 
calculated for 266.06 [M + H]+, found 266.2. Elemental analysis: calculated C, 58.85; H, 4.56; N, 
5.28, found: C, 59.01; H, 4.56; N, 5.30 
 
 
2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxylic acid (2b49, MG-3-97): An oven-
dried 100 mL round bottom flask was charged with methyl methyl 2-((2-fluorophenyl)amino)-5-
methylthiophene-3-carboxylate (490 mg, 1.85 mmol) and dissolved in to a solution of THF (20 
mL) and water (5 mL). Then lithium hydroxide monohydrate (1.43 gm, 34 mmol) was added and 




was then refluxed for 48 h. The progress was monitored using TLC. After completion, the reaction 
was allowed to be cooled and 5% citric acid (10 mL) was added (pH ~ 3-4). The resulting 
precipitate was filtered and dried in vacuo to give the title compound as a black solid 316 mg (68 
%). MP 55 oC. 1H NMR (400 MHz, DMSO-d6) δ 12.66 (s, 1H), 10.07 (s, 1H), 7.55 (td, J = 8.4, 
1.5 Hz, 1H), 7.31 (ddd, J = 11.6, 8.2, 1.4 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.08 – 7.01 (m, 1H), 6.79 
(q, J = 1.1 Hz, 1H), 2.31 (d, J = 1.2 Hz, 3H). Elemental analysis: calculated: C, 57.36; H, 4.01; N, 
5.57; found C, 57.56; H, 4.01; N, 5.55. 
 
 
2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxamide (2b56, MG-3-101): An oven-
dried 25 mL round bottom flask was charged with 2-((2-fluorophenyl)amino)-5-methylthiophene-
3-carboxylic acid (105 mg, 0.42 mmol), DMF (100 μL), and DCM (10 mL). The reaction mixture 
was cooled to 0 oC using ice-bath. Then oxalyl chloride (70 µL, 0.82 mmol) was added and the 
reaction was allowed to stir for additional 15 minute at 0 oC. The ice-bath was removed, and 
reaction mixture was stirred for additional 4 hours at room temperature. The solvent was removed 
under reduce pressure and the excess oxalyl chloride was chased with anhydrous DCM (3 × 2 mL). 
The intermediate acyl chloride (quantitative conversion) was dissolved in 1 mL of DCM. 
In a separate 25 mL round bottom flask 7 N NH3/methanol (1.5 mL, 10.5 mmol) was added to 
anhydrous DCM (6 mL) and cooled to 0 oC using ice-bath. To this intermediate acyl chloride was 
added in a dropwise manner. The reaction was allowed to stir at 0 oC for 2 hours after which it was 




TLC. After completion, the solvent was removed under reduce pressure and the contents were 
dissolved in DCM (10 mL) and washed with water (3 × 5 mL), brine, and dried over sodium 
sulfate. The crude product was isolated on SiO2 [the slurry was prepared in 1% 7 N NH3 (in 
methanol)/dichloromethane] using 1-3% 7 N NH3 (in methanol)/dichloromethane to provide 12 
mg (11 %) of light brown powder. MP: 348.3 oC. 1H NMR (400 MHz, Chloroform-d) δ 9.86 (s, 
1H), 7.60 (td, J = 8.2, 1.3 Hz, 1H), 7.19 – 7.12 (m, 2H), 7.04 – 6.97 (m, 1H), 6.86 (q, J = 1.3 Hz, 





(2b57, MG-3-102): An oven-dried 25 mL round bottom flask was charged with 2-((2-
fluorophenyl)amino)-5-methylthiophene-3-carboxylic acid (105 mg, 0.42 mmol), DMF (3-4 
drops), and DCM (10 mL). The reaction mixture was cooled to 0 oC using ice-bath. Then oxalyl 
chloride (70 µL, 0.82 mmol) was added and the reaction was allowed to stir for additional 15 
minute at 0 oC. The ice-bath was removed, and reaction mixture was stirred for additional 4 hours 
at room temperature. The solvent was removed under reduce pressure and the excess oxalyl 
chloride was chased with anhydrous DCM (3 × 2 mL). The intermediate acyl chloride (quantitative 
conversion) was dissolved in 1 mL of DCM. 
In a separate 25 mL round bottom flask 1-Methylpiperazine (0.55 mL, 5 mmol) was added to 




added in a dropwise manner. The reaction was allowed to stir at 0 oC for 2 hours after which it was 
stirred at room temperature for additional 12 hours. The progress of reaction was monitored using 
TLC. After completion, the solvent was removed under reduce pressure and the contents were 
dissolved in DCM (10 mL) and washed with water (3 × 5 mL), brine, and dried over sodium 
sulfate. The crude product was isolated on SiO2 [the slurry was prepared in 1% 7 N NH3 (in 
methanol)/dichloromethane] using 1-4% 7 N NH3 (in methanol)/dichloromethane to provide 54 
mg (39 %) of light-yellow powder. MP: 202.7 oC. 1H NMR (400 MHz, Chloroform-d) δ 8.96 (d, 
J = 2.4 Hz, 1H), 7.50 – 7.43 (m, 1H), 7.11 – 7.03 (m, 2H), 6.89 – 6.82 (m, 1H), 6.48 (q, J = 1.0 
Hz, 1H), 3.68 (t, J = 4.0 Hz, 4H), 2.41 (t, J = 4.0 Hz, 4H), 2.37 (d, J = 1.2 Hz, 3H), 2.30 (s, 3H). 
HRMS: (C17H19N3OS) calculated 333.1305 [M + H]+, found 333.1308. 
 
 
6,6-dimethylazepane-2,4-dione (2b75, MG-3-17): In a dry 500 mL RBF, hydroxylamine 
hydrochloride (20 g, 0.28 mol) was added to a solution of dimedone (40 g, 0.28 mol) in methanol 
(250 mL), and the reaction was heated to reflux for 6 hours. The reaction was concentrated in 
vacuo to give an orange oil. The resulting oil was dissolved in acetonitrile (250 mL), and 
triethylamine (42.9 mL, 0.31 mol) added. The reaction mixture was cooled to 0 °C and a solution 
of p-toluenesulphonyl chloride (56.0 g, 0.3 mol) in acetonitrile (300 mL) was added slowly 
dropwise using a dropping funnel, and the reaction stirred at room temperature for 2 hours. Water 
(16 mL) was then added and the reaction was heated to 60 °C for 24 hours. The reaction was 
cooled, K2CO3 (86 g, 0.62 mol) was added, and the suspension was stirred at room temperature 




was dissolved in DCM (500 mL) and washed with water (100 mL). The organic extracts were 
dried (MgSO4) and filtered through silica gel (100 g). The resulting filtrate was concentrated in 
vacuo to give a brown solid. The solid was dissolved in 1:1 THF/heptane (200 mL) and heated to 
50 °C for 1.5 hours. The mixture was cooled, and the resulting precipitate filtered and dried in 
vacuo to give 6,6-dimethylazepane-2,4-dione as a beige solid (16.1 g, 36%). 1H NMR (400 MHz, 





ethyl ester (2b76, MG-3-22): In a dry RBF (100 mL), sulphur (2.50 g, 78.1 mmol), and ethyl 
cyanoacetate (8.3 mL, 78.1 mmol) were added to a solution of 6,6-dimethylazepane-2,4-
dione  (10.1 g, 65.1 mmol) in ethanol (30 mL) and the reaction was stirred at room temperature 
for 0.5 hours. Morpholine (6.8 mL, 78.1 mmol) was added slowly dropwise and the reaction 
mixture was heated to 65°C for 18 hours. The reaction was cooled to 0°C and the precipitate was 
filtered and dried in vacuo to give the title compound as a white pink solid (11.2 g, 61%). 1H NMR 
(400 MHz, DMSO-d6) δ 7.74 (t, 1H), 7.69 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 2.80 (s, 2H), 2.77 (d, 







carboxylate (2b77, MG-3-80): An overnight oven-dried 100 mL high-pressure reaction vessel 
was charged with methyl 2-amino-5-methylthiophene-3-carboxylate (1412 mg, 5 mmol), 
iodobenzene (0.84 mL, 7.5 mmol), copper iodide (1428 mg, 7.5 mmol), potassium carbonate (1382 
mg, 10 mmol), dimethylformamide (45 mL), and water (5 mL). The reaction vessel was sealed 
with septum and it was subjected to argon filling and vacuum purging (3 times). The reaction 
mixture was allowed to stir at room temperature for 15 min. After this, it was heated at 120 oC for 
18 hours. The reaction mixture was allowed to cool down to the room temperature. The contents 
were filtered, and the filtrate was treated with a mixture of NH4OH:H2O:NH4Cl:DCM 
(15:30:45:90 mL). The aqueous layer was discarded, and the organic layer was treated with 50 mL 
water (5 times). The organic layer was washed with brine and dried over Sodium sulfate. The 
organic layer was concentrated under vacuum and subjected to SiO2 column chromatography 30-
60 % (ethyl acetate/DCM) mixture to give rise to 1.12 g of white crystalline solid (62.5 %). M.P: 
212 oC. 1H NMR (500 MHz, Chloroform-d) δ 10.54 (s, 1H), 7.43 – 7.36 (m, 4H), 7.17 – 7.13 (m, 
1H), 6.14 (s, 1H), 4.40 (qd, J = 7.1, 1.0 Hz, 2H), 3.03 (d, J = 0.9 Hz, 2H), 3.00 (d, J = 5.4 Hz, 2H), 
1.44 (td, J = 7.1, 1.0 Hz, 3H), 1.09 (d, J = 0.9 Hz, 6H). Elemental Analysis calculated for: C, 63.66; 







carboxylic acid (2b79, MG-3-73): Lithium hydroxide monohydrate (1.43 g, 59.8 mmol) was 
added to a solution of ethyl 5,5-dimethyl-8-oxo-2-(phenylamino)-5,6,7,8-tetrahydro-4H-
thieno[2,3-c]azepine-3-carboxylate (360 mg, 1 mmol) in THF (20 mL) and water (5 mL) and 
heated to reflux for 36 hours. The reaction mixture was concentrated in vacuo and 5% citric acid 
(10 mL) added. The resulting precipitate was filtered and dried in vacuo to give the title 
compound as a white solid (225 mg, 68 %). MP: 211.7 oC. 1H NMR (400 MHz, DMSO-d6) δ 7.65 
– 7.55 (m, 1H), 7.36 – 7.23 (m, 2H), 7.19 – 7.10 (m, 2H), 6.88 (p, J = 14.6, 7.3 Hz, 1H), 3.17 (s, 
1H), 2.88 (d, J = 5.0 Hz, 1H), 2.78 (d, J = 5.1 Hz, 1H), 2.60 (s, 1H), 0.94 (d, J = 6.6 Hz, 6H). 




thieno[2,3-c]azepin-8-one (2b81, MG-5-5): In an overnight oven-dried RBF was added 5,5-
dimethyl-8-oxo-2-(phenylamino)-5,6,7,8-tetrahydro-4H-thieno[2,3-c]azepine-3-carboxylic acid 
(100 mg, 0.3 mmol), and N,N-diisopropylethylamine (DIPEA, 0.14 mL, 0.8 mmol) to a solution 




reaction was allowed to stir at room temperature for 0.5 hours. Following this HATU (300 mg, 0.8 
mmol) was added and the reaction was stirred for 0.5 hours under argon. Argon was removed and 
the reaction was stirred for additional 24 hours with constant TLC monitoring at 6 hours interval. 
The reaction was diluted with DCM (30 mL), and NaOH (0.5 mL, 1N), and water (20 mL) was 
added. The mixture was allowed to stand for 0.5 hours. The organic and aqueous phases were 
separated, and the organic phase was washed with water (20 mL for five times). The organic phases 
were combined, washed with brine, and dried over Sodium sulfate. The organic layer was 
concentrated under vacuum and subjected to SiO2 column chromatography 0-6 % 
(methanol/DCM) mixture to give rise to 28 mg of the title compound as white crystalline solid (22 
%). MP: 228.7 oC. 1H NMR (500 MHz, Chloroform-d) δ 7.42 (s, 1H), 7.35 – 7.30 (m, 2H), 7.26 – 
7.23 (m, 2H), 7.06 – 7.02 (m, 1H), 6.43 – 6.36 (m, 1H), 3.68 (s, 2H), 3.57 – 3.45 (m, 2H), 3.02 (d, 
J = 5.1 Hz, 2H), 2.58 (s, 2H), 2.51 – 2.42 (m, 2H), 2.36 – 2.27 (m, 5H), 1.05 (s, 6H). HRMS: 
(C22H29O2N4S), Calculated for 413.2005 [M + H]+, Found 413.2002. 
 
Ethyl 2-((2-fluorophenyl)amino)-5,5-dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-thieno[2,3-
c]azepine-3-carboxylate (2b78, MG-3-81): by utilizing the same procedure as for the synthesis 
of 2b77, using methyl 2-amino-5-methylthiophene-3-carboxylate (1412 mg, 5 mmol), 2-
Fluoroiodobenzene (0.88 mL, 7.5 mmol), copper iodide (1428 mg, 7.5 mmol), potassium 
carbonate (1382 mg, 10 mmol), dimethylformamide (45 mL), and water (5 mL) the synthesis of 
2b78 was accomplished. White powder, (1.31 g, 70 %). MP: 152.2 oC.  1H NMR (400 MHz, 




1H), 6.18 – 6.03 (m, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.04 (s, 2H), 2.99 (d, J = 5.4 Hz, 2H), 1.43 (t, 
J = 7.1 Hz, 3H), 1.08 (s, 6H). Analysis calculated for C19H21FN2O3S . 0.5057 CH3CO2C2H5, 
calculated C: 59.97; H: 5.99; N: 6.65; found C: 59.94; H: 5.99; N: 6.68. 
 
2-((2-fluorophenyl)amino)-5,5-dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-thieno[2,3-c]azepine-
3-carboxylic acid (2b80, MG-3-93): by utilizing the same procedure as for the synthesis of 2b79, 
using lithium hydroxide monohydrate (1.43 g, 59.8 mmol), ethyl 2-((2-fluorophenyl)amino)-5,5-
dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-thieno[2,3-c]azepine-3-carboxylate (376 mg, 1 mmol), 
THF (20 mL), and water (5 mL)  the synthesis of 2b80 was accomplished. White creamish powder 
(260 mg, 74.6 %). MP: 178.3 oC. 1H NMR (400 MHz, DMSO-d6) δ 8.98 (s, 1H), 7.65 (t, J = 4.7 
Hz, 1H), 7.43 (t, J = 8.6 Hz, 1H), 7.21 (dd, J = 11.1, 8.4 Hz, 1H), 7.12 (t, J = 7.8 Hz, 1H), 6.98 – 
6.90 (m, 1H), 6.30 (s, 1H), 2.87 (d, J = 5.0 Hz, 2H), 2.58 (s, 2H), 0.94 (s, 6H). HRMS: (C17H17 




tetrahydro-8H-thieno[2,3-c]azepin-8-one (2b82, MG-5-7): by utilizing the same procedure as 




tetrahydro-4H-thieno[2,3-c]azepine-3-carboxylic acid (105 mg, 0.3 mmol), N,N-
diisopropylethylamine (DIPEA, 0.14 mL, 0.8 mmol), N-methylpiperazine (0.1 mL, 0.8 mmol), 
HATU (300 mg, 0.8 mmol), and DMF (4 mL) the synthesis of 2b82 was accomplished. White 
creamish powder (32 mg, 22 %). MP: 232.4 oC. 1H NMR (400 MHz, Chloroform-d) δ 7.57 (td, J 
= 8.2, 1.4 Hz, 1H), 7.22 (d, J = 3.3 Hz, 1H), 7.15 – 7.07 (m, 2H), 7.00 – 6.94 (m, 1H), 6.58 (t, J = 
4.7 Hz, 1H), 3.69 (d, J = 8.4 Hz, 2H), 3.55 – 3.44 (m, 2H), 3.04 (d, J = 5.2 Hz, 2H), 2.61 (s, 2H), 
2.52 – 2.42 (m, 2H), 2.36 – 2.26 (m, 5H), 1.06 (s, 6H). HRMS: (C22H28O2N4FS), Calculated for 
431.1911 [M + H]+, found 431.1895. 
 
 
6-(tert-butyl)-3-ethyl 2-amino-4,7-dihydrothieno[2,3-c] pyridine-3,6(5H)-dicarboxylate 
(2b60): A 250 mL one-neck round bottom flask was charged with ethyl cyanoacetate (3.2 mL or 
3.339 g, 24 mmol), tert-butyl 4-oxopiperidine-1-carboxylate (3.7 g, 20 mmol), sulfur (768 mg, 24 
g atom), triethylamine (4.2 mL, 30 mmol) and ethanol (50 mL). The reaction was stirred at 65 oC 
(internal temperature) for 18 hr. The reaction mixture was cooled, filtered, washed with cold EtOH 
followed by water. The solid was dried to yield 5.35 g (82 %) of a light yellow crystalline solid. 
MP 152 - 153 oC. 1H NMR (400 MHz, CDCl3): δ 6.06 (s, 2H), 4.36 (s, 2H), 4.29 (q, J = 7.2 Hz, 
2H), 3.63 (t, 2H), 2.82 (s, 2H), 1.49 (s, 9H), 1.35 (t, J = 7.2 Hz, 3H). Elemental analysis calculated 








dicarboxylate (2b61): An overnight oven-dried 100 mL high-pressure reaction vessel was 
charged with 6-(tert-butyl)-3-ethyl 2-amino-4,7-dihydrothieno[2,3-c] pyridine-3,6(5H)-
dicarboxylate (1632 mg, 5 mmol), iodobenzene (0.84 mL, 7.5 mmol), copper iodide (1428 mg, 7.5 
mmol), potassium carbonate (1382 mg, 10 mmol), dimethylformamide (45 mL), and water (5 mL). 
The reaction vessel was sealed with septum and it was subjected to argon filling and vacuum 
purging (3 times). The reaction mixture was allowed to stir at room temperature for 15 min. After 
this, it was heated at 120 oC for 18 hours. The reaction mixture was allowed to cool down to the 
room temperature. The contents were filtered and the filtrate was treated with a mixture of 
NH4OH:H2O:NH4Cl:DCM (15:30:45:90 mL). The aqueous layer was discarded, and the organic 
layer was treated with 50 mL water (5 times). The organic layer was washed with brine and dried 
over Sodium sulfate. The organic layer was concentrated under vacuum and subjected to SiO2 
column chromatography 20-40 % (Ethyl acetate/hexanes) mixture to give rise to 1.22 g of yellow 
solid (61 %). MP: 102.1 - 103.4 oC. 1H NMR (400 MHz, Chloroform-d) δ 10.16 (s, 1H), 7.42 – 
7.34 (m, 2H), 7.34 – 7.28 (m, 2H), 7.12 – 7.06 (m, 1H), 4.44 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 3.67 
(t, J = 5.6 Hz, 2H), 2.89 (s, 2H), 1.51 (s, 9H), 1.40 (t, J = 7.1 Hz, 3H). Anal calcd for C21H26N2O4S: 






dicarboxylate (2b62): An overnight oven-dried 100 mL high-pressure reaction vessel was 
charged with 6-(tert-butyl)-3-ethyl 2-amino-4,7-dihydrothieno[2,3-c] pyridine-3,6(5H)-
dicarboxylate (1632 mg, 5 mmol), 2-fluoroiodobenzene (0.88 mL, 7.5 mmol), copper iodide (1428 
mg, 7.5 mmol), potassium carbonate (1382 mg, 10 mmol), dimethylformamide (45 mL), and water 
(5 mL). The reaction vessel was sealed with septum and it was subjected to argon filling and 
vacuum purging (3 times). The reaction mixture was allowed to stir at room temperature for 15 
min. After this, it was heated at 120 oC for 18 hours. The reaction mixture was allowed to cool 
down to the room temperature. The contents were filtered, and the filtrate was treated with a 
mixture of NH4OH:H2O:NH4Cl:DCM (15:30:45:90 mL). The aqueous layer was discarded, and 
the organic layer was treated with 50 mL water (5 times). The organic layer was washed with brine 
and dried over Sodium sulfate. The organic layer was concentrated under vacuum and subjected 
to SiO2 column chromatography 20-40 % (Ethyl acetate/hexanes) mixture to give rise to 1.40 g of 
yellow solid (67 %). Yellow solid. MP: 151 - 152 oC. 1H NMR (400 MHz, Chloroform-d) δ 10.31 
(s, 1H), 7.60 (td, J = 8.1, 1.2 Hz, 1H), 7.20 – 7.13 (m, 2H), 7.05 – 6.98 (m, 1H), 4.47 (s, 2H), 4.37 
(q, J = 7.1 Hz, 2H), 3.68 (t, J = 5.9 Hz, 2H), 2.91 (s, 2H), 1.51 (s, 9H), 1.41 (t, J = 7.1 Hz, 3H). 





Ethyl 2-(phenylamino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate TFA salt 
(2b67, MG-4-32): In an overnight dried round bottom flask was added 6-(tert-butyl) 3-ethyl 2-
(phenylamino)-4,7-dihydrothieno[2,3-c]pyridine-3,6(5H)-dicarboxylate (57 mg, 0.14 mmol) to 
1/1 TFA/DCM (6 mL). The reaction was stirred at room temperature for 12 hours after which TLC 
showed full consumption of the starting material. The solvent was removed under reduced pressure 
to give 48 mg (81 %) of light brown powder. MP: 140.0 oC. 1H NMR (400 MHz, Chloroform-d) 
δ 10.16 (s, 1H), 9.74 (s, 2H), 7.41 – 7.35 (m, 2H), 7.28 – 7.23 (m, 2H), 7.15 – 7.10 (m, 1H), 4.33 
(q, J = 7.1 Hz, 2H), 4.18 (s, 2H), 3.45 (s, 2H), 3.16 (s, 2H), 1.38 (t, J = 7.1 Hz, 3H). HRMS: 




(2b68, MG-4-24): In an overnight dried round bottom flask was added 6-(tert-butyl) 3-ethyl 2-
((2-fluorophenyl)amino)-4,7-dihydrothieno[2,3-c]pyridine-3,6(5H)-dicarboxylate (60 mg, 0.14 
mmol) to 4M HCl/dioxane (6 mL). The reaction was stirred at room temperature for 2 hours after 
which TLC showed full consumption of the starting material. The solvent was removed under 
reduced pressure and the crude was washed with diethyl ether and filtered to give 42 mg (82 %) 




7.29 – 7.23 (m, 2H), 7.18 – 7.12 (m, 1H), 4.39 (qd, J = 7.1, 1.1 Hz, 2H), 4.29 (s, 2H), 3.53 (t, J = 
6.2 Hz, 2H), 3.20 (t, J = 6.1 Hz, 2H), 1.42 (td, J = 7.1, 1.1 Hz, 3H). HRMS: (C16H17FN2O2S) 
calculated for 321.1068 [M + H]+, found 321.1073. 
Sigma-2 receptor antagonists 
  
tert-butyl 4-(2-cyanopropan-2-yl)piperazine-1-carboxylate (3a17, MG-4-100): HCl (40.3 mL 
of a 2.0 M in Et2O, 80.6 mmol, 1.5 eq. titrated against standardized 1 N NaOH to a phenolphthalein 
pink end-point) was added dropwise to a stirred solution of tert-butyl piperazine-1-carboxylate 
(12.6 g, 53.7 mmol, 1.0 eq.) in MeOH (60 mL) and CH2Cl2 (60 mL) at 0 °C under Argon. The 
resulting mixture was stirred at 0 °C for 1 h. Then, the solvent was evaporated under reduced 
pressure and the residue was dissolved in water (150 mL). NaCN (2.63 g, 53.7 mmol, 1.0 eq.) and 
then a solution of acetone (9.4 g, 11.8 mL, 161.2 mmol, 3.0 eq.) in water (20 mL) were added 
sequentially. The resulting mixture was stirred at room temperature under air for 48 h. Then, water 
(100 mL) was added and the mixture was extracted with EtOAc (3 × 100 mL). The combined 
organics were dried (MgSO4) and evaporated under reduced pressure to give tert-butyl 4-(2-
cyanopropan-2-yl)piperazine-1-carboxylate as a white crystalline solid, 11 gm (64%). MP: 108.2 
oC (reported 108 – 110 oC) matching the literature.279 Residual NaCN was oxidized to cyanate 






tert-butyl 4-(4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (3a22, MG-
3-119): In an overnight oven dried and cooled three-necked round-bottom flask (RBF), under 
constant supply of argon, was added 1-ethynyl-4-fluorobenzene (1.98 gm, 16.5 mmol) and 50 mL 
of anhydrous THF. The reaction mixture was cooled to a temperature of -5 oC – 0 oC using ice-
bath (external temperature). Methylmagnesium bromide (5.25 mL, 16.5 mmol, 3.2 M, titrated 
against s-BuOH with 1,10-Phenanthroline as indicator) was added dropwise while maintaining the 
external temperature between 0 oC – 1.5 oC. The reaction was stirred for 30 min. (slight yellow 
solution). tert-butyl 4-(2-cyanopropan-2-yl)piperazine-1-carboxylate (2.3 gm, 9.2 mmol) as a 
solution in anhydrous THF (25 mL) was added dropwise while maintaining the temperature at ~ 2 
oC. After 2 hours the ice-bath was removed, and the reaction was allowed to stir at room 
temperature overnight. The progress of the reaction was monitored by TLC and after consumption 
of the starting material (1-ethynyl-4-fluorobenzene) the reaction was quenched by the addition of 
10 mL of water. After this 50 mL of water was added and the crude was extracted with ethyl acetate 
(3 X 40 mL). The combined ethyl acetate fractions were washed with brine, dried over sodium 
sulfate. The crude was isolated on SiO2 column chromatography using hexane/ethyl acetate (1/1) 
as the eluent to yield the desired compound as a white powder, 1.98 gm (63%). MP: 115.1 oC. 1H 
NMR (400 MHz, Chloroform-d) δ 7.36 (dd, J = 8.2, 5.6 Hz, 2H), 6.96 (t, J = 8.5 Hz, 2H), 3.46 (s, 
5H), 2.63 (s, 4H), 1.45 (s, 16H). HRMS: (C20H27FN2O2) calculated for [M + H]+  347.2129, found 





tert-butyl 4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine-1-carboxylate (3a10, MG-4-
110): In a clean conical flask 3a22 (2.25 gm, 6.5 mmol) was added to a mixture of ethanol and 
water (80 and 20 mL respectively). The reaction mixture was heated to 60 oC to dissolve the 
intermediate. After a clear solution is formed the reaction mixture was cool down to room 
temperature. To this 1 mL of glacial acetic acid (17.5 mmol) was added. 
In the hydrogenation vessel Pd/C (150 mg) was added. To this the contents from the conical flasks 
were added and the vessel was stirred for 5 min. After that the reaction was subjected to the 
hydrogenation apparatus for 1 hour. The progress of the reaction was monitored via TLC. To this 
potassium carbonate (5 gm) dissolved in water (20 mL) was added and the reaction was allowed 
to stir overnight (pH ~ 8 – 9) at room temperature. The reaction mixture was filtered over Celite® 
and the crude was extracted with ethyl acetate (3 X 50 mL), washed with brine and dried over 
sodium sulfate. The combined fractions were subjected to rotavap under vacuum to give rise to 
dark green crude which was purified using silica gel column chromatography using 7 N ammonia 
in methanol/dichloromethane (2/98) to give rise to a yellow oil (1.7 gm, 75%). 1H NMR (400 MHz, 
Chloroform-d) δ 7.12 (ddd, J = 8.4, 5.3, 2.6 Hz, 2H), 7.00 – 6.94 (m, 2H), 3.46 – 3.40 (m, 4H), 
2.66 – 2.59 (m, 2H), 2.55 – 2.49 (m, 4H), 1.71 – 1.65 (m, 2H), 1.48 (s, 9H), 1.08 (s, 6H). HRMS: 





1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (3a30, MG-4-115): In a dried RBF was 
added intermediate 3a10 (1.05 gm, 3 mmol) and 1N HCl in water/dioxane (1/1, 12 mL). The 
reaction was stirred for 2 hours at room temperature. The product 3a30 was isolated as a yellow 
oil (600 mg, 80%) after basic work-up (using NaOH) followed by the removal of the solvent. 1H 
NMR (400 MHz, Chloroform-d) δ 7.14 - 7.10 (m, 2H), 6.98 – 6.90 (m, 2H), 2.90 – 2.88 (t, J = 4.8 
Hz, 4H), 2.63 – 2.59 (m, 2H), 2.55 – 2.54 (m, 4H), 1.68 – 1.64 (m, 2H), 1.06 (s, 6H). HRMS: 
calculated for [M + H]+ = 251.1918, found 251.1917. 
General procedure for the N-arylation (Method A): A suspension of arylboronic acid (0.6 mmol), 
1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 mg, 0.45 
mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-
dichloroethane (10 mL, 0.03 M) was added to a 25 mL RBF charged with a magnetic stirring bar. 
The reaction mixture was stirred overnight at room temperature. Reaction progress was monitored 
by TLC. The suspension was then filtered through a plug of celite and purified by SiO2 column 
chromatography using 7 N NH3 in methanol and dichloromethane (2 % of 7 N NH3 in methanol 
and 98 % dichloromethane) to obtain the desired product.  
General procedure for the N-acylation (Method B): A solution of arylcarboxylic acid (0.6 mmol), 
1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 µl, 0.6 
mmol) in DMF (under argon) was stirred for 15 min. at room temperature in a 25 mL RBF 
(overnight dried). HATU (228 mg, 0.6 mmol) was then added and the reaction was allowed to stir 
for 12 hours (reaction progress monitored by TLC). The reaction mixture was diluted with water 
(30 mL) and extracted with ethyl acetate (15 mL X 5). The crude was then purified by SiO2 column 
chromatography using 7 N NH3 in methanol and dichloromethane (2 % of 7 N NH3 in methanol 




General procedure for the HCl salt formation (Method C): The compound of interest was dissolved 
in minimum quantities of diethyl ether (in case when the compound was partially soluble in diethyl 
ether few drops of 1,4-dioxane was added). Then a freshly prepared solution of HCl in diethyl 
ether was added dropwise (5 – 10 drops). The diethyl ether was decanted and the HCl salt was 
dried under vacuum to give the final compound as HCl salt. 
 
1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-phenylpiperazine (3a40, MG-3-155): Using the 
general method A, with phenylboronic acid (73 mg, 0.6 mmol), 1-(4-(4-fluorophenyl)-2-
methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 mg, 0.45 mmol), Et3N (83.6 µL, 
0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-dichloroethane (10 mL, 0.03 M); 
3a40 was prepared as a creamy white solid, 42 mg (43%). MP: 93 oC. 1H NMR (500 MHz, 
Chloroform-d) δ 7.31 – 7.26 (m, 2H), 7.17 – 7.12 (m, 2H), 7.01 – 6.95 (m, 4H), 6.87 (t, J = 7.0 
Hz, 1H), 3.27 – 3.18 (m, 4H), 2.80 – 2.73 (m, 8H), 2.70 – 2.63 (m, 2H), 1.77 – 1.70 (m, 2H), 1.13 
(d, J = 1.5 Hz, 6H). HRMS: (C21H27FN2) calculated for 327.2231 [M + H]+, found 327.2246. 
 
3-(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)benzonitrile (3a41, MG-3-153): 
Using the general method A, with (3-cyanophenyl)boronic acid (88 mg, 0.6 mmol), 1-(4-(4-




Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-dichloroethane (10 
mL, 0.03 M); 3a41 was prepared as a creamy yellow solid, 36 mg (38%). MP: 102.9 oC. 1H NMR 
(400 MHz, Chloroform-d) δ 7.36 – 7.31 (m, 1H), 7.18 – 7.08 (m, 5H), 7.02 – 6.95 (m, 2H), 3.26 – 
3.20 (m, 4H), 2.78 – 2.72 (m, 4H), 2.69 – 2.62 (m, 2H), 1.77 – 1.70 (m, 2H), 1.13 (s, 6H). 
HRMS: (C22H26FN3) calculated for 352.2184 [M + H]+, found 352.2201. 
 
1-(benzo[d][1,3]dioxol-5-yl)-4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (3a42, 
MG-3-156): Using the general method A, with benzo[d][1,3]dioxol-5-ylboronic acid (100 mg, 0.6 
mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 
mg, 0.45 mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-
dichloroethane (10 mL, 0.03 M); 3a42 was prepared as a white solid, 46 mg (41%). MP: 96.8 oC. 
1H NMR (500 MHz, Chloroform-d) δ 7.17 – 7.12 (m, 2H), 7.00 – 6.95 (m, 2H), 6.74 (d, J = 8.4 
Hz, 1H), 6.59 (d, J = 2.4 Hz, 1H), 6.39 (dd, J = 8.4, 2.3 Hz, 1H), 5.93 – 5.91 (m, 2H), 3.12 – 3.07 
(m, 4H), 2.77 – 2.72 (m, 4H), 2.68 – 2.63 (m, 2H), 1.77 – 1.69 (m, 2H), 1.13 (s, 6H). 







3-158):  Using the general method A, with (3,4-dimethoxyphenyl)boronic acid (109 mg, 0.6 
mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 
mg, 0.45 mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-
dichloroethane (10 mL, 0.03 M); 3a43 was prepared as a white solid, 56 mg (48%). MP: 86.2 oC. 
1H NMR (500 MHz, Chloroform-d) δ 7.17 – 7.12 (m, 2H), 7.01 – 6.95 (m, 2H), 6.82 (d, J = 8.7 
Hz, 1H), 6.62 (d, J = 2.7 Hz, 1H), 6.49 (dd, J = 8.7, 2.7 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.15 – 
3.11 (m, 4H), 2.79 – 2.74 (m, 4H), 2.69 – 2.63 (m, 2H), 1.76 – 1.71 (m, 2H), 1.13 (s, 6H). 
HRMS: (C23H31FN2O2) calculated for 387.2443 (M + H)+, found 387.2434. 
 
 
1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-(3-methoxyphenyl)piperazine HCl salt (3a44, 
MG-3-157): Using the general method A, with (3-methoxyphenyl)boronic acid (91 mg, 0.6 
mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 
mg, 0.45 mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-
dichloroethane (10 mL, 0.03 M); followed by the HCl salt formation using method C, 3a44 was 
prepared as a white solid, 68 mg (57%). MP: 172.2 oC. 1H NMR (400 MHz, Chloroform-d) δ 7.23 
– 7.12 (m, 3H), 7.02 – 6.95 (m, 2H), 6.58 (dd, J = 8.3, 2.3 Hz, 1H), 6.50 (t, J = 2.3 Hz, 1H), 6.46 
– 6.42 (m, 1H), 3.82 (s, 3H), 3.24 – 3.19 (m, 4H), 2.77 – 2.72 (m, 4H), 2.70 – 2.63 (m, 2H), 1.76 






1-(3-fluorophenyl)-4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (3a45, MG-3-165): 
Using the general method A, with (3-fluorophenyl)boronic acid (84 mg, 0.6 mmol), 1-(4-(4-
fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 mg, 0.45 mmol), 
Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-dichloroethane (10 
mL, 0.03 M); 3a45 was prepared as a white solid, 41 mg (39%). MP: 105.6 oC. 1H NMR (500 
MHz, Chloroform-d) δ 7.24 – 7.18 (m, 1H), 7.18 – 7.12 (m, 2H), 7.02 – 6.96 (m, 2H), 6.70 (dd, J 
= 8.4, 1.9 Hz, 1H), 6.62 (dt, J = 12.5, 2.3 Hz, 1H), 6.54 (td, J = 8.2, 2.1 Hz, 1H), 3.24 – 3.19 (m, 
4H), 2.76 – 2.72 (m, 4H), 2.69 – 2.63 (m, 2H), 1.76 – 1.71 (m, 2H), 1.13 (s, 6H). HRMS: 
(C21H26F2N2) calculated for 345.2137 [M + H]+, found 345.2173.  
 
1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-(4-methoxyphenyl)piperazine HCl salt (3a46, 
MG-3-166): Using the general method A, with (4-methoxyphenyl)boronic acid (91 mg, 0.6 
mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 
mg, 0.45 mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 1,2-
dichloroethane (10 mL, 0.03 M); followed by method C for HCl salt formation, 3a46 was prepared 




(m, 2H), 7.00 – 6.96 (m, 2H), 6.95 – 6.91 (m, 2H), 6.88 – 6.84 (m, 2H), 3.79 (s, 3H), 3.13 – 3.09 
(m, 4H), 2.78 – 2.74 (m, 4H), 2.68 – 2.63 (m, 2H), 1.75 – 1.71 (m, 2H), 1.13 (s, 6H). HRMS: 
HRMS: (C22H29FN2O) calculated for 357.2336 [M + H]+, found 357.2342. 
 
(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(phenyl)methanone HCl salt 
(3a54, MG-4-2): Using the general method B, with benzoic acid (73 mg, 0.6 mmol), 1-(4-(4-
fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 µl, 0.6 mmol), 
HATU (228 mg, 0.6 mmol), and DMF; followed by method C for HCl salt formation, 3a54 was 
prepared as a white solid, 102 mg (87%). MP: 176.7 oC. 1H NMR (400 MHz, Chloroform-d) δ 
7.42 (s, 5H), 7.12 (ddd, J = 8.7, 5.3, 2.6 Hz, 2H), 7.00 – 6.93 (m, 2H), 3.80 (s, 2H), 3.44 (s, 2H), 
2.71 – 2.60 (m, 4H), 2.52 (s, 2H), 1.72 – 1.66 (m, 2H), 1.09 (s, 6H). HRMS: (C22H27FN2O) 
calculated for 355.2179 [M + H]+, found 355.2218. 
 
 
methyl 3-(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)benzoate (3a47, MG-4-
3): Using the general method A, with (3-(methoxycarbonyl)phenyl)boronic acid (108 mg, 0.6 
mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 (81 




dichloroethane (10 mL, 0.03 M); 3a47 was prepared as a white solid, 21.7 mg (25%). MP: 119.0 
oC. 1H NMR (400 MHz, Chloroform-d) δ 7.62 (dd, J = 2.5, 1.5 Hz, 1H), 7.52 (ddd, J = 7.6, 1.5, 
1.0 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.18 – 7.11 (m, 3H), 7.02 – 6.94 (m, 2H), 3.93 (s, 3H), 3.29 – 
3.24 (m, 4H), 2.76 (dd, J = 5.8, 4.2 Hz, 4H), 2.69 – 2.63 (m, 2H), 1.76 – 1.70 (m, 2H), 1.13 (s, 
6H). HRMS: (C23H29FN2O2) calculated for 385.2285 [M + H]+, found 355.2291. 
 
methyl 4-(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)benzoate HCl salt (3a48, 
MG-4-5): Using the general method A, with (3-(methoxycarbonyl)phenyl)boronic acid (108 mg, 
0.6 mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), Cu(OAc)2 
(81 mg, 0.45 mmol), Et3N (83.6 µL, 0.6 mmol) and powdered 4 Å molecular sieves (0.25 g) in 
1,2-dichloroethane (10 mL, 0.03 M); followed by method C for HCl salt formation, followed by 
method C for HCl salt formation, 3a48 was prepared as a white solid, 48 mg (38%). MP: 184.4 
oC. 1H NMR (400 MHz, Chloroform-d) δ 7.97 – 7.92 (m, 2H), 7.15 (ddd, J = 8.4, 5.3, 2.6 Hz, 2H), 
7.02 – 6.95 (m, 2H), 6.91 – 6.86 (m, 2H), 3.89 (s, 3H), 3.38 – 3.30 (m, 4H), 2.77 – 2.71 (m, 4H), 
2.71 – 2.63 (m, 2H), 1.76 – 1.69 (m, 2H), 1.13 (s, 6H). HRMS: (C23H29FN2O2) calculated for 





(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(pyridin-2-yl)methanone HCl salt 
(3a55, MG-4-6): Using the general method B, with picolinic acid (74 mg, 0.6 mmol), 1-(4-(4-
fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 µl, 0.6 mmol), 
HATU (228 mg, 0.6 mmol), and DMF; followed by method C for HCl salt formation, 3a55 was 
prepared as a white solid, 94 mg (80%). MP: 235.7 oC. 1H NMR (400 MHz, Chloroform-d) δ 8.60 
(ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.80 (td, J = 7.7, 1.8 Hz, 1H), 7.64 (dt, J = 7.8, 1.1 Hz, 1H), 7.34 
(ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.11 (ddd, J = 8.4, 5.3, 2.6 Hz, 2H), 6.99 – 6.92 (m, 2H), 3.85 – 
3.78 (m, 2H), 3.61 – 3.54 (m, 2H), 2.71 – 2.66 (m, 2H), 2.66 – 2.60 (m, 2H), 2.59 – 2.54 (m, 2H), 




(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(pyridin-3-yl)methanone HCl salt 
(3a56, MG-4-7): Using the general method B, with nicotinic acid (74 mg, 0.6 mmol), 1-(4-(4-
fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 µl, 0.6 mmol), 
HATU (228 mg, 0.6 mmol), and DMF; followed by method C for HCl salt formation, followed by 
method C for HCl salt formation, 3a56 was prepared as a white solid, 108 mg (92%). MP: 231.2 
oC. 1H NMR (400 MHz, Chloroform-d) δ 8.71 – 8.67 (m, 2H), 7.80 – 7.76 (m, 1H), 7.38 (ddd, J = 
7.8, 4.9, 0.9 Hz, 1H), 7.15 – 7.09 (m, 2H), 7.01 – 6.94 (m, 2H), 3.81 (s, 2H), 3.45 (s, 2H), 2.72 – 
2.51 (m, 6H), 1.73 – 1.67 (m, 2H), 1.10 (s, 6H). HRMS: (C21H26FN3O) calculated for 356.2132 





(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(pyridin-4-yl)methanone HCl salt 
(3a57, MG-4-8): Using the general method B, with isonicotinic acid (74 mg, 0.6 mmol), 1-(4-(4-
fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 µl, 0.6 mmol), 
HATU (228 mg, 0.6 mmol), and DMF; followed by method C for HCl salt formation, followed by 
method C for HCl salt formation, 3a57 was prepared as a white solid, 66 mg (56%). MP: 236.9 
oC. 1H NMR (400 MHz, Chloroform-d) δ 8.73 – 8.68 (m, 2H), 7.32 – 7.29 (m, 2H), 7.13 – 7.09 
(m, 2H), 7.00 – 6.94 (m, 2H), 3.83 – 3.74 (m, 2H), 3.39 – 3.34 (m, 2H), 2.64 (ddd, J = 17.2, 9.2, 
4.8 Hz, 4H), 2.56 – 2.49 (m, 2H), 1.72 – 1.66 (m, 2H), 1.09 (s, 6H). HRMS: (C21H26FN3O) 
calculated for 356.2132 (M + H)+, found 356.2157. 
 
(2,3-difluorophenyl)(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)methanone 
HCl salt (3a58, MG-4-11): Using the general method B, with 2,3-difluorobenzoic acid (95 mg, 
0.6 mmol), 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (75 mg, 0.3 mmol), DIPEA (105 
µl, 0.6 mmol), HATU (228 mg, 0.6 mmol), and DMF; followed by method C for HCl salt 
formation, followed by method C for HCl salt formation, 3a58 was prepared as a white solid, 63 
mg (49%). MP: 246.3 oC. 1H NMR (400 MHz, Chloroform-d) δ 7.27 – 7.19 (m, 1H), 7.19 – 7.09 































List of Compounds prepared 
1. N-((9H-fluoren-9-yl)carbamoyl)-2,6-dichlorobenzamide (1a2, MG-42-AU) 
2. Ethyl 2-((9H-fluoren-9-yl)amino)-2-oxoacetate (1a34, MG-59-i1) 
3. 2-((9H-fluoren-9-yl)amino)-2-oxoacetic acid (1a35, MG-59-i2) 
4. N-(2,6-dichlorobenzoyl)-N-(9H-fluoren-9-yl)oxalamide (1a32, MG-83-DA) 
5. tert-butyl (R)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate 
(1a40, MG-67) 
6. (R)-2-amino-N-(9H-fluoren-9-yl)-3-methylbutanamide TFA salt (1a42, MG-73) 
7. (R)-N-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)-2,6-
dichlorobenzamide (1a45, MG-77) 
8. tert-butyl (S)-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate 
(1a39, MG-32) 
9. (S)-2-amino-N-(9H-fluoren-9-yl)-3-methylbutanamide TFA salt (1a41, MG-38) 
10. (S)-N-(1-((9H-fluoren-9-yl)amino)-3-methyl-1-oxobutan-2-yl)-2,6-
dichlorobenzamide (1a44, MG-79) 
11. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (2a37) 
12. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (2a71) 
13. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N,N-dimethylbenzamide (2a72) 
14. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-methylbenzamide (2a73) 






17. 2-((2-fluorophenyl)amino)benzoic acid (2a52)   
18. 2-((2-fluorophenyl)amino)benzamide (2a76) 
19. 2-((2-fluoro-4-iodophenyl)amino)benzoic acid (2a51) 
20. (2-((2-fluoro-4-iodophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
hydrochloride (2a77) 
21. 2-((2-fluoro-4-iodophenyl)amino)benzamide (2a78) 
22. 3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid (2a38) 
23. 3,4-difluoro-2-(phenylamino)benzoic acid (2a39)   
24. 3,4-difluoro-2-(phenylamino)benzamide (2a94) 
25. (3,4-difluoro-2-((2-fluorophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
(2a97) 
26. 3,4-difluoro-2-(phenylamino)phenyl)(4-methylpiperazin-1-yl)methanone (2a98) 
27. 2-fluoro-4-iodo-N-methylaniline (2a34) 
28. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid (2a40) 
29. 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzamide (2a79) 
30. Methyl 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoate (2a110) 
31. (3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)phenyl)(4-methylpiperazin-
1-yl)methanone (2a80) 
32. 3,4-difluoro-2-((4-iodophenyl)amino)benzamide (2a106) 
33. 3,4-difluoro-2-(methyl(phenyl)amino)benzoic acid (2a41) 
34. (3,4-difluoro-2-(methyl(phenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
(2a81) 











40. Methyl 5-methyl-2-(phenylamino)thiophene-3-carboxylate (2b39, MG-3-110) 
41. 5-methyl-2-(phenylamino)thiophene-3-carboxylic acid (2b48, MG-3-104) 
42. 5-methyl-2-(phenylamino)thiophene-3-carboxamide (2b51, MG-3-106) 
43. (5-methyl-2-(phenylamino)thiophen-3-yl)(4-methylpiperazin-1-yl)methanone (2b52, 
MG-3-108) 
44. Methyl 2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxylate (2b41, MG-3-
96) 
45. 2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxylic acid (2b49, MG-3-97) 
46. 2-((2-fluorophenyl)amino)-5-methylthiophene-3-carboxamide (2b56, MG-3-101) 
47. (2-((2-fluorophenyl)amino)-5-methylthiophen-3-yl)(4-methylpiperazin-1-
yl)methanone (2b57, MG-3-102) 
48. 6,6-dimethylazepane-2,4-dione (2b75, MG-3-17) 
49. 2-Amino-5,5-dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-thieno[2,3-c]azepine-3-
carboxylic acid ethyl ester (2b76, MG-3-22) 
50. Ethyl 5,5-dimethyl-8-oxo-2-(phenylamino)-5,6,7,8-tetrahydro-4H-thieno[2,3-





carboxylic acid (2b79, MG-3-73) 
52. 5,5-dimethyl-3-(4-methylpiperazine-1-carbonyl)-2-(phenylamino)-4,5,6,7-
tetrahydro-8H-thieno[2,3-c]azepin-8-one (2b81, MG-5-5) 
53. Ethyl 2-((2-fluorophenyl)amino)-5,5-dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-
thieno[2,3-c]azepine-3-carboxylate (2b78, MG-3-81) 
54. 2-((2-fluorophenyl)amino)-5,5-dimethyl-8-oxo-5,6,7,8-tetrahydro-4H-thieno[2,3-
c]azepine-3-carboxylic acid (2b80, MG-3-93) 
55. 2-((2-fluorophenyl)amino)-5,5-dimethyl-3-(4-methylpiperazine-1-carbonyl)-4,5,6,7-
tetrahydro-8H-thieno[2,3-c]azepin-8-one (2b82, MG-5-7) 
56. 6-(tert-butyl)-3-ethyl 2-amino-4,7-dihydrothieno[2,3-c] pyridine-3,6(5H)-
dicarboxylate (2b60) 
57. 6-(tert-butyl) 3-ethyl 2-(phenylamino)-4,7-dihydrothieno[2,3-c]pyridine-3,6(5H)-
dicarboxylate (2b61) 
58. 6-(tert-butyl) 3-ethyl 2-((2-fluorophenyl)amino)-4,7-dihydrothieno[2,3-c]pyridine-
3,6(5H)-dicarboxylate (2b62) 
59. Ethyl 2-(phenylamino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate TFA 
salt (2b67, MG-4-32) 
60. Ethyl 2-((2-fluorophenyl)amino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-
carboxylate (2b68, MG-4-24) 
61. Tert-butyl 4-(2-cyanopropan-2-yl)piperazine-1-carboxylate (3a17, MG-4-100) 





63. Tert-butyl 4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine-1-carboxylate (3a10, 
MG-4-110) 
64. 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (3a30, MG-4-115) 
65. 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-phenylpiperazine (3a40, MG-3-155) 






69. 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-(3-methoxyphenyl)piperazine HCl salt 
(3a44, MG-3-157) 
70. 1-(3-fluorophenyl)-4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazine (3a45, MG-
3-165) 
71. 1-(4-(4-fluorophenyl)-2-methylbutan-2-yl)-4-(4-methoxyphenyl)piperazine HCl salt 
(3a46, MG-3-166) 
72. (4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(phenyl)methanone HCl 
salt (3a54, MG-4-2) 
73. Methyl 3-(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)benzoate (3a47, 
MG-4-3) 
74. Methyl 4-(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)benzoate HCl 





HCl salt (3a55, MG-4-6) 
76. (4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(pyridin-3-yl)methanone 
HCl salt (3a56, MG-4-7) 
77. (4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-yl)(pyridin-4-yl)methanone 
HCl salt (3a57, MG-4-8) 
78. (2,3-difluorophenyl)(4-(4-(4-fluorophenyl)-2-methylbutan-2-yl)piperazin-1-
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VIII. Biological Evaluation and Discussion 
1) Biological evaluation of cyclophilin inhibitors 
First, the cytotoxicity of compounds (1a2, 1a32, 1a44, and 1a45) was measured in the HeLa and 
GHOST cell lines (Table 8.1). From this assay two nontoxic concentrations (low and high) of the 
compounds (1a2, 1a32, 1a44, and 1a45) were determined and it was used to determine inhibition 
of WT HIV-1 infection in two 2 cell lines: HeLa cells which are widely used cells in which 
cyclosporine A (CsA) has a modest effect on HIV-1 infection and GHOST in which CsA has a 
more dramatic effect on HIV-1 infection. Cyclosporine A (CsA) is used as the control. The 
compounds that significantly affect WT HIV-1 infectivity in both cell lines in a dose-dependent 
manner were 1a2, 1a44, and 1a32. Out of this 1a44 looks almost identical to CsA, while the others 
show subtler effects or stronger effects in both cell types. Compound 1a45 which is the enantiomer 
of analog 1a44 was found to be inactive in HIV-infectivity assay suggesting an important role of 
stereochemistry in inhibiting HIV-1 infectivity (Fig. 8.1). 
# Hela & GHOST Cell CC50 (µM) Conc. used to determine HIV Infectivity (µM) 
Hela Cells GHOST Cells Low  High 
1a2 2 7 0.025 0.5 
1a32 2 ND 0.025 0.5 
1a44 3 ND 0.025 0.5 
1a45 20 ND 0.5 10 
ND = not determined 










Figure 8.2. Synthesized analogs for cyclophilin project. 
The biological evaluation was performed by Dr. Zandrea Ambrose, at the University of 
Pittsburgh, PA, USA. 
2) Biological evaluation of MEK5 inhibitors 
The diphenylamine and thiophene derivatives were initially examined at a single concentration of 
10 μM on EGF-stimulated triple-negative breast cancer MDA-MB-231 cells (in triplicate). DMSO 
was used as the blank representing 100% activity, and compound activity is expressed as the 
percent decrease in activity normalized to the DMSO blank. U0126, XMD8-92, and PD325901 
were used as the standards. 




















DMSO     0 0 
2a37 OH 2-F,4-I 3-F,4-F H 20.1 98.5 
2a71 NH2 2-F,4-I 3-F,4-F H 59 96.8 
2a72 NMe2 2-F,4-I 3-F,4-F H 0.2 87.3 
2a73 NHMe 2-F,4-I 3-F,4-F H 20.4 99.6 
2a74 NHEt 2-F,4-I 3-F,4-F H 8.5 98.6 
2a75 Boc-piperazine 2-F,4-I 3-F,4-F H 8.4 70.9 
2a77 N-methylpiperazine 2-F,4-I - H 30.9 33.5 
2a78 NH2 2-F - H 39 -- 
2a38 OH 2-F 3-F,4-F H -- 31.7 
2a97 N-methylpiperazine 2-F 3-F,4-F H 39.1 1.6 
2a106 NH2 4-I 3-F,4-F H ND ND 
2a39 OH - 3-F,4-F H -- 43.5 
2a94 NH2 - 3-F,4-F H 14.8 35.3 
2a98 N-methylpiperazine - 3-F,4-F H 82.4 -- 
2a42 OH 2-F,4-F 3-F,4-F H 14.4 1.3 
2a109 N-methylpiperazine 2-F,4-F 3-F,4-F H 44.8 1.5 
2a107 N-methylpiperazine 3-CN 3-F,4-F H 2.4 9.3 




2a40 OH 2-F,4-I 3-F,4-F Me 18.4 67.1 
2a79 NH2 2-F,4-I 3-F,4-F Me 0 73 
2a110 OCH3 2-F,4-I 3-F,4-F Me 91.6 50.9 
2a80 N-methylpiperazine 2-F,4-I 3-F,4-F Me 27.2 -- 
2a41 OH - 3-F,4-F Me 1.9 -- 
2a81 N-methylpiperazine - 3-F,4-F Me 5.3 -- 
U0126     43 99.6 
XMD8-92     95.2 50.1 
PD 
0325901 
    95.9 99.7 
Table 8.2. MEK5 and MEK1/2 inhibition data of diphenylamine analogs. 
Compounds 2a37, 2a71–75 represent point variations of the sidechain R1 with the rest of the 
structure unaltered. Only analog 2a71 showed appreciable activity at MEK5. For the non-halogen 
left side ring variations (R3), both 2a77 and 2a78 were considerably less active at inhibiting MEK5 
suggesting 3-F,4-F substitutions are required for efficient MEK5 inhibition. Right side arene 
variations (R2) 2a38, 2a39, 2a94, 2a97, and 2a98 explored both right side arene variations and 
side chain variations (R1) with the left side ring (R3) held constant with a 3,4-difluorophenyl 
substitution pattern. Activity was variable across these series. When the carboxylate side chain 
compounds 2a37, 2a38, and 2a39 were compared, the point omission of the 4’-iodo and 2’-fluoro 
generates compounds that are inactive at inhibiting MEK5. For the primary amides 2a71 and 2a94 
removal of both the 2’-fluoro and 4’-iodo group leads to 3-4-fold reduction at both MEK1/2 and 
MEK5. For the primary amides, MEK5 activity is weak across the board. The piperazine of the 
terminal arene series 2a75, 2a97, 2a98, 2a107, and 2a108 identified compound 2a98 as the most 




contrasts to the neutral primary amide series and the anionic carboxylic series with the equivalent 
right side arene substitution pattern. This suggests that the cationic N-methylpiperazine, in the case 
of MEK5 inhibitors, may contribute more than halogen interactions of the right arene ring. 
Preventing internal hydrogen bonding by replacing the aniline NH with an aniline N-methyl has 
differential effects on MEK1/2 versus MEK5 activity. Comparison of 2a37 with 2a40 indicates 
that if the carboxylate is prevented from internal hydrogen/ionic bonding the compound is much 
more potent at inhibiting MEK1/2 than MEK5. The relatively high activity of the ester 2a110 at 
MEK5 requires additional examination. Comparison between 2a98 and 2a81 indicates that 
presence of N-methyl group on 2a98 completely abolishes MEK5 inhibitory activity suggesting 
intra-molecular hydrogen bond may facilitate bioactive conformation.  
The best inhibitor 2a98 identified from the diphenylamine series was further evaluated in the 
mammosphere assay and in the in vivo assay (the assays were conducted in the lab of Dr. Lucio 
Miele at Louisiana State University, LA 70803). Compound 2a98 was found to inhibit the 
mammosphere number in the MDA-MB-231 cells in a dose dependent manner (Fig. 8.3-8.4) and 
it also reduced tumor growth and metastasis in vivo when administered in the mice and mouse 
(Fig. 8.5). 





Figure 8.4. No effect of analog 2a98 in ERK-5 KO MDA-MB-231 cells. 
 
 
Figure 8.5. Analog 2a98 reduces metastasis and tumor growth in vivo. 
Our collaborators Dr. Matthew Burow at Tulane University, New Orleans further tested the 
compounds in cell proliferation and viability assays in the MDA-MB-231 cells. Normal duration 




discovery of a morphological change in the shape of the cells by compound 2a71. The treatment 
of MDA-MB-231cells presented a MET (mesenchymal to epithelial transition) when exposed to a 
concentration of 10 µM of compound for a 7-day interval. To validate the activation of MET 
analog 2a71 was then tested for the upregulation of epithelial markers (E-cadherin), reduction of 
mesenchymal markers (Vimentin, Snail, ZEB1, and stemness marker SOX2), reduction of the 
colony formation, reduction in the migration (by the wound healing assay), and the reduction in 
spheroid viability in the MDA-MB-231 cells (Fig. 8.6). The results confirm that compound 2a71 
is a potent inducer of MET. 
 
Figure 8.6. Compound 2a71 induces MET and decreases colony formation, cell migration, and 
spheroid formation in MDA-MB-231 cells. (A) Structure of compound 2a71. (B) Western blot of 
epithelial marker E-cadherin, mesenchymal markers Vimentin, Snail, and ZEB1, and stemness 
marker SOX2 in MDA-MB-231 cells. (C) Quantification of protein expression of E-cadherin, 
ZEB1, vimentin, Snail, Slug, and SOX2. (D) Compound 2a71 inhibited MDA-MB-231 colony 
formation after 14 days of treatment in a concentration-dependent manner. (E) Wound closure was 
measured as a percentage of untreated DMSO control group. (F) Quantification of the spheroid 






2.2) Biological evaluation of thiophene derivatives as MEK5 inhibitors 
 
 
# R1 substitution R2 
substitution 
pERK-5 




DMSO   0 0 
2b76 OC2H5 NA -- 14.3 ± 11.0 
2b77 OC2H5 H 15.4 76.0 
2b79 OH H 7.5 60.9 
2b81 N-methylpiperazine H 74.9 5.5 
2b78 OC2H5 2-F 68.2 -- 
2b80 OH 2-F 73.5 22.5 
2b82 N-methylpiperazine 2-F 33.7 -- 
U0126   43 99.6 
XMD8-92   95.2 50.1 
PD 0325901   95.9 99.7 
Table 8.3. MEK5 and MEK1/2 inhibition data of seven-membered fused thiophene analogs. 
In the seven-membered fused thiophene analogs installation of the aryl ring at the 2-amino group 
increases activity at MEK1/2 or MEK5 (2b76 vs 2b77-2b82). At R2 presence of ortho-fluoro group 




MEK5 (compare 2b77 vs 2b78 and 2b79 vs 2b80), analogs 2b81 and 2b82 are the exceptions. The 
presence of ortho-fluoro group could serve multiple purposes. First, its electron-withdrawing 
nature of the fluorine atom would make the NH of the aniline a stronger HBD thereby 
strengthening the intra-molecular H-bond with the carbonyl group. Second, the ortho-fluoro group 
could form an intra-molecular H-bond with the NH of the aniline and may lock the molecule into 
bioactive conformation. Third, the ortho-fluoro group may polarizes the arene ring thereby 







decrease (%)  
pERK-1/2 
decrease (%)  
DMSO   0 0 
2b60 NA Boc -- 4.6 
2b61 H Boc 0 32.4 
2b67 H H 0 56.3 
2b62 2-F Boc 48.1 0 
2b68 2-F H 32.5 0 
U0126   43 99.6 
XMD8-92   95.2 50.1 
PD 0325901   95.9 99.7 




In the six-membered fused thiophene analogs installation of the aryl ring at the 2-amino group 
increases activity at MEK1/2 or MEK5 (2b60 vs 2b61-62 and 2b67-68). At R2 presence of an 
ortho-fluoro group with the rest of the structure unaltered leads to increased potency and selectivity 
at MEK5 (compare 2b61 vs 2b62 and 2b67 vs 2b68). This is consistent with the biological data 
for the seven-membered fused thiophene ring analogs suggesting that they both are binding 
similarly to MEK5.  The removal of Boc group does not effect activity at MEK1/2 and MEK5 
suggesting that both hydrophobic groups and ionizable groups are tolerated at this position.  
 
# R1 substitution R2 
substitution 
pERK-5 
decrease (%)  
pERK-1/2 
decrease (%)  
DMSO   0 0 
2b37 OCH3 NA -- 16.1 
2b39 OCH3 H 24.1 6.5 
2b48 OH H 29.7 5.7 
2b51 NH2 H -- -- 
2b52 N-methylpiperazine H 21.7 -- 
2b41 OCH3 2-F 75.3 22.5 
2b49 OH 2-F 62.1 14 
2b56 NH2 2-F 25.7 -- 
2b57 N-methylpiperazine 2-F 43.1 9 




XMD8-92   95.2 50.1 
PD 0325901   95.9 99.7 
Table 8.5. MEK5 and MEK1/2 inhibition data of six-membered fused thiophene analogs. 
In the 5-methyl thiophene analogs installation of the aryl ring at the 2-amino group generally 
increases activity at MEK5 (2b37 vs 2b39, 2b41, 2b48-49, and 2b56-57). At R2 (consistent with 
the SAR of 7-membered fused thiophene analogs and 6-membered fused thiophene analogs) 
presence of ortho-fluoro group with the rest of the structure unaltered generally leads to increased 
potency and selectivity at MEK5 (compare 2b39 vs 2b41, 2b48 vs 2b49, 2b51 vs 2b56, and 2b52 
vs 2b57).  When the R2 is ortho-fluoro the ester analog 2b41 and acid analog 2b49 showed higher 
inhibition of MEK5 (with 3-4 fold selectivity) when compared with the primary amide 2b56 and 
N-methylpiperazinamide 2b57. The primary amide 2b56 and N-methylpiperazinamide 2b57 
although less potent at MEK5 showed no inhibition of MEK1 and MEK2 isoforms indicating they 
target MEK5 selective residue and these analogs could further be developed as more potent and 
selective MEK5 inhibitors. 
The best compounds in terms of MEK5 activity were further evaluated for the inhibition of PI3K 
pathway (Fig. 8.7 and Table 8.6). 
Compounds pERK-5 
decrease (%)  
pERK-1/2 
decrease (%)  
p-AKT decrease 
(%) 
2b78 68.2 -- 55.3 
2b81 74.9 5.5 89.2 
2b41 75.3 22.5 59.8 
2b49 62.1 14 49.4 




DMSO 0 0 0 
PD0329501 95.9 99.7 0 
LY294002 0 0 99 
Table 8.6. MEK5 MEK1/2, and Pi3K inhibition data of thiophene and diphenylamine analogs. 
 















3) Biological evaluation of Sigma-2 receptor antagonists 
 










3 3.8 9.6 3 
3a41 
 
6.5 6.3 14 2 
3a42 
 
15 20 19 1 
3a43 
 
0.6 38 26 1 
3a44 
 
0.6 4.9 3.2 1 
3a45 
 
1 13 40 3 
3a46 
 
>15 25 9.4 <1 
3a47 
 
>15 26 7.1 <1 
3a48 
 






15 217 143 1 
3a55 
 
0.3 302 286 1 
3a56 
 
0.3 926 831 1 
3a57 
 
0.6 320 648 2 
3a58 
 
0.3 196 157 1 
CT0109 
(Std.) 
 2.2 9 500 50 
Table 8.7. Biological evaluation of sigma-2 receptor antagonists. 
All the N-arylated analogs (3a40-3a48) showed 50 nM or better affinity at the sigma-2 receptors 
(Table 8.7). However, selectivity in this series of molecules need to be improved and will be done 
in future SAR. Combining the sigma-2 affinity and the Aβ assay activity (≤ 1.0 µM), from this 
series we identified analogs 3a43-3a45, and 3a48 as potential leads for further SAR elaboration. 
In the N-acylated analogs, even though the desired affinity at the sigma-2 receptors (≤ 100 nM) 
was not achieved still the promising activity of analogs 3a55-3a58 in the Aβ assay warrants their 










Cells, culture conditions, and viruses:  
HeLa and GHOST cells were cultured at 37 °C in Dulbecco’s Modified Eagle Medium (DMEM; 
Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA), and 100 U/mL penicillin, 100 g/mL streptomycin, and 0.3 mg/mL of L-
glutamine (Invitrogen). HIV-1NL4-3 luciferase reporter virus pseudotyped with the vesicular 
stomatitis virus glycoprotein (VSV-G) was made by transfection of 293T cells with the pNLdE-
luc reporter construct and pL-VSV-G plasmid, using Lipofectamine 2000 (Invitrogen). Virus was 
harvested and titered on GHOST cells.1, 2  
Cell viability assay:  
2 x 103 HeLa or GHOST cells were plated in sterile, tissue culture-treated flat-bottom 96-well 
plates the night before the experiment. Cells were incubated for 24 hours in duplicate with 5-fold 
dilutions of each synthesized drug and CsA (Bedford Laboratories, Bedford, OH). Drug stocks 
were made in DMSO and were diluted more than 400-fold in medium. Multiple wells with medium 
without drug were used as controls. The XTT assay (Roche, Indianapolis, IN) was used by addition 
of XTT labeling reagent for 4 hours, followed by addition of the electron-coupling reagent 
overnight. The plate was read on a SpectroMax ELISA plate reader (Molecular Devices, 
Sunnyvale, CA) at 570 nM.1, 2 
Virus inhibition assay:  
2 x 104 HeLa or GHOST cells were plated in 24-well plates the night before the experiment. Cells 
were infected in duplicate with HIV-1 at a multiplicity of infection of 0.02 in the presence or 




drug background controls for the assay. After 2 hours of incubation, cells were washed with 
phosphate-buffered saline and new medium with or without drug was replaced. Cell lysates were 
harvested 48 hours later with Glo Lysis buffer (Promega, Madison, WI) and measured for 
luciferase activity with the dual-luciferase reporter assay (Promega) on a Wallac microbeta 
luminometer (Perkin Elmer, Waltham, MA).1, 2  
Cell Culture and treatment 
MDA-MB-231 cells were grown on 10cm cell culture plates [Sarstedt] in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Gibco) with Ham's F12 Nutrient Mixture (1:1) (Invitrogen), 10% heat-
inactivated FBS [Atlanta Biological and 0.5% penicillin/ streptomycin [Gibco]. Cells were 
maintained at 37°C with 5% CO2. Plating of the cells was done 36 hours before treatment in 35mm 
culture plates [Sarstedt] and allowed to reach confluence. To test MEK-5 inhibitors, the cells were 
treated with epidermal growth factor (EGF; Sigma-Aldrich) 30 min after treatment with the 
compounds. 15 min after the addition of EGF, the cells were washed with 1XPBS [Sigma-Aldrich] 
and then lysed in 1% Triton X-100 buffer containing 20 mM Tris (pH 6.8), 137 mM NaCl, 25 mM 
beta glycerophosphate, 2 mM NaPPi, 2 mM EDTA, 1 mM Na3VO4, 10% glycerol, 5 μg/mL 
leupeptin, 5 μg/mL aprotinin, 2 mM benzamidine, 0.5 mM DTT, and 1 mM PMSF. The lysates 
were then centrifuged at 10,000 rpm for 10 min at 4°C.3 
Western Blot Analysis 
Protein levels of ERK1/2, ERK5, Akt and apoptotic markers were measured using western blot. 
Cells were plated at a density of 5x105 per well (6 well plate). Cells were allowed to attach 
overnight and then serum starved for 24 hours before treatment. Cells were treated with vehicle or 
inhibitors one hour prior to 5% FBS stimulation for 24 hours. For Bad signaling, 50 ng/mL EGF 




determined by a Bradford assay (Bio-Rad). 30 µg of protein was loaded on a 4-15% SDS-PAGE 
gradient gel (Bio-Rad). The contents of the gel were transferred to a membrane and then probed 
with various antibodies: anti-phospho-ERK1/2, anti-total ERK1/2, anti-total ERK5, anti-
phosphoERK5, anti-phospho-Akt (Ser 473), anti-Akt, anti-pS6 (Ser 240/244), anti-p21, anti- 57 
cMYC, anti-Bad, anti-phospho-Bad (Ser112, Ser136), and anti-Cleaved PARP (1:1,000, Cell 
Signaling). Anti-GAPDH (1:10,000; Millipore) was used as a loading control. The binding of 
antibody to antigen was detected by incubating membranes with secondary antibodies and 
scanning on an Odyssey Infrared Imager (LICOR biosciences). Blots were analyzed using 
ImageStudioLite by a blinded observer (LICOR biosciences). Phospho-Bad Ser112 was quantified 
with PathScan ELISA (Cell Signaling; 7182C) with the same lysates used in western blot analysis.4 
Spindle index calculation 
Spindle indices (SI) of individual cells were calculated from at least 200 cells per treatment from 
a minimum of three images as the ratio of length (l) to width (w); SI = l/w of each cell. Cells with 
SI < 3 were considered as epithelial. The percentage of cells <3 were calculated as the ratio of the 
number of cells with spindle index < 3 to the total number of cells per image. The method was 
adopted from reference. Length and width were measured using the Image J software, U. S. 
National Institutes of Health, Bethesda, Maryland, USA.5 
Western Blot analysis 
Cells were seeded in 12-well plates at a seeding density of 50,000 cells per well in 1 mL full media 
and treated with compounds after 24 hours at a 1μM concentration. The cells were lysed in 1X ice-
cold RIPA buffer (Cell Signaling Technology Cat. No. 9803S) and protease inhibitor cocktail (Cell 
Signaling Technologies Cat. No. 5871S). The proteins were resolved using 8% SDS 
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (LI-COR 




incubated at 4°C overnight with E-cadherin, ZEB1, Snail, Slug, primary antibodies, Cell Signaling 
EMT Antibody Sampler Kit (1:1000, Catalog No. 9782S), SOX2 antibody (1:1000, Millipore, Cat. 
No. AB5603S), and α-tubulin (1:10000; Cell Signaling Technology, Cat. No. 2144). The 
antibodies were diluted in casein blocking buffer (LI-COR Biosciences). The membranes were 
washed thrice with wash buffer (PBS 1X, Tween 0.02%). The membranes were incubated with 
goat anti-rabbit (1:10000, Invitrogen) and goat anti-mouse (1:10000, Invitrogen) secondary 
antibodies for 1 hour. Membranes were washed thrice with the PBS-tween wash buffer and 
scanned on an LI-COR’s Odyssey CLx Imager at 700 nm (goat anti-rabbit) and 800 nm (goat anti-
mouse). The blots were quantified with Image Studio Software. Results are represented as protein 
expression of treated group versus DMSO control as ± SEM of experiments repeated at least three 
times.5  
Colony formation assay  
Colony formation was performed using a Soft Agar Colony Formation assay (Cell Biolabs; CBA-
130) manufacturer’s protocol. Base agar layer was added first. MDA-MB-231 cells were cultured 
in 5% FBS growth media and 1.2 % agar solution at a seeding density of 5000 cells/well. DMSO 
or compound 2a71 at 0.1, 1, and 10 µM concentrations were added on the top of cell layer. The 
colonies were seeded to grow for 7 days. The agar layer was then solubilized, colonies were lysed, 
and stained with CyQuant dye. Florescence was measured on VICTOR3 1420 Perkin Elmer multi-
label counter at 485 nm.5  
Spheroid culture 
Cells were cultured in 96-well low attachment plates (Corning Cat. No. 4520) at a seeding density 
of 5000 cells/ well. DMSO or compound 2a71 at 0.1, 1, and 10 µM concentrations was added after 
24 hours. Pictures were taken using the EVOS™ FL inverted microscope (Life Technologies) 




After 7 days of treatment, 10 µl of Reliablue viability reagent (ATCC® 30-1014™) was added to 
each well. The plates were incubated for 3 hours in the incubator at 37 °C. The absorbance was 
measured at a wavelength of 570 nm using Wallac 1420 software on a Perkin Elmer 1640 
multilabel counter. Results are represented as spheroid viability normalized to DMSO control ± 
SEM of triplicate experiments.5 
Scratch assay 
Cell migration was assessed using a scratch assay after treatment with DMSO or compound 2a71 
at 0.1, 1, and 10 µM concentrations for 72 hours. Cells were seeded in 12-well plates at a seeding 
density of 50,000 cells/ well in 1 ml full media in the presence of 5% FBS. Scratches were made 
after 48 hours of the treatment. Images were taken at the time of scratch and after 24 hours from 
the time of scratch. The current scheme of treatment was employed to observe the effect of the 
treatment on cell migration at a longer time-point. The closure rates were calculated as Wound 
closure = (border width at 24 hr-border width at 0 hr) X 100. Results are represented as wound 
closure normalized to DMSO control ± SEM of triplicate experiments repeated three times.5 
Aβ trafficking assay 
The assay measure vesicular trafficking. Briefly, the neurons were cultured and treated with 
compounds of interest and/or Abeta oligomer preparations and incubated for 1 to 24 hr at 
physiological temperature. To this (3-(4,5-dimethylthiazol-2yl)-2,5diphenyl tetrazolium bromide) 
was added and kept for 60– 90 min at 37 oC. The remaining vesicular formazan in cells was 







Sigma receptor radioligand binding assay 
Sigma 2: Radioligand competition assays were performed in membranes from human Jurkat cells 
using 5 nM [3H]1,3-di(2-tolyl) guanidine in 50 mM Tris HCl, pH 8.0, RT (buffer) in the presence 
of 1 μM (+)-pentazocine with 10 μM haloperidol to define non-specific binding. 
Sigma 1: Radioligand competition assays were performed in membranes from human Jurkat cells 
using 5 nM [3H]-pentazocine in 50 mM Tris HCl, pH 8.0, RT (buffer) in the presence of  10 μM 
haloperidol to define non-specific binding.6 
Modelling studies 
Docking of proposed analogs: all the docking studies were carried out using MOE. For the 
cyclophilin project x-ray crystal structure of the sanglihfehrin-A bound to CypA was used (PDB 
ID: 1NMK, resolution 2.1 Å) for determining the binding of the analogs. Crystal structures were 
prepared using QuickPrep function in MOE. The docking settings were set to default (Placement: 
triangle matcher, Rescoring 1: London Dg, Refinement: forcefield, Rescoring 2: GBVI/WSA Dg). 
Docking validation was carried out by docking the bound ligand in the x-ray crystal structure back 
into the pocket using the aforementioned settings and then comparing the docked pose with the 
pose in the x-ray crystal structure. The rmsd values were 1.5 Å. Thus, the docking protocol was 
deemed fit for the docking of our proposed analogs. 
MEK project 
X-ray crystal structure of MEK1 bound ligands was used for the docking of analogs in MEK1 
(PDB ID: 3EQC for diphenylamine analogs and PDB ID: 3SLS for thiophene analogs). The above-
mentioned settings were used and the rmsd value was less than 1.5 Å. 
Several homology models were constructed on the structure of MEK1 (3EQC, 3SLS).7, 8  The 




with 448 amino acid residues was chosen for sequence to be used for the homology model. 
Multiple models representing the DFG-in and the DFG-out conformations, as well of the various 
phosphorylated forms were examined.  MOE 2016 was used to examine the proteins and ligand 
interactions.  Docking was conducted with default MOE settings. 
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